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Abstract
The product of the ink4a/arf\ocu^ is induced by a variety of oncogenic
signals. pl4*^^ can facilitate growth aixest through the p53 pathway by 
hindering the down-regulation of p53 activity through its interaction with 
MDM2, which interferes with formation of the complex between p53 and 
MDM2. Here I have explored the possibility that pl4^^^ may be integrated 
with growth regulatory pathways other than p53, and report that pl4*^^ can 
modulate the activity of the cell cycle regulating E2F transcription factor.
p l4  regulates E2F-1 activity in both SAOS2 cells and p53'^Vmdm2'^' MEFs, 
excluding the possibility that the effects of pl4^^^ on E2F are influenced by 
MDM2. pl4**^ down regulates E2F-dependent transcription, S-phase entry, 
apoptosis and colony formation. The mechanism responsible for this activity 
may be through regulation of E2F stability at the post-translational level. 
p^^ARF a physical complex with E2F both in vitro and in cells.
binds to E2F through distinct, binding domains, one of which resides in 
the N-terminal region and is capable of down-regulating E2F activity. These 
results highlight the potential interplay and cross talk between pl4*^^ and E2F- 
1, and establish pl4^^^ as an antagonist of cell growth that acts by targeting 
two of the key pathways involved in controlling proliferation, namely E2F and 
p53.
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Chapter 1. Introduction
1.1.1 The Cell Cycle
Mammalian cells have developed the ability to divide and grow by a process termed 
the cell cycle. The cell cycle is divided into four distinct phases; G l, where growth 
and acquisition of proteins required for S phase occurs, S phase, where the cell 
replicates its DNA, G2, a second gap phase and M, mitosis, the process of cell 
division. A large number of cellular proteins are important for maintaining the 
integrity of the cell cycle, and cell cycle "check points" are employed where these 
proteins determine progression into the next stage. The crucial ‘restriction point’ in 
the cell cycle is at the end of G l phase, following the first growth stage. At this point 
the cell has to make a commitment to proliferation, differentiation or apoptosis.
Regulatory circuits governing the cell cycle aie complex and highly interlinked. 
Many of the proteins implicated in this process are DNA binding transcription factors 
and their associated proteins. Tumour cells arise when the lack of, or overexpression 
of, specific proteins upsets the intrinsic workings of the cell cycle and cells begin to 
proliferate uncontrollably. It is therefore highly important that we understand the 
worldngs of the cellular pathways which regulate cell cycle control, in order to 
develop new and effective cancer therapies.
17
Chapter 1.____________________________________________________Introduction
1.1.2 The E2F Pathway.
The E2F pathway is frequently deregulated in tumour cells and so is an important 
target for anti-cancer therapies. Deregulated E2F activity leads to uncontrolled 
cellular proliferation and drugs which target components of the E2F pathway could 
be important anti-cancer agents. Although E2F itself is rarely mutated, its upstream 
regulators are frequently mutated or deregulated in human cancers and disruption of 
this pathway is thought to be a common event leading to oncogenesis (Dyson, 1998).
1.1.3 The E2F Families.
The E2F family is a heterodimeric group of transcription factors where each 
heterodimer consists of one E2F and one DP partner. To date, six E2Fs (termed 1-6) 
and three DPs (termed 1-3) have been identified (Helin et al, 1992; Girling et al 
1993; Ivey-Fioyle et al, 1993; Lees et a l, 1993; Beijersbergen et a l, 1994; Girling et 
al, 1994; Hijmans et al, 1995; Ormondroyd et al, 1995; Rogers et al, 1996; 
Cartwright et al, 1998). Ail family members share a central conserved DNA binding 
region and a separate heterodimerisation domain (Figure 1.1). The E2F and DP 
heterodimerisation domain contains a region of similarity, which has been identified 
as likely to foim an amphipathic a-helix (La Thangue, 1994).
E2F family members have also been identified in a number of other organisms, 
including Drosophila melanogaster, which has homologues of the E2F, DP, and pRb 
proteins. The Drosophila genome encodes two E2F genes, de2fl and de2f2 (Ohtani 
et a l, 1994; Frolov et a l, 2001), a DP gene dDP (Royzman et a l, 1997) and a pRb 
homologue RBF (Du et a l, 1999). dE2F and dDP are involved in proliferation and S-
18
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phase entry (Brook et al., 1996; Du et al., 1996; Duronio et al, 1998) and provide an 
interesting model system in which to study the cellular roles of the E2F transcription 
factor.
Recent studies have identified homologues of E2F and DP in Caenorhabditis 
elegans (Ceol et al, 2001, Page et al, 2001). C. elegans efl-1 is most similar to 
mammalian E2F-5 and dpl-1 is most similar to DP-1. EFL-1 and DPL-1 interact 
with each other and with the C. elegans pRb homologue, LIN-35, and may act 
together to mediate transcriptional repression. As yet no specific role has been 
defined for the C.elegans Elf-1 and Dpl-1 in transcription or cell cycle control, 
however animals lacking these genes have protein asymmetries and vulval 
abnormalities (Ceol et a l, 2001; Page et a l, 2001), indicating the importance of 
these proteins in developmental regulation.
Xenopus laevis also has E2F homologues and XI DP-1 and XI DP2 have been 
cloned and shown to be expressed early in development (Girling et a l, 1994). This 
conservation of the E2F proteins across species indicates an important role for these 
proteins, and model systems such as Drosophila melanogaster and Caenorhabditis 
elegans, allow us to study these proteins in detail.
During the course of this thesis E2F-X or DP-X refers to an individual family 
member, while the term E2F refers to the activity of an E2F heterodimer.
19
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1.1.4 The E2F family members
All of the E2Fs, with the exception of E2F-6, have a C-terminal rra^^activation 
domain, and embedded within this, a region which allows pocket proteins to bind and 
repress transcription (La Thangue, 1994) (Figure LI). E2F-6 lacks a 7ra7r5activation 
domain and so is thought to act solely as a repressor of transcription (Morkel et ah, 
1997; Cartwright et ah, 1998). In fact, recent data show that E2F-6 interacts with 
components of the mammalian polycomb transcriptional repressor complex, 
suggesting that a physiological role of E2F-6 may stem from its ability to recruit this 
repressor complex (Trimarchi et al, 2001).
E2F1-3 contain an N-terminal region of approximately 100 amino acid residues, 
which encompasses a cyclin A-cdk2 binding domain and also a nuclear localisation 
signal. The presence of this N-terminal NLS places E2Fs 1,2 and 3 in a sepaiate sub­
family from E2F-4 and E2F-5. Interestingly, through the use of a second downstream 
promoter, the e2f-3 gene has been shown to encode a second transcript. The two e2f- 
3 gene products are referred to as E2F-3a and E2F-3|3; the first is structurally more 
similar to E2F-1, and the second lacks the N-terminal cyclin binding domain more 
similarly to the second E2F sub-family (Adams et al, 2000).
E2F-4 and E2F-5 both lack the N-terminal region, and so aie distinct from the other 
family members in that they aie localised to the cytoplasm and are only able to enter 
the nucleus when bound to a DP partner or pocket protein; DP3 a  and 5 proteins 
have a central, bi-partite nucleai’ localisation signal which mediates this nuclear
20
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localisation (de la Luna et al, 1996; Allen et al, 1997). Recently E2F-7 has been 
cloned, and resembles E2F-6 in that it lacks a fraii^activation domain (La Thangue. 
Personal Comm.).
1.1.5 The DP family members
Originally, the E2F-DP heterodimeric transcription factor was referred to as 
DRTF1/E2F, where E2F was an activity induced in HeLa cells after adenovirus 
infection and DRTF was defined as a transcription factor down-regulated during the 
differentiation of F9 cells (Partridge and La Thangue, 1991; Girling et a l, 1993).
DP-1 was the first member of the DP family to be identified and was isolated from 
cellular DRTF complexes (Girling et al, 1993). The most characterised function of 
the DP protein family is their ability to co-operate with E2F in DNA binding and 
transcriptional activation, little else is known about their function. However, a DP-1 
polypeptide has been shown to be phosphorylated in a cell cycle dependent fashion 
and to undergo a phosphorylation-dependent mobility shift during the cell cycle, 
indicating that its level of phosphorylation is probably regulated during cell cycle 
progression (Bandara et al, 1993; Bandara et al, 1994). DP-1 and DP-2 are 
integrated with another growth regulating pathway, which involves signal 
transduction emanating from activated Ras protein (Jooss et al., 1995). Both DP-1 
and DP-2 are able to replace myc and co-operate with Ha-ra.y in a transfoiTuation 
assay (Jooss et a l, 1995). These data suggest an E2F independent effector function 
for the DP family members (Jooss et a l, 1995).
21
Figure 1.1 The E2F and DP family members.
(A) Summary of the structures of the E2F family members, showing the location 
of the conserved DNA binding (white), dimérisation (red), pocket protein binding 
(blue) and transactivation (yellow) domains.
(B) Summaiy of the structures of the DP family members.
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DP-2 was cloned in Xenopus, as a DP-1 homologue, and shown to have greater than 
70% protein similarity to DP-1 (Girling et aL,1994). Generally, in the literature DP-2 
refers to the human form and DP-3 to the mouse form of what is thought to be the 
same protein. Human DP-2 was identified as an E2F binding protein in a yeast two- 
hybrid screen of a HeLa cell library and exists as at least three DP-2 related proteins 
that are regulated by alternative splicing of the five prime region (Rogers et al, 
1996). DP-3 was cloned from a murine library and is present in four different splice 
forms termed alpha (a), beta (p), delta (ô) and gamma (y), determined by their 
different N terminal organisation (Ormondroyd et al, 1995).
The four DP-3 isoforms vary in their cellular localisation (de la Luna et a l, 1996). 
An N terminal basic region, that encompasses a bi-partite NLS controls whether the 
protein is nuclear or cytoplasmic (de la Luna et al, 1996). DP-3a and DP-35 contain 
the NLS, while the family members DP-3P and y are normally found in the 
cytoplasm, unless bound to a pocket protein which can take them into the nucleus (de 
la Luna et al, 1996). DP-4, a new member of the family has recently been identified 
which shows high homology to DP-1 (La Thangue. Personal Comm.).
1.1.6 The Pocket Proteins
E2F transcriptional activity is tightly regulated during the cell cycle through binding 
to members of the pocket protein family; pRb, pl07 and pl30 (Dyson, 1998). pRb 
and its related family members, pl07 and pl30 contain a C teiTninal “pocket” region, 
which binds to members of the E2F family (La Thangue 1994; Dyson 1998).
23
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The individual pocket protein family members seem to bind preferentially to 
different E2F family members. E2F-1, E2F-2 and E2F-3 bind almost exclusively to 
pRb, while E2F-4 binds to all three pocket proteins and E2F-5 interacts preferentially 
with p i30. E2F-pocket protein complexes are found at different stages of the cell 
cycle. pRb-E2F complexes can be found in quiescent or differentiated cells but are 
most evident at the Gl-S phase boundary. pl30-E2F complexes are found in 
quiescent or differentiated cells while pl07-E2F complexes are found mainly in S- 
phase (Dyson, 1998; Takahashi et al., 2000.).
There are thought to be three possible ways by which this pRb/E2F mediated 
repression can occur. Firstly that pRb directly blocks the E2F transcriptional 
activation domain through binding, or secondly that pRb indirectly prevents E2F 
from contacting the basal transcription machinery (Dyson, 1998). Thirdly, pocket 
proteins are able to repress transcription through the binding and recruitment of 
histone deacetylases, which deacetylate histones, thereby promoting chromatin 
condensation that in turn prevents transcription factors from contacting DNA and 
therefore, transcription from occuning (Ferreira et al, 1998, Luo et al, 1998).
Different types of E2F complexes are thought to exist during the cell cycle (Figure 
1.2). Repressive complexes, where a pocket protein is bound to a heterodimer in its 
hypophosphorylated form, thus actively preventing transcription. Inhibitory 
complexes, in which a pocket protein is bound to a heterodimer, but is preventing, as 
opposed to actively repressing transcription. Active complexes, where the pocket 
protein is hyperphosphorylated and the heterodimer is free to activate transcription
24
Figure 1.2 E2F complexes during the cell cycle
Inhibitory complexes occur when pocket proteins physically block the E2F 
tra/ii'activation domain and repressive complexes result when the pocket protein 
is recmited to the DNA. Activating complexes occur when the pocket protein 
becomes phosphorylated by CDKS and loses affinity for the heterodimer. Inactive 
complexes exist when the DP partner becomes phosphorylated and the 
heterodimer loses affinity for the DNA.
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(Dyson 1998), and inactive complexes where the DP paitner becomes 
phosphorylated by cellular Idnases, and prevents the heterodimer from binding DNA 
(Figure 1.2) (Bandara et al, 1994).
Regulation of E2F transcription is controlled primarily through phosphorylation of 
the pocket protein member, and the importance of this regulation is highlighted by 
the fact that single point mutations in E2F-1 which abolish pRb binding lead to 
enhanced S phase entry, and development of tumours (Shan et a l, 1996; Conner et 
al, 2000). pRb phosphorylation during the cell cycle is initiated by cyclin D/cdk4 
and maintained by cyclin E/cdk2 (Muller and Helin, 2000). Only 
hypophosphorylated pRb is able to bind to E2F, and in this situation the E2F-pocket 
protein complex is repressive and no transcription is able to occur. However, when 
pRb becomes phosphorylated by cellular cyclin-cdk complexes at the G1 stage of the 
cell cycle, the E2F heterodimer is released and is able to activate transcription.
The phosphorylation of pRb is a highly orchestrated process and coiTesponds with an 
increase in the expression of cyclins and an up-regulation of cyclin dependent Idnase 
activity (Hatakeyama and Weinberg, 1994; Lundberg and Weinberg, 1998). pRb is 
phosphorylated on a number of potential S/T-P motifs throughout its sequence, and 
the in vivo phosphorylation of pRb by individual cyclin/cdk complexes is important 
for the cellular function of pRb. Cell cycle progression and loss of pRb repressive 
function involves the sequential activation of cyclin D/cdk4, cyclinE/cdk2 and 
cyclinA/cdk2 complexes during late G1 and S phases (Hatakeyama and Weinberg, 
1994; Lundberg and Weinberg, 1998; SheiT and Roberts, 1999). Attempts have been
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made to elucidate the mechanism of pRb phosphorylation and studies on the 
cumulative effect of phosphorylation on pRb have shown that disruption of 
transcriptional repression results from an accumulation of phosphate groups on the 
S/T residues in the pRb molecule and that no one paiticular site is responsible 
(Brown a/., 1999).
Recently, the mechanism by which Rb acts to repress transcription has been analysed 
in an in vitro transcription assay, using order of assembly experiments (Ross et a l, 
2001). Data presented suggested that active pRb dependent repression (independent 
of E2F binding) was observed on a chromatin template but not on a naked templete, 
and that this transcription occured independently of histone deacetlylases. These 
experiments also showed that pRb mediated repression was able to occur after 
assembly of the transcriptional pre-initiation complex, in contrast with E2F inhibition 
by pRb which is thought to occur before assembly of the pre-initiation complex 
(PIC) (Ross et al, 2001). These data suggest discrete mechanisms by which pRb is 
able to directly inhibit an activator such as E2F or actively repress other transcription 
factors which are bound to the DNA. pRb also represses transcription by recruiting 
histone methyltransferase enzymes to DNA (Ferreira et a l, 2001), however the 
mechanism by which these act has not yet been fully elucidated.
c-mos is a protein Idnase which is able to transform cells and disrupt E2F-pl30 
complexes (Afshaii et al., 1997). Loss of these E2F-pl30 complexes may be an 
important step in allowing alteration of cell cycle control and conferring a growth 
advantage to these cells (Afshari et a l, 1997).
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The importance of the pocket protein-E2F regulation is highlighted by the fact that 
viral oncoproteins such as adenovirus ElA, SV40 large T and papilloma virus E7 
protein are able to block the Rb/E2F interaction, through binding to the pocket region 
of pRb, therefore allowing un-regulated proliferation to occur (Bandara et aL, 1991; 
Zamanian and La Thangue, 1992 ; Dyson, 1998).
1.1.7. Upstream Regulators.
Progression through the cell cycle is dependent on phosphorylation of key regulatory 
proteins by cyclin-dependent Idnases (CDKs), which are themselves regulated by 
subunits known as cyclins. Whilst the levels of cyclin proteins oscillate throughout 
the cell cycle, regulated through the actions of cell cycle regulated transcription and 
proteolysis, the levels of CDKs are relatively stable (Lees, 1995). Cyclin/cdk 
complexes are regulated by the cyclin dependent kinase inhibitors (CDIs) that 
sequester CDKs to halt cell cycle progression in response to a variety of signals. 
Signalling pathways activate the p53 transcription factor, in response to stress and 
up-regulate its downstream CDI targets such as CKIs include two distinct
families, the INK4 (INhibitors of CDK4) family, that specifically inhibit certain 
cdldcyclin species and consists of pl5^^^"\ p i8''^'" and p i9''''''', and the
CIP/KIP family whose three members p27^ ^^  ^ and p57™  ^ inhibit the
activity of all the CDKs via binding to the cyclin fold (Roussel, 1999).
The G1 regulator pRb, is regulated by a number of upstream cyclins/CDK complexes 
and CDIs, and cell cycle progression normally occurs when pRb is inactivated by
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phosphorylation, catalyzed by a CDK in complex with their cyclin partner. Most of 
the studies of pRb phosphorylation have relied on overexpresion of cyclins and/or 
CDKS, so it is still unclear which cyclin-cdks normally phosphorylate pRb in vivo. 
However, it is thought that cyclin D/cdk4/6 phosphorylates pRb early in G l, cyclin 
E/cdk2 phosphorylates the protein near the end of G l, and cyclin A/cdk2 may 
maintain phosphorylation of pRb during S-phase (Harbour and Dean, 2000). In vitro 
studies have shown that E2F recruits the pre-initiation complex factor, TFIID to gene 
promoters, and that pRb blocks this E2F mediated recruitment of the pre-initiation 
complex (Ross et al, 1999).
1.1.8. Importance of E2F
The importance of the E2F pathway is highlighted by the fact that it is so frequently 
de-regulated in transformed cell lines and human cancers. Although E2F itself is not 
frequently mutated, mutations in pRb, cyclin D, CDK4 and p i a r e  frequent in a 
range of human tumours (SheiT, 1996). The pRb gene rbl is mutated in 
approximately 30% of human cancers, and the pl6 (INK4a) gene is methylated, 
deleted or mutated in a majority of gliomas, leukaemias and melanomas (Kamb et 
al, 1994). The cyclin D1 locus is amplified in a wide range of tumours, including 
lymphomas, squamous cell tumours and breast carcinomas (Pines, 1995).
The E2F family members themselves are a multi-functional group of proteins, which 
are involved in gene activation, repression, cell cycle proliferation or cell death and 
are able to inhibit tumorigenesis. E2F also has important roles in cells, which are not
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actively proliferating, indicating a wider role than just regulator of the restriction 
point (Dyson, 1998). The dual function of E2F as both a tumour suppressor and 
oncogene is particularly interesting, and may be tissue specific, or dependent on as 
yet undefined extrinsic factors (McLeod, 1999). Depending on the tissue studied, loss 
of E2F-1 has opposite consequences in terms of regulation of proliferation and 
apoptosis, and in the same organ, loss and gain of E2F function can have similar 
consequences (Muller and Helin, 2000).
1.1.9 Transcriptional regulation
Transcription is the process by which DNA is transcribed into RNA by one of three 
cellular RNA polymerases. RNA polymerase I synthesises large ribosomal RNA 
(Paule and White, 2000), RNA polymerase II transcribes messenger RNA (Hirose 
and Manley, 2000) and RNA polymerase III transcribes tRNA and some ribosomal 
RNAs (Paule and White, 2000). As RNA polymerase II mediates the transcription of 
mRNA, which is then translated into proteins, it is important to understand Pol II 
mediated transcription in order for us to know how the transcription of cellular genes 
is regulated.
The promoters of protein encoding genes consist of an initiator element, where 
transcriptional initiation occurs and frequently a down-stream TATA box (so called 
for the TATA nucleotide sequence) (Figure 1.3). Additionally promoters may contain 
other DNA elements, refeiTed to as enhancer elements, which mediate binding of 
DNA binding transcription factors, or sites for DNA site-specific transcription factors
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to bind to. Promoter DNA can be packaged into inactive chromatin and in this 
situation transcription can be prevented through DNA binding sites being 
inaccessible to transcription factors.
The basal, or general transcription factors (GTFs) are typically defined as the 
minimal proteins necessary to reconstitute accurate transcription from a minimal 
promoter. Basal transcription is mediated by GTFs, which associate with RNA 
polymerase on the DNA to form the PIC, and activate basal transcription (Roeder, 
1996) (Figure 1.3). In the case of Pol II transcription, these transcription factors are 
referred to as TFIIA-TFIIH and have a number of properties ranging from 
stabilisation of the TBP-DNA complex to phosphatase and helicase activities (Liu, et 
a l, 1999; Vandel and Kouzarides., 1999).
TATA Binding Protein (TBP) is the universal transcription factor which is involved 
in transcription of RNA pol I, II and III genes (Comai, et aL, 1994). TBP binds to the 
TATA box in TATA driven promoters (Figure 1.3A). The transcription factors SLl, 
TFIID and TFIIID are composed of TBP and a number of TBP associated factors 
(TAFS), and different promoters have different requirements for transcription by 
TBP or the TBP containing complexes (Comai et al., 1994). Recently it has been 
shown that acétylation of core histones can facilitate the binding of TBP to a 
nucleosomal TATA sequence (Sewalk et al., 2001). Positioning of a nucleosome 
over the TATA region appears to be a common mechanism for repressing basal 
transcription, and these data show that one consequence of induced histone
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Figure 1.3. The Pre-initiation Complex
Assembly of the pre-initiation complex on TATA and TATA less promoters.
(A) The pre-initiation complex forms after recruitment of TBP to the TATA box. 
The general transcription factors assemble on the promoter of RNA pol II 
responsive genes. The general transcription factors assemble step-wise on the 
promoter.
(B) The pre-initaiation complex also fonns on TATA less genes although in this 
situation Pol II is thought to bind prior to the general transcription factors
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acétylation at a native promoter is the alleviation of nucleosome mediated repression 
of the binding of TBP (Sewal et aL, 2001).
Initiation of mRNA synthesis by RNA pol II depends on the controlled and co­
ordinated activities of a large number of proteins (Figure 1.4). RNA polymerase II 
and the general transcription factors assemble into a pre-initiation complex at the 
core promoter elements of pol II regulated genes (Roeder, 1996) (Figure 1.3). TFIID 
consists of the TATA binding protein TBP, and a number of other TBP associated 
factors, and TFIID plays a central role in transcriptional initiation as it binds 
specifically to the TATA box and nucleates PIC assembly.
The multisub-unit transcription factor TFIID is an essential component of the RNA 
polymerase II machinery that works in concert with TFIIA and TFIIB to assemble 
initiation complexes at eukaryotic promoters (Andel et aL, 1999). As the pre­
initiation complex forms, TBP binds to the TATA box in TATA containing 
promoters, and then sequentially the GTFs and RNA polymerase bind to the DNA, 
and the downstream initiator element (Figure 1.3). Non TATA containing promoters 
also exist and in these cases the PIC is thought to assemble from RNA Pol II binding 
at the initiator element (Fig 1.3B).
The crystal structure of the IID-IIA-IIB complex shows that TFIID is a trilobed, 
horseshoe structure with TFIIA and TFIIB bound on opposite lobes and flanldng a 
central cavity. TBP is also shown to be in between TFIIA and TFIIB in this crystal 
structure (Andel et aL, 1999). Studies in yeast have shown that activator dependent
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Figure 1.4 Pre-initiation Complex Associated Factors
Many proteins bind and regulate components of the pre-initiation complex. The 
assembled PIC is represented and transcription factors which bind to the PIC are 
indicated by aiTOWS pointing to the appropriate binding partners (Chen et ah, 
1993; Hagemeier et aL, 1993; Quadri et aL, 1995; Scully et aL, 1997; De Luca et 
aL, 1998; Vandel and Kouzaiides, 1999).
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alterations of chromatin structure occur and that the association of TBP with 
promoters is stimulated by other, transcriptional activators (Kuras and Struhl., 1999). 
The general transcription factors play varying roles in transcriptional initiation. 
TFIIA binds to TBP and is thought to be involved in stabilisation of the TBP-TATA 
complex (Lui et a l, 1999). TFIIH has been shown to have both phosphatase and 
helicase activity (Vandel and Kouzarides., 1999)
A large number of transcription factors have been identified. Many are DNA binding, 
site specific transcription factors (Roeder, 1996). The diversity of these 
transcriptional proteins is important for the regulation of gene expression. As well as 
these DNA binding factors, other transcriptionally associated proteins exist which 
bind to transcription factors and cause either repression or activation of target genes. 
These proteins are termed co-activator or co-repressor proteins.
Many transcription factors bind directly to TBP, including cellular and viral 
fran^activators and repressors (Figure 1.4). One such viral protein is the hepatitis B 
virus transactivator protein X, which activates a number of cellular genes (Qadri et 
aL, 1995). Protein X binds specifically to TBP in vitro, and this interaction requires 
ATP (Qadri et aL, 1995). PU.l, a sequence specific transcription factor with an Ets- 
like DNA-binding domain can bind to both pRb and TFIID (Hagemeier et aL, 
1993a). These data then showed that sequence similarities exist between the pRb 
pocket and the general transcription factors TFIID and TFIIB, and the authors discuss 
the possibility that pRb may cany out functions similar to TFIID and TFIIB 
(Hagemeier et aL, 1993a). The site-specific DNA binding transcription factors E2F-1
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(Hagemeier et aL, 1993b) and p53 (Chen et aL, 1993) also bind directly to TBP, and 
interestingly E2F-1 has also been shown to interact with another component of the 
pre-initiation complex TFIIH (Vandel and Kouzarides, 1999). pRb can down- 
regulate transcription mediated by all three RNA polymerases and can also bind to 
TBP (De Luca et aL, 1998).
Transcription factors can activate and repress transcription or can be bi-functional, 
for example NC2. NC2 is the Drosophila homologue of the transcriptional repressor 
Dr-1 and can activate DPE-driven (down-stream promoter element) promoters and 
repress TATA driven promoters (Willy et aL, 2000). DNC2 acts at the time of PIC 
assembly, suggesting that dNC2 may either be a component of the PIC or, may be 
required for PIC assembly (Willy et aL, 2000). These data indicate that dNC2 could 
be an important target of regulatory factors (for example, sequence-specific 
transcriptional factors and co-activator proteins) for recruitment to core-promoters. 
Even-sldpped is another Drosophila protein which has been shown to repress 
transcription through binding to TBP and blocldng the TFIID-TATA box interaction 
(Li and Manley, 1998).
Cell-specific and spatially localised patterns of gene expression depend on 
combinations of sequence-specific activators and repressors that bind to extensive 
ci.s’-regulatory elements. Co-regulatory proteins are thought to be recruited to the 
DNA template by sequence-specific transcription factors (Mannervik, et aL, 1999). 
Co-activator proteins and complexes can link upstream activators to the core RNA 
polymerase II complex (Mannervik et aL, 1999). CBP is a component of large
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protein complexes containing additional histone acetyltransferases, including p/CAF 
(p300/CBP associated factor) and steroid receptor co-activators. CBP itself may have 
dual roles in chromatin decondensation and Pol II recruitment and has been shown to 
interact with a sub-unit of RNA pol II (Mannervik et al., 1999) (Figure 1.4).
Polycomb group proteins (PcG) act as repressive multiprotein complexes that may 
render target genes inaccessible to the transcriptional machinery, inhibit chromatin 
remodelling, influence chromosome domain topology and recruit histone 
deacetylases (Breiling et al., 2001). PcG proteins have been found to bind to core 
promoter regions and have been shown to bind to general transcription factors 
(GTFs) in vitro. Chromatin immunoprécipitation experiments showed that binding of 
PcG proteins to core promoters included GTFs, and that depletion of PcG proteins 
led to de-repression of developmentally regulated genes (Breiling et a l, 2001). These 
data suggest that PcG proteins may maintain gene silencing by inhibiting GTF- 
mediated activation of transcription.
1.1.10 The role of E2F as a transcription factor.
All of the E2F and DP family members have DNA binding activity, and have been 
shown to bind to promoters which contain the consensus E2F site TTTc/gGCGCg/c 
(Lees et al, 1993, Buck et al, 1995). Recently, the crystal structure of an E2F-4-DP- 
2-DNA complex has been resolved (Zheng et al, 1999). Analysis of this complex 
suggests that protein heterodimerisation is required before DNA binding and hence 
this paper increases our insight into the mechanism of DNA recognition by E2F.
37
Chapter 1.____________________________________________________Introduction
Although E2F and DP are able to form homo dimers that bind weakly to DNA, the 
heterodimer binds DNA much more efficiently (Krek et aL, 1993; Bandara et aL, 
1994). In vitro studies have shown that different heterodimer complexes 
preferentially bind specific E2F sequences within the promoters of E2F regulated 
genes, implying that the sequence within a promoter may specify its role in 
transcriptional regulation (Tao et al, 1997). These authors showed that E2F, DP and 
pRb proteins are all capable of influencing the choice of promoter sites, an 
observation which suggests that architectural attributes of the heterodimer/pocket 
protein complexes play a role in the regulation of E2F dependent promoters. 
Although these studies give us an interesting insight into potential mechanisms 
underlying the diverse effects of different E2Fs, further work is required to determine 
the relationship to promoter activation by individual E2Fs.
Much of the data on E2F transcription compiled to date relies on in vitro 
experiments, which may not exactly mimic the situation in vivo. Presently however, 
our ability to look at physiological promoter situations is restricted by the techniques 
available. One technique, which does allow us to look at these physiological 
situations, is described by Takahashi et al (2000). In this study, the authors used a 
cross-linking approach in synchronised living cells in order to examine the E2F and 
pocket protein presence on promoters (Takahashi et al., 2000).
It was found that promoter repression in quiescent cells is associated with pI30-E2F- 
4 recruitment and low histone acétylation, while in late G l E2F-1 and E2F-3
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replaced E2F-4 and histones became acetylated (Takahashi et aL, 2000). The authors 
propose a model in which E2F-4 may function on certain promoters as a dedicated 
repressor in GO and G l, then in late G l and S-phase E2F-4 is replaced by E2Fs 1 and 
3. In this situation, inhibition of one E2F may lead on to binding of another and 
individual E2Fs may play a role in distinguishing the timing of gene expression 
(Takahashi et aL, 2000).
E2F has been shown to be important for the regulation of a number of genes involved 
in cell cycle control {cyclin A, e2fl,), DNA replication {dhfr, replication protein a 
(Kalma et aL, 2001)) and apoptosis (Bates et aL, 1998), apaf-1 (Moroni et aL,
2001)) (Table 1.1, adapted from Helin 1998). More recent technology, exploring the 
use of micro anays has revealed a large number of genes to be regulated by E2Fsl-3 
(Muller et aL, 2001). Bioinformatics has also been used as a tool to identify new E2F 
target genes; a computer program which identified binding sites for members of the 
E2F family was used to find the promoters of genes containing an E2F binding site 
(Kel et aL, 2001). The genes so far identified are implicated in a wide range of 
cellular processes including differentiation and development, and these studies 
further highlight the broadening importance of the E2F pathway in cell cycle control 
and determination of cell fate.
Formation of the E2F-DP heterodimer is important for transcription, as E2F-1 and 
DP-1 together are able to tran^activate exogenous reporter genes much more 
efficiently than E2F-1 alone (Krek et aL, 1993; Bandara et aL, 1994). It is widely 
accepted that the E2F family members 1-5 have overlapping abilities to form
39
Table 1.1 Genes regulated by E2F.
Table showing some genes involved in cell cycle control and DNA synthesis 
which are regulated by E2F binding to sites within their promoter regions.
Adapted from Helin (1998), and including data from:(Ohtani et al., 1995,
Schulze et al., 1995, Irwin et al., 2000, Muller 2001)). Recent data from Moroni et 
a/.,(2001) increases greatly the number and variety of genes regulated by E2F.
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Gene Role in Cell Cycle
cyclin A 
cyclin E 
cyclin D 
e2f-l 
e2f~2 
c2f-3 
e2f-4 
e2f-5 
DNA polymerase a  
thymidine kinase 
dihydrofolate reductase 
PCNA
p2lWAFl/CIPl
pl4/pl9^^^ 
topoisomerasel 
mcm 
cdc6 
cdc2 
cdk2 
cdc25A 
cdc25C 
orc-1 
p l0 7 ~  
pRb 
c-myc ~
N~myc 
B~myb _
DP-1 
p73 
apaf-1
Act with a cdk partner to phosphorylate 
other cellular proteins, eg, pRb, DP-1
Family of DNA binding, site 
specific transcription factors.
Have roles in cellular proliferation
Involved in DNA replication
Proliferating Cell Nuclear Antigen 
Cyclin dependant kinase inhibitor (CDI) 
Regulators of tumour suppressor pathways 
DNA supercoiling 
Involved in DNA synthesis
Mediate phosphorylation of cell cycle 
proteins in partnership with cyclins
Involved in DNA replication 
Pocket protein family members.
Regulators of E2F transcription.
Involved in cell proliferation
Heterodimeric partner of E2F.
Member of the p53 family of transcription 
factors. Involved in apoptosis.
Apoptosis causing factor_____________
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activating complexes and repressive complexes, depending on cellular conditions. 
Further support for this comes from studies in Drosophila melanogaster, where 
identification of dE2F2 showed that dE2Fl acts as an activator while dE2F2 acts as a 
repressor (Frolov et aL, 2001). An interesting in vitro study however has shown that 
an E2F-4/DP-1 complex which is repressing one consensus promoter site in an in 
vitro CASTing assay, a repetitive immuno-precipitation and PCR procedure, is able 
to activate on another, different E2F site. This suggests that the DNA composition of 
promoter sites rather than transcription factors can determine whether activation or 
repression occurs (Tao et al, 1997).
A novel E2F site has been identified in the cyclin E promoter, termed CREM (Cyclin 
E Repressor Module). It consists of a variant E2F binding site and upstream A/T rich 
region. This promoter region is able to delay the expression of cyclin E until Gl 
phase by preferentially binding a high molecular weight complex called, CERC, 
(Cyclin E Repressor Complex) consisting of E2F, DP, a pocket protein and an as yet 
unidentified number of low molecular weight components (Le Cam et al, 1999). 
CERC2 has recently been identified as binding to this region and having a TSA- 
sensitive histone deacetylase activity (Polanowska et aL, 2001). These data indicate 
that the cell-cycle dependent control of the cyclin E promoter is embroiled in 
acétylation pathways via the CREM-like E2F element (Polanowska et aL, 2001).
Interestingly, it has been shown that E2F-1 levels are upregulated in response to UV 
and y-irradiation, and that in these cases the E2F-1 DNA binding activity is up- 
regulated (Hofferer et aL, 1999). This indicates a role for E2E-1 in the DNA damage
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pathway, particularly as it is involved in transactivating many genes which are 
required for DNA replication and repair, such as dhfr, mcm and thymidine kinase 
(Helin 1998).
Méthylation is a process by which methyl groups are attached to cytosine residues in 
DNA. The promoter regions of many cancer-associated genes are methylated and 
transcriptionally silenced (Baylin and Herman, 2000), Studies on synthetic DNA 
segments have shown that none of the E2F family members are able to bind, or 
transmiivdlQ,, the methylated dhfr, e2f-l and cdc2 promoters, while all family 
members except E2F-1 are able to bind and rra/i^activate the c-myc and c-myb 
promoters (Campanero et al, 2000). These data suggest a role for méthylation in the 
regulation of the transcription of E2F target genes by E2F-1.
1.1.11. E2F Co-activators.
Many molecules have been identified which act as co-activators, proteins which 
enhance the transcriptional activity of some transcription factors by bridging their 
interactions with other transcriptional components. E2F-1 transcription, and 
apoptosis can be enhanced by the co-activator protein p300 (Lee et al, 1998). A 
p300 binding protein involved in nucleosome assembly (NAP) has also been shown 
to augment E2F-1 transcriptional activity, possibly through its interaction with p300 
(Shikama et al, 2000), These data suggest that E2F may exist in a large multi-protein 
complex within the cell and regulate transcription through a variety of different 
mechanisms.
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1.1.12. Co-operation
Another DNA binding site specific transcription factor, Sp-1 has been shown to 
interact directly with E2F-1 and together E2F-1 and Sp-1 act synergistically in 
activation of dhfr gene transcription (Lin et al, 1996). Interestingly the cdk inhibitor 
p2 j^ cipi/wAFi^  a protein which blocks CDK activities upstream of pRb, to keep pRb in 
its hypophosphorylated form and preventing the release of transcriptionally active 
E2F has been shown to regulate E2F-1 in a non-pRb dependent fashion. is
able to bind directly to both E2F-1 and DP-1 and this binding abrogates the 
transcriptionally repressive effect of both in a reporter assay system in
cells and in an in vitro transcription assay (Delavaine and La Thangue, 1999).
1.1.13. Regulators of E2F activity.
Recently some cellular proteins other than members of the pocket protein family 
have been identified that suppress E2F-1 transcriptional activity. Pur a, a sequence 
specific single stranded DNA binding protein which has been implicated in both 
transcriptional regulation and DNA replication has been shown to bind to E2F-1 and 
decrease its binding to DNA and the transcriptional activation of the dhfr promoter 
(Darbinian et al, 1999). NPCD-1 a neural factor involved in the control of 
proliferation and differentiation binds to the hetero-dimerisation domain of both E2F- 
1 and DP-1 and is able to also reduce DNA binding and transcriptional activation of 
E2F target genes, through disruption of the heterodimeric complex (Sansal et al,
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2000). This suggests that the role of NPCD-1 in proliferation and differentiation may 
be through the E2F interaction.
Another protein which has been described as being able to down-regulate E2F 
transcription is p202. p202 is an interferon inducible murine protein which can bind 
to pRb, and whose over-expression inhibits proliferation (Choubey et al., 1996). 
p202 can inhibit E2F stimulated transcription of both exogenous reporter genes and 
endogenous genes, in a pRb independent manner (Choubey et ah, 1996).
Recently, E2F-1 activity has been shown to be inhibited by the Rep78 protein of 
Adeno-associated virus (AAV), a virus which inhibits the transforming potentials of 
DNA tumour viruses (Batchu et al., 2001). Rep78 binds to E2F-1 to stabilise the 
pRb-E2F-l complex, and also binds directly to the E2F-1 promoter and down- 
regulate s adenovirus induced transcription (Batchu et al., 2001). This paper outlines 
an important molecular mechanism for the anti-oncogenic property of AAV Rep78.
1.1.14 E2F in Proliferation
Knock-out mouse models have provided us with an insight into the importance of the 
individual E2F family members in proliferation. It has been shown through a variety 
of studies that some E2F family members are essential for development and cell 
cycle regulation, while others are dispensable for these but still exhibit some defects. 
Over-expression of E2F-1 promotes cell cycle progression and S phase entry, and 
quiescent cells can be driven into S phase by the introduction of E2F-1 (Johnson et
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al., 1993). Over-expression of cyclinE-cdk2 can also induce S-phase when over­
expressed in quiescent cells and together E2F-1 and cyclin E/cdk2 can collaborate to 
induce S-phase progression (Leone et al., 1999). Interestingly, in this study, 
inhibition of cyclinE-cdk2 blocks S-phase progression in normal, but not in rb~‘~ cells 
implying an important role for cyclinE/cdk2 in the regulation of cell cycle control. In 
contrast to these observations, over-expression of dominant-negative DP-1, which 
retains E2F binding but lacks DNA binding activity, creates inactive E2F-1 
complexes, which are unable to bind DNA and can cause cell cycle anest in G1 (Wu 
et al., 1996). Mitogen stimulated cells deprived of E2F activity can still maintain 
physiologically relevant levels of cyclin E protein, through ectopic expression of the 
transcription factor Myc (Santoni-Rugiu et ah, 2000). These data indicate the 
involvement of a parallel pathway to E2F/Rb in the G 1-S-phase transition, and 
implies that cyclin E is particularly important for S phase progression.
Studies on Drosophila have further highlighted the importance of E2F, DP and 
Cyclin E in proliferation. dDP and dE2F are necessary for viability and mutations 
cause lethality at late larval/pupal stage (Royzman et al., 1997). Mutations in dDP 
and dE2F distinguish Gl-S progression from an associated transcriptional program 
and show that dcyclin E is essential for S phase late in Drosophila development 
(Royzman et al., 1997). Mutations in dE2F can compromise DNA replication by 
eliminating transcriptional activation of several essential replication factors at Gl-S 
phase (Duronio et al., 1998). Mutations in dDPl however, cause a block of cyclin E 
transcription indicating that, while lack of certain replication factors as a result of
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mutations in either dE2F or dDP can cause graded effects on replication, cyclin E is 
required for an “all or nothing” S phase transition (Duronio et al., 1998).
Studies on transgenic mice that over-express E2F-1 have shown that E2F-1 over­
expression leads to a lack of hair growth, probably due to hyper-proliferation in the 
epidermis (Peirce et al., 1998b). Over-expression of E2F-1 has also been implicated 
in liver dysplasia (Conner et al, 2000).
Surprisingly, the E2F-1 knockout mouse is viable and fertile, although these mice do 
develop a broad and unusual range of tumours, and experience testicular atrophy and 
endocrine gland dysplasia (Yamasaki et al, 1996). These observations highlight the 
role of E2F-1 as a tumour suppressor and also suggest a role for E2F-1 in the 
development of some tissue lineages. The fact that E2F-1 mice are viable suggests 
that some of its roles can be compensated for by other family members. Indeed, in 
e2f-l'' mouse embryonic fibroblasts a delayed S-phase is observed, suggesting an 
important, but not unique role for E2F-1 in progression through the restriction point. 
(Wang et al, 1998). E2F-1 has also been shown to have oncogenic properties 
(Johnson et al, 1994), and together with DP-1 is able to co-operate with activated 
Ras to form transformed foci and tumours in nude mice.
Embryos mutant for both E2F-1 and pRb demonstrate a significant suppression of 
apoptosis and impaired S phase entry (Tsai et a l, 1998). rb''' embryos die at E14.5 
and mutation of e2f-l in these animals resulted in an extended survival (Tsai et a l, 
1998). Loss of E2F-1 in rb'^ * mice leads to a reduction in tumours and increased life­
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span as a result of E2F-1 interference with the apoptosis observed in the animals 
(Yamasald et a l, 1998). These data indicate that E2F-1 regulation is not the sole 
function of pRb in development, and that mutation of e2f-l is not sufficient to rescue 
the lethality caused by the rb'^ ' mutation (Tsai et al., 1998; Yamasaki et al., 1998).
Interestingly, E2F-3 has been shown to be critical for full cell viability. e2f-J'' MEFs 
demonstrate a proliferation defect, and a down-regulation of the expression of E2F 
responsive genes. However, the loss of E2F-3 does not affect the regulation of other 
family members and re-introduction of exogenous E2F-3 or over-expression of E2F- 
1 is able to compensate for this loss (Humbert et al, 2000a). Both E2F-1 and E2F-3 
activity is cell cycle regulated, mostly disappearing by G2. E2F-3 activity has been 
shown to be required for S-phase entry, as well as E2F-1 and immuno-depletion 
experiments have shown that lack of E2F-3 inhibits S-phase entry in proliferating 
cells. More recent studies demonstrated that E2F-3 is able to partially alleviate some 
of the defects in rb '' embryos, including inappropriate proliferation in the developing 
lens and CNS. It has been shown that rb'''\e2f3''' mutant mice are more viable than rb' 
'', although noticeably they are smaller and embryonic lethal, probably due to cardiac 
failure (Zeibold et al, 2001). Interestingly, these embryos showed the presence of the 
developmental defects which had previously been observed in viable late stage rb''' 
',e2fï'' embryos (Tsai et a l, 1998).
More recent studies have centred on the roles of E2F-4 and E2F-5 in proliferation. 
E2F-4 is the most abundant member of the family found in cultured cells and E2F-4 
knock out mice die within the first few weeks of life. The offspring from these
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animals suffer from a number of developmental defects including; haematopoietic 
lineage development and defects in gut epithelium development (Rempel et al, 
2000). Also, a defect in erythrocyte maturation, craniofacial defects and an increased 
susceptibility to bacterial infections, perhaps as a direct result of these developmental 
defects, is observed (Humbert et al, 2000b). The E2F-5 knock-out mouse embryos 
develop normally but new-born mice develop nonobstructive hydrocephalus 
(Lindeman et a l, 1998). These mice excrete excessive cerebrospinal fluid and cell 
cycle Idnetics were not found to be disturbed in MEFs from these animals. This 
indicates a role for E2F-5 in the secretory behaviour of a differentiated neural tissue 
(Lindeman et a l, 1998).
The double knock out e2f-4'\e2f-5''' mouse is embryonic lethal, suggesting an 
overlapping essential role for the two proteins in development. MEFs from these 
mice are able to proliferate normally, but are unable to undergo cell cycle arrest in 
response to p i I n t r o d u c t i o n  of exogenous E2F-4 or E2F-5 into these cells is 
able to reintroduce the p l6  response, however E2F-1 cannot compensate for loss of 
E2F4 and 5, indicating that the two sub-families have different functions (Gaubatz et 
al, 2000). These data suggest that E2F-4 and 5 make an essential contribution to 
pocket protein dependant G1 arrest, and together with the E2F-1 and E2F-3 results 
further support the model of different roles for the E2F family members in 
development. The DP-1 knockout mouse has also been shown to be embryonic 
lethal, possibly due to a lack of proliferation in developing cells (Yamasald., 2001).
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Although the main role for E2F is thought to be in regulation of the Gl-S phase 
transition, E2F has also been identified as being involved in the co-ordination and 
timing of S-phase entry. B2F activity during S phase was shown to be required for 
the accumulation of the mitotic regulatory cyclin, cyclinB, and also to keep the 
anaphase promoting complex (AFC) molecule cdhl phosphorylated in order to 
prevent degradation of important mitotic regulatory factors (Lukas., et al. 1999). The 
AFC is a multi-protein complex, which has ubiquitin ligase activity and is essential 
for mitotic cyclin proteolysis (Lukas et al., 1999).
1.1.15 The Role of E2F in Apoptosis.
Apoptosis is the process of programmed cell death. Cells are able to self-destruct in 
response to specific signals from the cellular proteins. In response to specific, 
intracellular signals, nuclear condensation occurs, followed by fragmentation and 
destruction of nuclear DNA, loss of cell volume and membrane integrity (Bates and 
Vousden 1999). Two main apoptotic pathways have been identified, and a variety of 
diverse extra and intra-cellular signals have been shown to be able to regulate cell 
death (Figure 1.5).
The first pathway is mediated by death receptors and occurs as a response to ligand 
binding to receptors, such as members of the TNFR family. TNF receptors bind 
ligands such as TNFa, and activation of these receptors leads to a number of 
responses including apoptosis and induction of anti-apoptotic signals such as NF-kB 
(Fhillips et al., 1999). Ligand binding stimulates recruitment of a group of proteases
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called caspases, which act as signal transducers and death effectors (Guo and Hay,
1999). Pro-caspases cleave down-stream caspases, and caspases are thought to have a 
major role in cleaving cellular substrates that lead to cell death (Guo and Hay, 1999).
The second apoptotic pathway works through different caspase molecules, and a 
protein termed Apaf-1, which can bind and activate caspase-9 in a cytochrome C 
dependant manner. Cytochrome C is released from the mitochondria in response to 
intracellular signals and can be regulated by the Bax/Bcl2 family of apoptotic factors 
that includes Bax, Bcl2 and Bid (Bates and Vousden, 1999; Ming and Hay, 1999) 
(Figure 1.5).
Cellular growth and development involves competing pathways of proliferation and 
apoptosis. The key to effective tumour therapies may well be found through 
understanding the link, and switch between apoptosis and cellular proliferation. 
Transcription factors such as p53 and c-myc are inducers of apoptosis (Ming and 
Hay, 1999), particularly p53 which has been shown to activate the downstream 
apoptosis promoting factor Bax. Interestingly the p53 apoptotic effect can be 
overcome by over-expression of its negative regulator, MDM2 (Chen et al, 1996).
The E2F family of transcription factors are well characterised regulators of cellular 
proliferation and have also been found to have important roles in apoptosis. 
Induction of E2F-1 in quiescent fibroblasts leads to S-phase entry followed by 
apoptosis (Qin et al, 1994). The importance of E2F-1 in apoptosis is highlighted by 
the observation that e2f-l'' mice exhibit a defect in T lymphocyte development due to
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Figure 1.5. Apoptosis pathways.
Two main apoptotic pathways have been identified, and a variety of diverse extra 
and intra-cellular signals have been shown to be able to regulate cell death. In the 
death receptor pathway cell surface receptors are activated by ligand binding and 
caspases become activated. This leads to cytochrome C release and the subsequent 
activation of effector caspases which instigate apoptosis. Intracellular death 
signals also lead to release of cytochrome C through activation of the Bax and 
Bcl2 family members and the apoptotic factor Apaf-1.
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a maturation stage specific defect in thymocyte apoptosis (Field et al, 1996). 
Tumour cell proliferation has also been shown to be impaired in the absence of E2F- 
1, suggesting that E2F-1 is required for tumour development (Pan et al., 1998).
E2F-1 promotes apoptosis in both p53 dependent and independent manners (Wu and 
Levine, 1994; Lee, 1998). Initially, various studies concluded that E2F-1 is the only 
family member with this apoptotic inducing activity (DeGregori et al., 1997, Wang 
et al, 2000), however it has been shown that E2F-4 is also able to induce apoptosis 
through a caspase dependant mechanism, independently of E2F-1 (Chang et al, 
2000). Recently, E2F-2 and E2F-3 have also been described as having some 
apoptotic properties (Moroni et al, 2001; Zeibold et al, 2001).
The ability of E2F-1 to induce apoptosis has been shown to be separable from it’s 
ability to promote DNA synthesis. In a study which shows that the DNA binding 
domain, but not the ?rarî5activation domain of E2F-1 is required for apoptosis (Hsieh 
et al, 1997; Phillips et a l, 1997). Analysis of E2F mutants indicates that although 
DNA-binding is required, transcriptional activation is not necessary for the induction 
of apoptosis by E2F-1, suggesting that it may be mediated through alleviation of 
E2F-dependent transcriptional repression (Phillips et a l, 1997).
This E2F-1 induced apoptosis can be overcome by expression of Bcl2, an anti- 
apoptotic factor, suggesting that in part, the caspase dependent pathway may be 
involved. Interestingly, it has been shown that over-expression of pRb is also able to 
overcome E2F-1 mediated apoptosis. However this is probably not due to direct
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suppression of the E2F ^ran.sactivation domain, due to the TAD not being required 
for the apoptotic phenotype (Hsieh et al, 1997, Phillips et a l, 1997). MDM2, the 
oncogene that regulates p53 activity, also binds to E2F-1 (Martin et al .,1995) and 
inhibits the apoptosis induced by E2F-1 (Loughran and La Thangue, 2000), 
indicating a role for MDM2 as a regulator of the E2F pathway.
An increase in the levels of p53 protein has been observed in response to apoptotic 
induction by E2F-1 (Kowalik et al, 1998). This information, together with the 
observation that a deficiency of E2F-1 leads to a decrease in the amount of p53 
dependent apoptosis, indicates that E2F-1 may act upstream of p53 in the apoptotic 
response (Pan et al, 1998). It has also been suggested that the induction of the 
p 14/19*^ tumour suppressor is important for stabilisation of p53 and it’s ability to 
induce apoptosis (Irwin et al, 2000). E2F-1 has been shown to induce apoptosis 
through a death receptor mechanism, through the inhibition of anti-apoptotic 
pathways, partially due to the down-regulation of TRAF2 (Philips et al, 1999). This 
down-regulation of TRAF2 is due to increased protein degradation in response to 
E2F activity, and this TRAF2 down-regulation inhibits normal induction of anti- 
apoptotic signals such as NF-kB (Phillips et a l, 1999).
More recent studies have highlighted a role for p73, the p53 homologue, in E2F-1 
mediated apoptosis (Irwin et al, 2000, Lissy et al, 2000). E2F-1 is able to 
rran^activate p73, and induce apoptosis in the absence of p53. TCR-activation- 
induced cell death, an apoptotic response in peripheral T cells is blocked by 
expression of a dominant negative E2F-1, or p73 protein and from this the authors
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conclude that TCR-activation-induced cell death is dependent on both E2F-1 and p73 
activities (Lissy et al, 2001).
Interestingly, recent studies have identified a role for E2F-3 in apoptosis. rb''\e2f3''' 
embryos, show a rescue of the apoptosis found in rb'' embryos, suggesting that 
endogenous E2F-3 makes a major contribution to the apoptosis resulting from the 
loss of the pRb tumour suppressor (Zeibold et al, 2001). It may be possible that 
E2F-3 acts as an upstream regulator of E2F-1, contributing indirectly to the induction 
of apoptosis in vivo. However, the effect of E2F-1 is much less than that of E2F-3. It 
may be more likely that both E2F-1 and E2F-3 contribute to the activation of 
apoptosis, or that the two family members have overlapping functions.
Recently, a model has been proposed by Moroni et al, (2001) for E2F mediated p53 
independent apoptosis. In this study the authors show that the Apaf-1 gene is a direct 
transcriptional target of E2F (Moroni et al, 2001). E2F-1 is able to preferentially 
activate Apaf-1 over E2F-2 or E2F-3 and this provides a direct link between 
deregulation of the Rb pathway and apoptosis (Moroni et a l, 2001). This model 
proposes a mechanism by which E2F-1 directly up-regulates pI4^^^, p73 and Apaf-1, 
leading to transcriptional activation of Bax via p53 and p73 and at the same time, 
accumulation of Apaf-1 and subsequent release of cytochrome C (Moroni et al, 
2001).
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1.1.16 Post-translational modifications.
Most cellular proteins are regulated by a combination of a number of post- 
translational mechanisms including, phosphorylation, acétylation, méthylation and 
ubiquitination. It is of particular importance that cell cycle protein levels are tightly 
regulated to allow for specific cellular transitions and to establish a base for the next 
round of the cell cycle. Many of these cellular mechanisms ai*e important for 
regulation of the E2Fs, particularly E2F-1, which has been shown to undergo a 
number of post-translational modifications.
1.1.17 Cell Cycle Regulation.
E2F activity is regulated by cell-cycle dependent changes in sub-cellular localisation 
of the E2F and DP sub-units (Verona et al, 1997). In cycling cells the majority of 
E2F-pl07, E2F-pl30 and free E2F complexes are found in the cytoplasm, while 
E2F-pRb complexes are found mainly in the nucleus. These nuclear E2F~pRb 
complexes are found to be high in G1 and then decrease as the cell cycle progresses. 
The induction of S-phase entry by E2F family members is dependent on their nuclear 
localisation (Muller et al, 1997). Using chimeric proteins it was shown that the N- 
terminus of E2F-1 was sufficient to induce nuclear accumulation and S-phase entry. 
Under these conditions chimeric E2F-4 was able to behave as E2F-1 (Muller et a l, 
1997). The NES in E2Fs 1,2 and 3 is important for their nuclear accumulation, 
however E2F-4 and E2F-5 depend on the DP or pocket proteins to bind in the 
cytoplasm and take them into the nucleus (de la Luna et al, 1996). E2F-1 binds
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MDM2 and localises to the nucleus. However MDM2 targeted degradation of the 
E2F and DP sub-units probably occurs in the cytoplasm (Loughran and La Thangue, 
2000).
1.1.18 Phosphorylation.
The Rb protein and E2F are both regulated by various signalling cascades, including 
the cdk, stress induced Idnases JNK-1 and p38 Idnase (Wang et ah, 1999). JNK-1 
inhibits E2F-1 activity by phosphorylation and reducing its DNA binding affinity 
while divergently, p38 reverses pRb repression of E2F through pRb phosphorylation 
(Wang et al., 1999). E2F-1 activity is regulated by the direct binding of cyclinA/cdk2 
to the N terminus of E2F-1 (Krek et al., 1994; Xu et al., 1994). This cyclinA/cdk2 
phosphorylation occurs in vitro and in vivo and inhibits the DNA binding activity of 
the E2F-1/DP-1 heterodimer. Interestingly phosphorylation of DP-1 by cyclin A 
bound to E2F-1 also results in the elimination of E2F DNA binding. The importance 
of this phosphorylation by cyclin A is highlighted by the fact that disruption of cyclin 
A-E2F binding resulted in an S-phase delay followed by either regrowth or apoptosis 
(Krek et al, 1995), indicating an important role for E2F-1 phosphorylation in S phase 
entry. Recent studies have shown that E2F-1 is selectively induced in response to 
DNA damage and this induction is mediated by ATM-dependent phosphorylation 
(Lin et al., 2001). The amino terminus of E2F-1 contains a site for ATM/ATR 
phosphorylation and mutational studies showed that this site is required for the 
observed DNA-damaged induced apoptosis in mouse thymocytes (Lin et al., 2001).
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Studies in yeast showed that phosphorylation of E2F-1 is important for it’s 
interactions with other proteins, including pRb (Fagan et al, 1994). Phosphopeptide 
mapping experiments show that E2F-1 is phosphorylated by a number of as yet 
unidentified kinases, and it is likely that E2F is a focal point for multiple signalling 
pathways that affect growth and cell cycle regulated transcription (McLeod, 1999).
E2F-5 has also been shown to be phosphorylated, by the cyclinE/cdk2 complex 
(Morris et al ., 2000). This phosphorylation was also shown to stimulate its binding 
to the co-activator protein p300. As E2F-5 is known to rraii^activate the cyclin E 
gene, this indicates an auto-regulatory mechanism by which E2F transcription 
switches on cyclin E expression and in turn this phosphorylates E2F-5 to augment 
transcriptional activation.
1.1.19 Acétylation.
E2F-1 has been shown to be acetylated both in vitro and in vivo, by the 
acetyltransferase p300, and much more efficiently by the p300/CBP associated 
enzyme P/CAF (Martinez-Balbas et al., 2000). The acétylation of lysine residues 
within E2F-1 was shown to increase E2F-1 DNA binding, transcriptional activation 
and protein stability, although the observed increase in rra/i.?activation could be a 
result of either increased DNA binding or protein stability (Martinez-Balbas et al,
2000). The acetylated residues have been mapped mainly to the DNA binding 
domain and although are not directly involved in binding may allow a 
conformational change in the E2F/DNA complex, which would allow increased
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fra/inactivation. Interestingly, the acetylated residues are only conserved in the 
‘activating’ E2F family members suggesting that this novel regulatory mechanism 
may have physiological implications for activation of E2F target genes (Martinez- 
Balbas et al, 2000).
Acétylation has recently been identified as a new type of modification and level of 
control in pRb function (Chan et al., 2001). Adenovirus ElA, which binds p300/CBP 
through an amino-terminal transformation-sensitive domain, stimulates the 
acétylation of pRb by recruiting p300 and pRb into a multi-protein complex (Chan et 
al., 2001). Furthermore, the acétylation of pRb is cell cycle regulated and hinders the 
phosphorylation of pRb by cyclin dependent Idnases. These data define a new level 
of cell cycle control mediated by HAT activity and identifies a new cellular target for 
acétylation (Chan et al., 2001).
1.1.20 Degradation
E2F-1 and E2F-4 have been observed to be unstable proteins and studies have shown 
that they are degraded by the ubiquitin-proteasome pathway (Hateboer et al, 1996). 
E2F stability is mediated by a C terminal region close to the pocket protein binding 
domain, and E2F bound pocket protein complexes are found to be stable. 
Interestingly, the E lA  virus transforming protein E6 also increases stability of the 
E2F, a result which would not have been expected as these proteins disrupt the E2F- 
pocket protein interaction (Hateboer et al., 1996). Viral proteins may have evolved
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this mechanism to ensure S-phase entry and replication of the virus infected cell, 
while simultaneously preventing apoptosis.
Further studies have identified the SCF/SKP2 complex as being specifically involved 
in the cell-cycle dependent destruction of E2F-1. E2F-1 is rapidly degraded in late 
S/G2 phase, around the same time as the SCF component p45^^^ accumulates (Marti 
et al.,1999). Binding of p45^ '^ ^^  to the N terminal of E2F-1, in a region distinct from 
cyclin A binding was required for ubiquitination and targetting for degradation and 
implies a model in which the SCF complex regulates the destruction of E2F-1 
towards the end of S-phase while phosphorylation of E2F-1 by cyclin A is still 
required to regulate the duration of S-phase (Marti et al, 1999).
Both the E2F-1 and DP-1 sub units have also been shown to be down-regulated by 
the MDM2 protein (Loughran and La Thangue 2000). MDM2 has been described as 
having E3-ligase activity, suggesting that multiple E3-ligases may be involved in 
degradation of the E2F components (Honda et al., 1997). Interestingly recent work 
has shown E2F-1, 2 and 3, levels are also down-regulated by over-expression of the 
pl9^^^ tumour suppressor protein (Martelli et al., 2001), indicating a broader range of 
regulation involving regulatory feedback loops and cross-talk between pathways. 
DP-1 sub-units which are unable to bind E2F end up poly-ubiquitinated in the 
cytoplasm, and degradation of these peptides is required for cell cycle progression, 
indicating that DP-1 is probably also targeted for degradation in vivo (Magae et al., 
1999).
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1.2 The d 53 Pathway
1.2.1 Introduction
A key regulator of cellular growth is the tumour suppressor p53. The gross over­
expression of mutated forms of p53 witnessed in a variety of tumours regardless of 
the transforming agent and cell type underlies the vital importance of p53 in genome 
stability (Rotter et aL, 1981; Rotter et al., 1983). The p53 pathway is frequently 
targeted for de-regulation in human cancer and p53 itself is the most commonly 
mutated gene in tumour cells (Friend, 1994). The high frequency of p53 mutations 
observed in human tumours clearly helps define p53 as the “guardian of the genome” 
(Friend, 1994)
1.2.2 p 53
p53 is a sequence specific transcription factor that forms tetramers and binds to 
DNA (Fields and Jang 1990). p53 has the ability to both activate and repress the 
target promoters of a large number of cellular genes (Budde and Grummt, 1998; 
Murphy et al., 1999; Yu gf al., 1999; Woods and Vousden, 2001). Many of the 
genes targeted by p53 are cell cycle anest, DNA repair or apoptotic associated genes 
(Momand et al., 2000 ; Woods and Vousden, 2001). Normally, p53 levels in the cell 
are low, however in response to most stress situations such as DNA damage, or heat 
shock, p53 levels in the cell increase (Momand et al., 2000). This increase in p53 
levels is due to a combination of an increase in p53 translation and its extended half- 
life (Momand et al., 2000).
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p53 is a negative regulator of cellular proliferation and transformation. p53 is a 
phosphorylated protein and can be targeted by many cellular kinases, however 
phosphorylation of p53 is not essential for DNA-damage induced stabilisation of p53 
(Ashcroft et al., 1999). DNA damage leads to the stabilisation of p53, increased 
transcriptional activity, followed by cell cycle arrest through induction of the CDKIs 
such as and DNA repair (Prives 1998). When DNA damage is beyond
repair, p53 initiates apoptosis through activation of apoptotic inducing genes, 
including apaf-1 (Moroni et al., 2001) and Bax (Miyashita et al., 1994).
p53 is a nuclear protein and contains three nuclear localisation signals in the C- 
terminal region. Mutation of these signals leads to p53 accumulation in the 
cytoplasm and loss of p53 growth-inhibitory activities (Woods and Vousden, 2001). 
p53 also contains a nuclear export signal within its tetramerization domain (Stommel 
et al., 1999). Mutation of residues in the NES prevents p53 export and hampered 
tetramer formation (Stommel et al., 1999).
1.2.3 MDM2
MDM2 was first identified as an amplified gene in a transformed mouse 3T3 cell line 
(Cahilly-Snyder et al, 1987). Since then it has been shown that the human form of 
MDM2 is overexpressed in a number of human tumours, particularly sarcomas, 
leukaemias, breast carcinomas and malignant gliomas (Ladanyi, et al, 1993; Leach 
et al, 1993; Sheikh et al, 1993; Cordon-Cardo et al, 1994). MDM2 has been shown
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to exist as alternatively spliced transcripts in tumour cells (Sigalis et al., 1996). These 
alternatively spliced mdm2 proteins show loss of p53 binding, consistent with partial 
deletion of sequences encoding the p53 binding domain (Sigalas et al., 1996).
A high proportion of transgenic mice overexpressing MDM2 develop breast tumours 
implying that deregulation of MDM2 is important for oncogenesis (Lundgren et al,
1997). MDM2 binds to and regulates a number of cell cycle regulatory proteins. Of 
particular interest, the transcriptional co-activator p300 (Grossman et a l, 1998), pRb 
(Xiao et al, 1995) and pl4'^^*'(Quelle et al, 1995).
MDMX is a homologue of MDM2, and is structurally almost identical (Jackson and 
Berberich, 2000). However, MDMX cannot substitute for MDM2 in early embryonic 
development (Shvarts et a l, 1996). MDMX can form stable heterodimers with 
MDM2 through its ring finger domain and is also able to associate with p53 
(Tanimura et a l, 1999), Although MDMX is able to associate with p53, it is unable 
to facilitate nuclear export or induce p53 degradation (Jackson and Berberich, 2000). 
However, expression of MDMX can reverse MDM2 mediated degradation of p53 
whilst maintaining suppression of p53 fran^activation (Jackson and Berberich, 2000).
1.2.4 The MDM2-P53 Feedback loop
MDM2 is involved in a negative feedback loop with p53 (Wu et al, 1993). p53 
upregulates MDM2 expression and in turn, MDM2 can export p53 from the nucleus, 
and target it for ubiquitin mediated degradation (Haupt, et al, 1997; Honda et al.
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1997). MDM2 binds directly to the p53 fra/i^activation domain and downregulates 
p53 dependent transcription and apoptosis (Haines et al, 1994). The functional 
relationship between MDM2 and p53 is dramatically illustrated by the finding that 
p53-null mice can completely rescue the early embryonic-lethal phenotype of 
MDM2 deficiency (Jones et a l, 1995), demonstrating that the p53-MDM2 pathway 
is essential in development.
1.2.5 P300-MDM2
Control of p53 turnover is critical to p53 function. Adenovirus E lA  binding to 
p300/CBP translates into enhanced p53 stability, implying that these co-activator 
proteins normally operate in p53 turnover control (Grossman et a l, 1998). Most 
endogenous MDM2 is bound to p300 in the cell, suggesting that at least one MDM2 
function operates on, or with p300 and specific interactions of both p53 and MDM2 
with the CH-1 region of p300 aie important steps in p53 turnover (Grossman et al,
1998). Elements of the p300 N terminal region, including the CH-1 region are 
homologous to HPV E6 protein, suggesting a role for p300-MDM2 complexes in p53 
degradation. Furthermore, these data taken together highlight a role for specific 
p300/CBP, CH-1, p53 and MDM2 interactions in the MDM2 mediated control of 
p53 abundance (Grossman et al, 1998). p300 also acts in an MDM2 negative 
feedback loop to regulate p53, and is required for mdm.2 induction by p53 and the 
subsequent inhibition of p53 stabilisation (Thomas and White, 1998). This p300 
dependent stabilisation of p53 also results in apoptosis (Thomas and White, 1998), 
hence, p300 regulation of mdm2 expression controls the apoptotic activity of p53.
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1.2.6 The pRb and p 53 relationship
There are numerous points of interaction between p53 and pRb mediated tumour 
suppression, some of which are mediated by E2F. Co-operation between the p53 and 
pRb pathways has been amply demonstrated. Classic examples involve the 
oncoproteins encoded by the DNA tumour viruses, which cancel pRb function to 
drive cells into S-phase and neutralise p53 to prevent host cell suicide. pRb loss 
induces E2F and p53 dependent apoptosis (Shen- 1998). pRb can regulate the 
stability and the apoptotic function of p53 via MDM2, and a pRb-MDM2-p53 
complex can exist in cells (Hsieh et al., 1999). pRb specifically rescues the p53 
apoptotic function but not the transcriptional activity of p53, so transactivation by 
p53 is not required for the apoptotic function of p53 (Hsieh et a l, 1999).The recent 
observation that both E2F and p53 can independently activate apaf-1, shows a further 
degree of cross talk between the two pathways (Moroni et al, 2001)
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1.3 The INK4a/ARF Tumour Suppressor.
1.3.1 Introduction
The INK4a/ARF locus is one of the most frequently mutated genes in human cancer, 
irrespective of the tumour type (Sharpless and DePhino, 1998). This unique genetic 
locus encodes two major tumour suppressor proteins, which is an inhibitor of
cyclin D-dependent kinases and so feeds into the pRb/E2F pathway, and pl4/pl9'^’^ , 
which regulates the p53 pathway through inhibition or regulation of MDM2 (Chin et 
al, 1998). As loss of cell cycle control through inactivation of the pRb and p53 
pathways appeals to be a vital step in the development of cancer cells, this places the 
INK4a/ARF locus and its two gene products at the nexus of these two growth 
controlling pathways.
1.3.2 The INK4a/ARF locus.
The INK4a/ARF locus is located at position p21 on the short arm of chromosome 9 
in humans (9p21), and the cognate loci on chromosome 4 in mouse and 5 in rat 
(Sharpless and DePhino, 1998; Stott et al, 1998). The locus extends over 
approximately 20Kb and the promoters for the two gene products are widely spaced 
(Robertson and Jones, 1998). The 9p21 position is a chromosomal hot spot, 
frequently subject to deletions and reaiTangements in a wide range of human cancers, 
including T cell acute lymphoblastic leukaemia, mesothelioma, bladder and 
nasopharyngeal carcinomas (Gardie et al, 1998; Yang et al, 2000).
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The ink4a larf' knock out mice exhibit a cancer prone phenotype, developing 
spontaneous tumours and have high sensitivity to carcinogenic treatments. 
Fibroblasts from these mice proliferate rapidly, have high colony forming efficiency 
and can be transformed by introduction of activated Ha-Ras (Serrano et al, 1996). 
Together, these results establish the INK4a/ARF locus as a bona fide tumour 
suppressor (Chin et al, 1998). Recent papers detailing the phenotype of the plb'^ '^ '^ 
knock-out mouse show that these p i m i c e  are more susceptible to tumours than 
wild-type littermates (Krimpenfort et a l, 2001; Sharpless et a l, 2001). However, the 
observed phenotype is mild compared to that of the ink4a larf~ locus knock out 
mice, indicating that although pl6^ '^^ '‘“ is a tumour suppressor gene, the strong 
phenotypes observed in the double knock-out mice was probably due to loss of arf 
(Krimpenfort et a l, 2001).
1.3.3 Genomic Organisation of the INK4A/ARF Locus
The INK4a/ARF locus has an interesting genomic organisation, in that two proteins 
are encoded in distinct reading frames within a common coding sequence. This is a 
common feature in bacteria and viruses but exceedingly rare in eukaryotes. Two 
transcripts, which are driven by distinct promoters that encode two functionally 
separate tumour suppressor proteins, are expressed from the INK4a/ARF locus, 
p^ i^NK4a (Quelle et al, 1995). Within the INK4a/ARF locus are four
exons, Eloc, E ip , E2 and E3. E la , E2 and E3 encode p l6 ’^ ’^'‘“ and E lp , E2, and E3 
encode pl4/pl9'^’^ . Splicing of exon ip  to exon 2 allows translation to continue in
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the -1 reading frame relative to resulting in the expression of the pl4/pl9^^
protein (Figure 1.6).
Both the pl6^ ^^ '*'' and pl4/pl9*^ promoters reside within CpG islands, which can be 
silenced by DNA méthylation (Robertson and Jones, 1998). CpG islands are regions 
rich in the CpG nucleotide which are often associated with genes and are normally 
kept un-methylated in cells. CpG islands are frequently associated with tumour- 
derived promoter silencing events, although the presence of Spl sites in both the 
INK4a and ARF promoters may allow the promoters to be retained in an 
unmethylated form and hence maintain the expression of both proteins under 
physiological conditions.
1.3.4 INK4a/ARF Expression
The TATA-less pl4/19^^’" promoter contains several potential consensus E2F sites, 
while the p i6’^ '^^ '^  promoter contains none. The pl4^^ promoter contains at least four 
potential negative strand E2F binding sites, two of which are high affinity and two 
are poor matches (Robertson and Jones, 1998). The pl9^^ promoter contains two 
high affinity E2F sites, one coded by the negative strand and one positive strand 
(Inoue et ah, 1999).
E2F is able to induce pl4/pl9'^'^ expression, and fran^activate the pl4^^ promoter 
(Bates et al, 1998; Robertson and Jones., 1998; Inoue et a l, 1999). Over-expression 
of E2F-1 induces pl4^^ mRNA expression in a non cell cycle regulated manner
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Figure 1.6 The lNK4a/ARF locus
Schematic diagram of the INK4a/ARF locus and the pathways its two gene 
products feed into, pl4/19^^^ targets p53 through its interaction with MDM2, 
while inhibits the activity of cdks. Other cellular proteins involved in the
INK4a/ARF pathways ai'e shown.
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(Bates et al, 1998; Inoue et al, 1999). Further studies showed that E2F-1 and E2F-2 
are able to increase pl9^^ mRNA levels, but not E2F-3, 4 or 5 (DeGregori et al,
1997). The induction of pl4^^ mRNA expression by E2F is paralleled by a marked 
increase in the levels of pl4^^ protein (Bates et al, 1998).
Neither pl9^^ nor p l6 ‘^ ’^'*“ are expressed during mouse embryonic development, but 
upon culture mouse fibroblasts begin to express both p l6 ‘'^ '^*“ and p i9'^ ’^ . The distinct 
spacial expression pattern of plb^^'^'^and pl4/pl9*'^ during both human and mouse 
development and ageing suggests that the transcriptional regulation of the two 
products differ. is only found to be expressed in a few tissues while pl9^^ is
more ubiquitously expressed. (Quelle et a l, 1995, Zindy et al, 1998).
In transformation assays, pl6'^'^‘‘“ and pl9^^ displayed both distinct activity profiles, 
and additive effects, which suggests that these proteins suppress neoplasia through 
separable but co-operative mechanisms of action. The action of pl9^^ in 
transformation has been shown to be p53 dependent (Pomerantz et al, 1998). 
Interestingly, data shows that efficient execution of an apoptotic response depends on 
the entire INK4a locus function. In knock out mouse lens studies, rb'^ ' animals display 
apoptosis, while rb''link4a' animals have abrogation of this response. Since pl6''^‘^"“ 
is presumed to be without effect when Rb is absent, the doubly null lenses can be 
taken as the equivalent of rb'''\pl9^^'’', and so these findings can explain how pI9^^ 
functions as a suppressor of neoplasia, through its capacity to enhance the p53- 
mediated elimination of inappropriately cycling cells in vivo (Pomerantz et al,
1998). In this model, as pI6^ *^^ '*" acts upstream of pRb and ARF responds to
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deregulated E2F, this effect most likely reflects an ARF, cell-cycle checkpoint 
function (SheiT and Weber, 2000).
1.3.5 nl6'™
pj^ iNK4a .g commonly mutated or deleted in human cancers, particularly in leukemia, 
melanomas and lymphomas (Ruas and Peters, 1998; Sharpless and DePhino, 1998) 
p^ giNK4a first identified as a CDK associated protein and inhibitor of CDK4 
activity (SeiTano et al, 1993). Inhibition of CDK4/6 leads to the 
hypophosphorylation of pRb which in turn represses E2F and blocks G1 progression 
(Figure. 1.7), and this arrest can be rescued by introduction of exogenous CDK4/6 
(Ruas and Peters, 1998). It has recently been shown that pI6^ '^ '^*“ cell cycle arrest is 
dependent on pRb, and either pl07 or p i30, Mutation of pRb alone is not sufficient 
for pl6™‘^'^ “-dependent cell cycle arrest (Bruce et al, 2000).
pl6i^^4“ levels do not fluctuate significantly during the cell cycle, and the lack of pl6 
and pRb mutations found in the same tumour together with the observation that rb 
negative cells display high levels of p i i n d i c a t e s  the lack of a selective 
advantage in deregulation of two genes in the same pathway (Raus and Peters, 1998). 
pl6iNK4a  ^ role in senescence and its expression profile is up-regulated in 
senescent cells (Ruas and Peters, 1998). When p i i s  induced DNA synthesis is 
inhibited and cells acquire morphological features of senescence (Dai and Enders, 
2000).
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Figure 1.7 inhibition of cvclin dependent kinases
Inhibition of cdk activity by pI6INK4a leads to E2F transcriptional inhibition 
through hypophosphorylation of pRb.Viral proteins EIA  and SV-40 large T- 
Antigen can also block the E2F pocket protein interaction.
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1.3.6 p 14/ p 19^^ "
is a 132 amino acid residue protein in humans, and a 169 amino acid residue 
protein in mouse, both proteins are highly basic, with no homology to other proteins 
in the database, have no functional motifs and have only 50% amino acid identity to 
one another (Quelle et al, 1995; Stott et al, 1998). p 14/19^ '^' induces cell cycle anest 
at both the G1 and G2 stages, resulting in a decrease in S phase cells (Quelle et al., 
1995; Pomerantz et al, 1998; Zhang et at., 1998; Kurokawa et a i, 1999). To date, 
the major role of pl4/19*'^ described in the literature is the ability to positively 
regulate p53 through the oncogene MDM2 (Pomerantz et al, 1998). Although 
pl4/19'^’^  regulates p53 there is no difference in pl9^^^ expression when a 
temperature sensitive p53 cell line is moved to the permissive temperature, 
suggesting that p53 does not directly regulate p i9^ ’^' expression (Kamijo et al, 
1997).
Both and p i9^“" have been shown to bind directly to MDM2 and form a
ternary complex with p53 (Pomerantz et al, 1998). Whether or not p i4/19^“" is able 
to bind directly to p53 or not is yet to be elucidated but evidence suggests that 
pl4/pl9'^^^ is unable to bind p53 directly (Stott et al, 1998; Zhang et al, 1998). 
However, p i9'^ “’ has been shown to bind directly to p53 in one study, via the N 
terminal region of pl9'^*  ^(Kamijo et a l, 1998). Also, data has been reported in which 
p i9'^ “' can retard the mobility of a p53-oligonucleotide complex in an electrophoretic 
mobility shift assay (Sherr, 1998). The interactions between p i4*"^  and p53 have not 
yet been fully documented (Sherr and Weber, 2000).
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The MDM2-pl4/19'^’^  interaction is mediated by the N terminal region of p i 4^ '^ '' and 
the C“terminus of MDM2 (Zhang et al, 1998). The pl4'^’^ ''-MDM2 binding domain 
has recently been elucidated and is thought to involve a number of regions from 
PI4 ARF 2 2 2 , 22-64 and 65-132 (Lohrum et al, 2000) in cells. In vitro, however, only 
a peptide coixespending to the first 20 amino acids of pl4*^^ binds to MDM2 
(Midgley et al, 2000). In pl9^*^ the two regions from 1-14 and 26-37 are required for 
binding to the central 210-304 region of MDM2 (Weber et a l, 1999).
p l4 '^ '^  has recently been identified as interacting with topoisomerase I and 
stimulating its activity (Kaiayan et a l, 2001). Topoisomerase I activity is required 
for proliferating cells to go through S-phase into mitosis, p i4^^ physically associates 
with topoisomerase I and recombinant pl4"^^ stimulated the DNA relaxation activity 
of topo I (Karayan et a l, 2001). pl4^^^ and topoisomerase I were also shown to co- 
localise in the nucleolus (Karayan et a l, 2001). These data suggests that the growth 
suppression induced by p i4^^ may be partially due to its effect on topoisomerase I.
1.3.7 014/19^^  ^nucleolar localisation
pl4/pl9*^ has an interesting cellular localisation in that the protein localises to the 
nucleolus (Zhang et al, 1998; Lindstrom et al, 2000; Rizos et al, 2000.). This 
localisation is poorly understood, although nucleolar structures are known sites of 
rRNA localisation, rRNA synthesis and ribosomal assembly (Scheer and 
Weisenburger, 1994). Much controversy surrounds the subject of pl4'^’^’' nucleolar
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localisation. While it has been shown that two arginine rich domains mediate this 
localisation in p i o n e  in each of the exonip and exon 2 encoded regions ( Quelle 
et ah, 1995; Stott et a l, 1998; Lohrum et al, 2000; Rizos et al, 2000), other studies 
have shown that only the C terminus of p l4 ‘^'^  ^mediates nucleolar localisation, and 
that a region from amino acid 83-101 is required for this (Zhang et a l, 1999). 
Evidence which backs up this experimental data is the fact that tumour associated C 
terminal mutants in pl4/pl9*^ lose their ability to localise to the nucleolus (Zhang et 
a/.,1999).
1.3.8 Role of p 14/19^^ in p53 Stability
Overexpression of pl4"^^ activates a p53 response, and results in a cell cycle anest 
(Stott et al, 1998). This effect may be partially due to the ability of pl4/pl9'^’^  ^ to 
promote the degradation of MDM2 (Zhang et al, 1998). Recent experiments have 
shown that although (in the context of pl4^^^), most MDM2 in the cell is bound to 
pl4' '^^”', only a small fraction of pl4'^'^ is bound to MDM2, implicating a wider role 
for p i4^’^'’ in cell cycle control (Llanos et al, 2001).
MDM2 normally shuttles between the nucleus and the cytoplasm in order to target 
p53 for degradation (Roth et a l, 1998). Honda et a/.,(1999) demonstrated that 
association of p i9'^ ’^  with MDM2 inhibits the ubiquitin ligase activity of MDM2 for 
p53, and that the activity of a pl9^^^-MDM2 complex in a ubiquitination assay is 
lower than the activity of free MDM2. These data highlight the importance of p i9“  ^
mediated p53 stabilisation.
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Co-expression of p i9^^ and MDM2 prevents nuclear-cytoplasmic shuttling of 
MDM2, and as time increases, MDM2 can move to the nucleolus (Tao et al, 1999). 
Much data supports this MDM2 nucleolar localisation and this relocalisation also 
occurs following Myc activation and replicative senescence (Weber et al, 1999). 
MDM2, p53 and pl4/19'^^ are able to form nuclear bodies, ARF can block nuclear 
export of p53 and MDM2, or else retain them in the nucleolus. Formation of these 
nuclear bodies requires both the N and C terminus of pl4"^^  ^ (Zhang et a l, 1999). 
Studies have suggested that p i9^^ contains two nucleolar localisation signals (NrLS) 
which both contribute to nucleolar localisation, however, MDM2 also contains a 
NrLS and so the nucleolar co-localisation of p i9'^^ and MDM2 can be viewed as a 
bi-directional interaction (Weber et a l, 1999). Data imply that p i9^’^  binding to 
MDM2 may induce a conformational change that facilitates nucleolar import of the 
ARF-MDM2 complex (Weber et al, 1999).
It has been shown that the regions in pl4^^^ which interact with MDM2 are also able 
to relocalise MDM2 to the nucleolus and inhibit MDM2-dependent p53 degradation 
(Lohrum et al, 2000). However, recently, a more physiological approach has 
suggested that nucleolar localisation of pl4^^^ is not essential for its function (Llanos 
et al, 2001). The experiments showed that stabilisation of MDM2 and p53 occurs 
without relocation of MDM2 to the nucleolus and that forms of p i4^^ which aie not 
nucleolar retain the ability to stabilise p53 and MDM2 (Llanos et a l, 2001). Further 
work is required in order to elucidate the importance and function of the observed 
ARF-MDM2 nucleolar bodies.
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1.3.9 Importance of the pl4/19*'^ -p53 pathway
Established MEF cell lines that lack ARF preserve p53 function, while those that 
retain ARF have sustained p53 mutations (Sherr and Weber, 2000). Cells lacldng a 
functional p53 gene are resistant to pl9*'^-induced cell cycle arrest, implying that 
p53 acts downstream of ARF (Kamijo et al, 1997). However, ARF-null cells exhibit 
an intact p53 checkpoint following ionising or UV iiTadiation, so p i 9^ "^  does not 
relay signals to p53 in response to DNA damage. Loss of p53 can occur in cancer 
cells that arise in ARF-null mice, again indicating that ARF plays a more specialised 
role in tumour suppression than p53, and that selection against p53 can further 
contribute to malignancy (Kamijo et al, 1997; Sherr 1998).
A murine tumour progression model for pancreatic cancer further highlights the 
importance of the pl4/19'^'^-p53 pathway (Wagner et al, 2000). A transgenic mouse 
overexpressing TGFa, when crossed with a p53' '^ mouse displayed greatly 
accelerated tumour progression, and it was observed that one in three tumours 
developing in the TGFa/p53'^ mice sustained biallelic deletion of the INK4a/ARF 
locus (Wagner et al, 2000). These data identify the p53 protein as a rate limiting step 
in tumourigenesis and indicate that the INK4a/ARF locus is synergistic to p53 in 
tumour progression (Wagner et al, 2000).
In order to investigate the role of MDM2 in the p53-ARF pathway, triple knock out 
mice were generated (TKO) lacking pl9'^ '^ ,^ MDM2 and p53 (Weber et al, 2000).
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TKO mice developed more tumours that p53^7mdm2‘\  or p53''' mice and the 
réintroduction of ARF into TKO cells resulted in a G1 aiTest (Weber et al, 2000). 
Interestingly, re-introduction of ARF into p53~'~larf'~ cells did not result in G1 arrest. 
As cells lacking p53 or p53 and p i9'^ '  ^are resistant to ARF induced arrest, these data 
showed that when present, MDM2 antagonises the ability of ARF to induce cell 
cycle anest through targets other than p53 (Weber et al., 2000). MDM2 antagonises 
some activity of ARF on targets other than p53, and in the absence of MDM2 this 
other ARF activity is revealed. These data suggest that ARF and p53 loss contribute 
independently to aspects of tumour progression (Weber et al., 2000).
1.3.10 Activation of p 14/19'^^
pl4/19'^^is activated by hyperproliferative signals from cellular oncogenes such as 
Myc (Zindy et al., 1998), EIA (De Stanchina et al., 1998), E2F-1 (Bates et al,
1998), mutated Ras (Palmero et al, 1998; Lin and Lowe, 2001) and v-Abl (Radfar et 
al, 1998), and also by cellular transcription factors such as DMPl (Inoue et al, 
2000).
The activation of pl4/pl9*'^ is highly important for cell cycle regulation and so it is 
important to understand the cellular mechanisms by which it occurs. Moreover, the 
induction of ARF by oncoproteins such as Myc, EIA, Ras and v-Abl highlights its 
role in sensing hyperproliferative signals in cancer cells (Shen' and Weber, 2000).
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Myc selectively induces p i9"^  ^ and not plô'^ '^ "^ and rapidly activates p53 dependent 
apoptosis (Zindy et al, 1998). An Ep-Myc mouse model system was used to 
elucidate the effect of Myc on the p i9*^ tumour suppressor (Eischen et al, 1999; 
Schmitt et al, 1999). Myc activation strongly selects for spontaneous inactivation of 
the ARF-MDM2-p53 pathway.
In the E|Li-Myc mouse model, initially Myc activation induces p53 dependent 
apoptosis and then gradually selects for cells mutated in either p53 or pl9^^^ 
therefore cancelling its protective checkpoint function and accelerating progression 
to mailignancy. Ep-Myc mice develop B cell lymphoma through loss of p53 or 
pl9^^^ (Eischen et al, 1999). In addition to these INK4A/ARF mutations, Ep,-Myc 
mice can accelerate tumour progression and impair apoptosis by compromising p53 
function (Schmitt et al, 1999). These INK4A/ARF null lymphomas form rapidly, are 
highly invasive and interestingly, are highly resistant to chemotherapy. Previous 
studies have suggested that pl6^ ^^ '*'^  is not involved in this process and that 
tumourigenesis is dependent on p i9*"^  mutation (Schmitt et a l, 1999). It is thought 
that disruption of Myc-p53 induced apoptosis in these cells leads to selection of 
chemoresistant cells and that these mutations can have a negative impact on the 
outcome of cancer therapy (Schmitt et al, 1999). Cytotoxic drugs can Idll cells via 
DNA damage induced apoptosis and this again highlights synergy between the ARF 
and DNA damage induced pathways leading to p53 activation (Sherr and Weber 
2000). Hence, a better understanding of pl9'^’^  mutations may lead to more effective 
cancer therapies.
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DAP kinase, a pro-apoptotic, calcium regulated serine/threonine Idnase activates a 
p53/pl9'^'^ mediated apoptotic response (Ravel et al, 2001). DAP kinase expression 
is frequently lost in human tumours and interestingly, both E2F-1 and Myc are able 
to increase DAP kinase levels, indicating a role for p53 induced apoptosis in the E2F 
and Myc apoptotic pathways. Induction of this apoptotic response probably underlies 
the anti-oncogenic activity of DAP kinase (Ravel et al, 2001).
Adenovirus EIA proteins function in cells to inactivate check-point controls by the 
pRb pathway through binding to pRb, and activation of p53 transcription (de 
Stanchina et al, 1998). Experiments in pl9^^'^‘ cells showed that the induction of 
p53, and hence, p53 mediated apoptosis is compromised in knock out cells, and that 
réintroduction of p i9^^ can restore these functions (de Stanchina et al, 1998).
DMPl is a cyclin D binding, b-Myb like protein that binds to a single recognition 
site in the pl9'^’^  promoter to upregulate p i9^^ transcription. DMPl is able to 
activate transcription in conjunction with the transcription factor E2F-1 that also 
activates the ARF promoter (Inoue et al, 1999; Bates et al, 1998). Expression of 
DMPl induces growth arrest in wild-type MEFs but not in ARF' MEFs (Inoue et al,
1999), and disruption of dmpl facilitates cell immortalisation, Ras transformation 
and tumourigenesis (Inoue et al, 2000). DMPl  ^ MEFs have low levels of p53, 
MDM2 and p i9'^ “’, and are unable to senesce. Also these DMPl cells aie 
transformed by activated Ras similarly to p53 or pl9^'^'^' MEFs indicating a de­
regulation of the p53-pl9^’^  pathway in dm pl' MEF^ (Inoue et a l, 2000).
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BRCAl is a tumour suppressor gene, which functions as a transcriptional co­
activator (Scully et al, 1997) and has been shown to activate p53 expression 
(Somasundaram et al, 1999). Intriguingly, SAOS2 cells infected with adenovirus 
expressing BRCAl, showed a two fold increase in pl4^^^ mRNA, suggesting a role 
for BRCAl in p i4^^activation, and hence a role in p53 stabilisation (Somasundaram 
et al, 1999).
v-Abl is a viral protein, expressed in Abelson murine leukemia virus mediated pre-B 
cell transformation, and is able to activate the oncogenes Myc and Ras (Radfar et al, 
1998). Normally, v-Abl infected cells go through a ‘crisis point’ that characterises 
the transition from primary transformant to fully malignant cell line. However 
deletion of the INK4a/ARF locus allows cells to bypass this crisis point (Radfar et 
al, 1998). Overexpression of pl9^“’ but not plô'^ *^ **" induced apoptosis in v-Abl 
transformed B cells, indicating that p i9^“" is responsible for the bypass of apoptotic 
crisis (Radfar et al, 1998). This study identifies pl9^^^ as one of the components of 
the cellular defence mounted against v-abl mediated transformation.
Knock-out c-myc ''' mice die at E9.5, and myc itself is deregulated in many human 
cancers (Jacobs et al, 1999b). Bmi-1 collaborates with c-myc in tumorigenesis 
through its ability to downregulate the INK4a/ARF locus and inhibit c-myc induced 
apoptosis (Jacobs et al, 1999b). bmi-1 ''' cells proliferate slowly and prematurely 
senesce while increased apoptosis is observed, a phenomenon that can be rescued by 
the deletion of the INK4a/ARF locus (Jacobs et al, 1999a).
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Activation of oncogenes increases susceptibility to apoptosis so tumourigenesis must 
depend in part on compensating mutations that protect from apoptosis. twist, is a 
potential oncogene, which inhibits p53 dependent apoptosis, and bypasses p53 
mediated growth anest (Maestro et al, 1999). The effect of twist on ARF is 
interesting in that it is able to impair p53 transcription. However, twist over­
expressing cells showed a huge decrease in ARF expression, which is unexpected, 
given that loss of p53 usually leads to ARF up-regulation (Maestro et al, 1999).
1.3.11 Roles of p 14/p 19'^ ^^  and in Senescence
Both p l6 ‘^ '^ '^ '^  and pl4/19'^^ have been implicated in cellular senescence, the process 
by which cells lose the ability to proliferate after the completion of a finite number of 
cellular divisions (Campisi, 1996). Senescence is characterised by a growth arrest, 
apoptotic resistance and an altered spectrum of differentiation types, and often comes 
about as a result of telomere shortening (Campisi, 1996). Cultured primary cells 
express increasing amounts of pl6'^’^‘'‘ as they approach the limit of their in vitro life 
span, and forced expresssion of activated ha-Ras in primary cells induces senescence 
that is relieved following inactivation of either p l6 ’^ '^ '^ “ or p53 (Haber, 1997)
E2F-1 is able to induce a senescence phenotype in normal human cells as a result of 
its ability to upregulate pl4"'^  ^and as this phenomenon is p53 independent it can be 
assumed that pl4"^^ is the critical component in the induction of senescence (Dimri et 
al, 2000).
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Antisense vectors were employed in an interesting study, which showed that both 
and are involved in senescence, and that they work in overlapping
pathways (Carnero et al, 2000). Experiments showed that while p i i n d u c e d  
growth anest can be overcome by compromising the function of its upstream 
regulator pRb, to overcome pl9^ '^" growth arrest requires the inactivation of both the 
pRb, and p53 pathways. Interestingly, loss of either one of or p i9^^
contributes to a bypass of senescence. However loss of p i9"^  ^ bypasses senescence 
more efficiently than loss of p i ( L l o y d  et al., 2000), The importance of this 
observation is highlighted by the fact that pl9^“"'^ ' fibroblasts are able to proliferate 
indefinitely, so are immortal (Lloyd et al, 2000).
The SV40 large T antigen has at least three domains which participate in cellular 
transformation through taigeting the cell-cycle regulatory proteins pRb and p53 
(Chao et a l, 2000). Further evidence to suggest that p i 9^ ^^  may be involved in pRb 
regulation is provided by Chao et a l, 2000. who found that loss of plO'^^ eliminates 
the requirment for the pRb binding motif in SV40 virus Large T transformation, and 
that this regulation is through the LXCXE motif required for pRb binding to large T. 
In rb'' MEFS all three transforming domains were required for full transformation, 
however in ARF' MEFs anchorage-independent growth was acquired (Chao et a l, 
2000).
A new regulator of p i9^^ was recently identified using a senescence bypass screen, 
TBX2, which is a T box transcription factor which represses the p i9"^  ^promoter by 
binding to the initiator -19-54 region of the promoter (Jacobs et al, 2000). TBX2 is
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found to be amplified in a subset of human breast cancers and prevents E2F-1, Myc 
and H-Ras induction of pl9^’^  (Jacobs et al, 2000).
1.3.12 Therapeutic Strategies.
As the p53 pathway is a member of an integral DNA damage response in cells 
(Levine, 1997), it is of interest to ask how pl4/19'^“' affects the p53 response to DNA 
damage? One such study has shown that pl9^^ is required to induce p53 responses to 
DNA damage and microtubule disruption, but not other cellular stresses such as 
ribonucleotide reduction or RNA synthesis, which are both independent of pl9^^^ 
(Khan et al, 2000). A situation, which emphasises the complexity of the biochemical 
and cell cycle responses to diverse stresses that activate the p53 pathway.
The mutated adenovirus d ll520 (ONYX-015) does not express the ElB protein 
which binds and inactivates p53 and so is able to selectively replicate only in tumour 
cells with mutant p53 (Ries et al, 2000). This therapeutic virus has shown promising 
responses in patients with solid tumours, with a high percentage of full regression. 
Loss of has also been identified as a mechanism which allows replication of
this virus in tumour cells that retain wild type p53, and réintroduction of pl4'^ '^" into 
these cells is able to suppress d ll520 replication in a p53 dependent manner (Ries et 
al, 2000)
ATM induces cellular responses to DNA damage and mutations in the atm gene 
cause ataxia telengiectasia. This is a progressive, degenerative disease characterised
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by cerebella degeneration, immunodeficiency and a pre-disposition to cancer. ATM 
encodes a protein kinase activity specific for serine and theronine residues and has 
been shown to phosphorylate p53 (Kamijo et al, 1999). ATM null fibroblasts 
undergo premature replicative anest, which is relieved by loss of p53. In these cells, 
loss of ARF extends the life span of the ATM fibroblasts but does not alter their 
sensitivity to ionising radiation or their disposition to development of lymphoma 
(Kamijo et al, 1997). These data suggest that loss of ARF can modify p53 dependent 
features of the ATM null phenotype, and that ARF and ATM can likely reinforce the 
others activities and response to stress (Kamijo et al, 1999). These data furthermore 
highlight a prospective cross talk between cellular stress pathways (Shen and Weber, 
2000).
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1.4 Conclusions and Objectives
1.4.1 Concluding remarks
The de-regulation of many components of the pRb~E2F pathway in human cancer 
shows how important it is to elucidate the physiological processes within this 
pathway and develop efficient tumour therapies. The role of E2F-1 as both a tumour 
suppressor and an oncogene, and its importance in both cellular proliferation and 
apoptosis highlights it as an essential cell cycle regulator. Recent knockout mouse 
models have provided us with great insight into the roles of the individual E2F 
family members, however, much more work is required to fully elucidate their roles 
in the cell. The identification of post-translational mechanisms such as 
phosphorylation and acétylation, which affect E2F function are of particular interest 
and more work is required to elucidate the proteins involved in these processes.
The INK4a/ARF locus and its two gene products p i a n d  p 1 4 / 1 both play a 
key role in regulating the cell cycle check point controlling proteins, p53 and pRb 
respectively. Given the high level of germ-line mutations in the INK4A/ARF locus 
in cancer cells, the importance of this locus in the maintenance and development of 
the healthy cell is seemingly unquestionable. The transcription of two unrelated 
genes from the same genetic locus has undoubtedly come about through a genetic 
selection event. Given that each protein plays a role in the control of two similar 
cellular pathways, this genetic locus is of great interest. The reason for such
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conservation of genetic information in mammalian cells is unknown but will provide 
an exciting avenue for future research.
Clearly the ability to fully understand both the p53 and pRb tumour suppressor 
pathways, and the interplay that exists between them will be of great benefit in the 
design of drugs for the treatment of cancer.
1.4.2 Objectives
The main function of p i4^^ identified to date is its ability to regulate the p53 
pathway through sequestration of MDM2. Recent studies have identified p53 
independent functions of pl9'^^ (Camero et a l, 2000; Weber et ah, 2000) and 
indicate that pl4^^m ay also play a role in p53 independent pathways in cell cycle 
regulation. Given that E2F-1 function and sub-unit composition is down-regulated by 
MDM2 (Loughran and La Thangue 2000), and pl4"^^ is a negative regulator of 
MDM2 function (Kamijo et al., 1998), MDM2 could also be important in other 
p i4^^ cellular pathways, such as the regulation of E2F.
The objectives of this thesis were to investigate a role for pl4'^‘^  ^in the E2F pathway, 
primarily using E2F-1 and further to investigate whether pl4^'^’" can interact with 
E2F-1. Furthermore to look for MDM2 independent roles of p i4'^ *^  and to define the 
mechanism of action of pl4"^ ^^  upon the E2F pathway. Understanding the role of 
and its interacting proteins should ultimately help us to understand the roles of 
the tumour suppressor proteins in the cellular pathways they regulate.
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Chapter 2. Materials and Methods.
2.1. Plasmids.
The following plasmids have been previously described pRcCMVHA-E2F-l (Helin 
et a l, 1992), pCMVE2FlY411C (Helin et a l, 1992), CMV-DPl (Bandara et a l, 
1993), CMV-pl4^^^ (Stott et a l, 1998), pCHDM2 (Chen et al., 1996), pcMDM2 
(Martin et a l, 1995), pCMVPgal (Zamanian and La Thangue, 1992), myc-ARF, 
myc-ARF(N), myc-ARF(C) (Zhang et a l, 1998), Tx-ARF-1-132, Tx-ARF-1-22, Tx- 
ARF-1-34, Tx-ARF-1-64, Tx-ARF-65-132, Tx-ARF-54-64, (Lohrum et al 2000), 
E iP “luciferase (Bates et a l, 1998), cyclinE-luciferase (Botz et a l, 1996), 3XWT- 
luciferase, 3XMT-luciferase (Zamanian and La Thangue, 1992), Apaf-l-luciferase 
promoters (-871/+208), (-396/+208), (+35/+208) (Moroni et a l, 2001).
CMV-DPldl70, CMV-DPldll71, CMVDPldl230, CMV-DP1205-310 and HA-DP- 
1 were a gift from Chang-Woo Lee (University of Glasgow). His-E2F-1, GST-DPl, 
pRcCMVHA-E2F-1 AC were a gift from Laurent Delavaine (University of Glasgow). 
pRcCMVHA-E2F-1 AC was made by Bglll/BamHl digestion of the pRcCMVHA- 
E2F-1 plasmid, removal of the rran^activation domain fragment and re-ligation of 
the vector. HA-E2F-1 181-221 and HA-E2F-1 141-221 were prepared by PCR 
amplification using the following pairs of primers HA-E2F-1 181-221 5’
’ GGGGATCCGCCAAGAAGTCCAAGAACCAC’ and 3 ’
‘GGTCTAGACTCCGAAGAGTCCACGGCTTG’, HA-E2F-1 141-221 5’
‘GGGGATCCGAGCTGCTGAGCCACTCGGCT’ and 3 ’
‘GGTCTAGACTCCGAAGAGTCCACGGCTTG’ and were a gift from Laurent
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Delavaine. PGEX-pl4*'^'' was prepared by digestion of CMVpl4*'^^ with 
BamHl/EcoRl (Promega) and ligation of the fragment into the BamHl/EcoRl site 
in the pGEX^° vector (Pharmacia). Similarly, pGEXpl4"^^-N62 was generated by 
cutting the myc-ARF(N) construct (Zhang and Xiong 1998) with EcoRl/Xhol 
(Promega) and ligation of the fragment into the EcoRl/Xhol site of pGEX*^^
pGEX-p 14^^^mycC was cloned by PCR amplification (using taq p/w-Promega) of 
the myc-ARF(C) fragment (Zhang and Xiong 1998) using the primers 5’-3’ 
GGA ATTCCGGTC ATG ATGATGGGC AG and 3 ’ -5 ’
CTCTAGAGTCAGCCAGGTCCACGGGC to introduce restriction sites for EcoRl 
and Xbal and the resulting fragment was gel purified using the Gelclean Idt 
(Quiagen). The gel-purified pl4^^^ fragment was then TA tailed (with taq 
polymerase-Promega) and cloned into the pGEMEasy vector (Promega). pGEMEasy 
ligations were transformed into JM109 cells (Promega) and colonies determined as 
containing the insert were mini-prepped and checked for fragment orientation, the 
fragment was then digested out with EcoRl and then non-directionally cloned into 
the EcoRl site of pGEX^^
Orientation of all cloning was verified by restriction digest and sequencing of all 
vectors was carried out at Leicester University.
2.2 Antibodies 
Primary
The E2F1 antibody (KH95) (Santa Cruz) was used at at 1: 500 dilution and is a 
monoclonal antibody which interacts with the Rb binding domain of mouse, rat and
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human E2F-1. DP-1 (098) is a rabbit polyclonal anti-serum raised against a DP-1 C 
terminal peptide (Sorenson et al., 1996), and was used at a 1:200 dilution. pl4 
(C-18) (Santa Cruz) was used at a 1:200 dilution and is an affinity purified goat 
polyclonal antibody raised against a peptide mapped to the C terminus of human 
PJ4ARF p]^ 4 ARPpoi (Stratech Scientific) is a monoclonal antibody raised against 
recombinant pl4*^^ and was used at a 1:200 dilution. The HA-11 antibody 
(Cambridge Bioscience) was used at a 1:1000 dilution and is a monoclonal antibody 
to the influenza HA tag, HA (F-7) (Santa Cruz) was used at a 1:200 dilution and is a 
rabbit polyclonal antibody raised against the HA tag. c-Myc (9E10) (Santa Cruz) was 
used at a 1: 500 dilution and is a mouse monoclonal antibody.
Secondary
Anti-Ig-TRITC rhodamine conjugated (Southern Biotechnology Association inc.) 
and Anti-Ig-FTTC fluorescein conjugated (Southern Biotechnology Association inc.) 
were used for immunostaining. Anti-Ig-AP alkaline phosphatase conjugated 
antibodies were used for western blotting (Promega).
2.3 Transformations
25^1 of cells (XLl Blue for DNA preparations and BL21 (DE3) pLysS for GST 
fusion and His-tagged protein preparations) were thawed on ice. After thawing, 
0.2|ig of the appropriate DNA was added and the mixture was placed on ice for 30 
minutes. The mixtures were heat-shocked at 42^2 for 45 seconds and then cooled on 
ice for two minutes. 900pl of LB was added to the cells, which were then incubated
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at 37°C for 30 minutes. After incubation cells were spread on a LB plate (with either 
ampicillin or kanamycin at lOOpg/ml) and incubated at 37“C overnight.
2.4 DNA Preparation
Plasmid minipreps (small scale DNA preparation) were prepared using the Wizard 
Plus SV Miniprep DNA Purification System (Promega) according to the 
manufacturers instructions and DNA maxipreps (large scale DNA preparation) were 
prepared using the Quiagen Maxiprep kit, according to the manufacturers 
instructions.
2.5 Restriction Digests and DNA Analysis.
Restriction digests were performed as previously described. 20 |li1 reactions contained 
l|ig  DNA, l|il enzyme, 2|il enzyme buffer and were made up to volume with H^O. 
All enzymes were supplied by Promega or Roche. Digests were analysed on 2% 
agarose gels containing ethidium bromide (Sigma) in 6x Agarose Gel DNA Loading 
Buffer (0,25% Bromophenol Blue, 0.25% Xylene Cyanol, 30% Glycerol) and 
visualised on a ultraviolet light box
The concentrations of nucleic acid solutions were determined spectrophotometrically 
using a quartz cuvette.
1 A260 = 50pg/ml dsDNA
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2.6 Tissue Culture
SA0S2 cells were purchased from the American Type Culture Collection and 
cultured in DMEM (Gibco) supplemented with 10% PCS, lOOU/ml penicillin and 
streptomycin (Gibco). Cells were passaged 1:3 when confluent p53 ''mdm2’' MEFs 
were a Idnd gift from David Lane (Ninewells hospital, Dundee) and were cultured in 
DMEM, 10% ECS and lOOU/ml P/S and split 1:6 upon reaching confluence. SA0S2 
cells and p5J''/mdm2'^' MEFs were kept at 37'’C in an atmosphere of 5% CO^
2.7 Transfection
Transfections were carried out in SAGS2 cells or early passage MEFs grown in 
DMEM/FCS. Cells were plated at 5x10^ per 6cm dish or 2x10^ per 10cm dish 
(SAOS2) or 1x10  ^ per 6cm dish or 5x10^ per 10cm dish (MEFs). Cells were 
transfected by the calcium phosphate method as described in (Sambrook et al.,). 
DNA/H^O mixtures were prepared and then mixed with 10% volume 2M CaCl^ 
before being added drop wise to an equal volume of 2xHBS (280mM NaCl, 50mM 
Hepes acid, 1.5mM Na^HPOJ. Calcium phosphate precipitate was allowed to fomi at 
room temperature for 15 minutes before being added to cell monolayers. After 6-20 
hours cells were washed twice in PBS, re-grown in DMEM/FCS and then harvested 
24-48 hours post transfection.
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2.8 Reporter Assays
Reporter gene assays were performed by transfection of the indicated amounts of 
plasmids together with 500ng CMV-(3gal as an internal control per 6cm plate. 
Quantities of DNA per plate were kept constant by the addition of equivalent 
amounts of pcDNA3 or pSG5 control vectors, in order to control for promoter 
specificity. Assays were performed in duplicate. Transfected cells were washed twice 
in PBS, regrown in DMEM/FCS and harvested in 300pi Ix RLB ( Promega ( 25mM 
Tris-HgPO^ pH7.8, 2mM 1,2-diaminocyclohexane tetra acetic acid, 2mM DTT, 10% 
glycerol and 1% Triton X-100)), micro-centrifuged at 10,000 for 5 minutes to 
remove cell debris and the lysates analysed for reporter gene activity.
For the luciferase assay: 60^1 cell lysate was mixed with 300 \i\ luciferase reagent 
(Diluted 1:4 (Promega)) and luciferase light units measured in a luminometer 
(Beithold Lumat).
For the pgalactosidase assays: lOOpl cell lysate was incubated with lOOpl 2xPgal 
reagent (200mM sodium phosphate buffer pH 7.2, 2mM magnesium chloride, 
lOOmM B-mercaptoethanol, 1.3|Xg/ml ONPG) and incubated at 3TC  until a yellow 
colour developed. Reactions were stopped by the addition of 600 |L il H^O and the 
activity was measured in a spectrophotometer (Pharmacia Biotech Ultraspec 1000) at 
420nm.
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2.9 GST Protein Purification
l\xg of plasmid was transformed into BL21 DE3 competent cells (Stratagene). A 
single colony was inoculated into 50ml and allowed to grow to saturation.
This culture was diluted 1:10 and grown at 3TC  until log phase, at which point the 
culture was induced with 0.4mM IPTG. Induced cultures were allowed to grow for 3 
hours, with the addition of ImM PMSF every 20 minutes and then bacteria harvested 
by spinning at 5000 rpm. Pellets were re-suspended in 10ml PBS/l%Triton/lmM 
PMSF. The bacteria were then lysed by sonication (2x 20 seconds) and spun to 
collect cell debris. The supernatant was added to 500 |il pre-equilibrated GST beads 
(Amersham) and incubated at 4°C for 30 minutes with shaking. The beads were then 
washed 2 times in PBS/Triton/PMSF and 2 times in PBS. GST proteins were stored 
at -20”C in GST storage buffer (20mM Tris pH 8.0, lOOmM NaCl^, 20%Glycerol).
When required proteins were eluted from the GST beads in an equal volume of 
elution buffer (lOmM Glutathione, 50mM Tris pH 8.0), Dialysis was carried out 
overnight at 4°C in Slyde-a-lyser mini dialysis units (Peirce) in dialysis buffer 
(25mM sodium phosphate buffer pH 7.8, ImM EDTA, 5mM mercaptoethanol, 10% 
glycerol)
2.10 HIS tagged protein purification
BL21 cells were transformed, grown and induced as described above. Bacteria were 
pelleted by centrifugation at 5000G, the pellet resuspended in 10ml sonication buffer 
(lOmM Tris pH 8.0, 0.5M NaCI,, 10% Glycerol, 0.1% NP-40, 5mM DTT, ImM
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PMSF, Ix Protease Inhibitor Cocktail (Sigma)) and sonicated for 3x15 seconds on 
ice. Following centrifugation the supernatant was added to 500|ll1 previously 
equilibrated (lOmM Tris pH 8,0, 0.5M NaCl^, 10% Glycerol, 0.1% NP-40) nickel 
agarose beads (Promega) and incubated at 4°C for 1 hour with rotation. Beads were 
washed 3x in BClOO buffer (20% Glycerol, 20mM Tris pH 8.0, lOOmM KCl, 5mM 
DTT, 20mM Imidazole, ImM PMSF) and, if required, eluted from the beads with 
200mM imidazole. Dialysis was carried out as described in 2.9.
2.11 Cell Extracts
Nuclear extracts were prepared from SA0S2 cells or early passage MEFs by 
scraping monolayers and swelling in Buffer A (20mM Hepes, 20% Glycerol, 
250mM NaCL,, 1.5 mM MgCl,, ImM EDTA, 0.1 % TritonX) for 30 minutes. 
Followed by centrifugation at 2000 rpm for 10 minutes before lysis in TNE buffer 
(50mM Tris pH 8.0, 150 mM NaCl^, 5mM EDTA, 0.5%NP-40) for 30 minutes on 
ice. Supernatants were collected by centrifugation at 13000 rpm for 30 minutes.
Whole cell extracts were prepared by lysis in TNN buffer (50mM Tris 7.4, 120mM 
NaCl„ 5mM EDTA, 0.5 % NP-40, 50mM NaF, ImM DTT, ImM PMSF, Ix 
Protease Inhibitor Cocktail) on ice for 30 minutes. Cell debris was collected by 
micro-centrifugation at 13000 rpm.
2.12 Determination of Protein Concentration and Electrophoresis
The protein concentration of cell extracts for biochemical assays was determined by 
Bradfords assay as described in (Sambrook et al.). All biochemical assays were
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analysed by SDS-PAGE using Mini-protein 2 (Biorad) kits and western blotting 
using Mini-protein 2 blotting kits (Biorad).
2.13 Biochemical Assays
For GST-pull down assays nuclear extract (200 pg) was incubated with Ipg GST or 
GST-p 14"^^  protein overnight at 4°C. The reactions were earned out in 200pl TNE 
buffer containing ImM DTT, ImM PMSF and Ix protease inhibitors (Sigma). Beads 
were washed 3 times in TNE buffer and re-suspended in 3xSDS buffer for gel 
analysis.
Alternatively proteins were in vitro translated using the T7 TNT coupled system 
(Promega) as described by the manufacturers. An equal amount of in vitro translated 
protein was added to Ipg GST protein in 200pl TNE buffer. Reactions were 
incubated at 4°C for 1 hour and then beads washed 3 times in binding buffer and re­
suspended in SDS buffer for gel analysis. Gels were dried and exposed overnight by 
autoradiography (Biorad).
For the in vitro binding assay, 0.5 pg of each eluted purified GST protein was 
incubated with an equimolar amount of His-E2F-1 for 30 minutes at 4°C in 200pi 
TNE. Reactions were washed three times in binding buffer and subjected to SDS- 
PAGE analysis and Western blotting.
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2.14 Immunoprécipitations.
For the endogenous immunoprécipitation HeLa cell nucleai' extract (Computer Cell 
Culture) (500pg) was incubated in lOOpl TNE with anti-E2F-l, anti-pI4"^^, anti- 
MDM2 or anti-HA antibody overnight at 4°C with rotation. Protein A agarose was 
then added to samples for 3 hours at 4°C with rotation. Immunoprecipitates were 
washed 3 times in binding buffer and resuspended in 3x SDS loading buffer, 
analysed by SDS-page and western blotting.
For the over-expression immunoprécipitation experiments SAOS2 cells (2 x 10^ ) 
were transfected with equal amounts (25pg) of the indicated plasmids. Cells were 
washed 8 hours post transfection and hai'vested 24 hours post transfection. Extracts 
were prepared by lysis of cell pellets in lOOpl IP buffer (150mM NaCl^, 1% NP-40, 
50 mM Tris pH 8.0) containing protease inhibitors. Extracts were incubated with 
anti-E2Fl (KH95 Santa Cruz) overnight at 4“C. Protein A agarose was then added to 
samples for 3 hours at 4“C and the samples washed 3 times in IP buffer. Beads were 
re-suspended in 20pl SDS buffer for analysis on SDS gels. Western blots were 
probed with anti-myc (Santa Cruz) and anti-HA-11 (Cambridge Bioscience) 
respectively.
2.15 Immunostaining
Cells were plated at 3x10^ on coverslips in 35mm dishes and transfected 24 hours 
later with the indicated plasmids. Transfections were washed after 20 hours and 
harvested 36 hours post transfection. Cells were fixed in 4% paraformaldehyde for
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10 minutes and then peiTnealised in 0.1% Triton, 0.1% sodium citrate in PBS for 10 
minutes. Immunostaining was performed using HA-11, c-myc or HA rabbit 
polyclonal antibodies in % PCS as indicated, followed by washing 40 times in 
10%FCS/PBS and staining with FITC or TRITC conjugated secondary antibodies 
(Europath ) in 10%FCS. Coverslips were mounted on Citiflour (Agar Scientific) and 
examined using an Olympus fluorescence microscope BX-60. Photographs were 
taken using an Olympus PM-30 automatic micrographie system.
2.16 TUNEL Assay
SA0S2 cells were plated 3x10^ on coverslips and transfected by with 6pg of each 
indicated plasmid. Following transfection, cells were washed twice in PBS and 
serum starved overnight in DMEM 0.2% PCS. Post-transfection, cells were fixed 
for 15 minutes (4% paraformaldehyde) and permeablised for 10 minutes 
(0.1%Triton, 0.1% Sodium Citrate in PBS). TUNEL staining was performed, using 
the TUNEL kit (Roche) as described by the manufacturer. Coverslips were mounted 
in Citriflour (Agar Scientific) and examined using an Olympus fluorescence 
microscope. Positively stained cells were counted a minimum of 3 times, under low 
and high power fluorescence microscopy. Counts were normalised for transfection 
efficiency (Determined by double staining for HA-E2F-1).
2.17 BrdU assay
Cells were plated at 3x10^ (SAOS2) or 1x10  ^ {mdm2'‘lp53'''MEP?>) on coverslips and 
transfected with 5pg of each indicated plasmid. Following transfection, cells were
97
Chapter 2__________________________________________ Materials and Methods
washed twice in PBS and left overnight in DMEM 10% ECS. Labelling was earned 
out for 15 minutes at 37°C and cells were then fixed (ethanol,glycine buffer pH 2) for 
a minimum of 30 minutes at -20°C, and stained with the 5-Bromo-2' -deoxy-uridine 
Labelling and Detection Kit 1 (Roche) according to the manufacturers instructions. 
Cells going through S-phase incorporate BrDU into newly synthesised DNA. BrDU 
incorporation was assayed by detection with anti-BrDU antibody, followed by 
staining with a FITC-conjugated secondary antibody. Cells were mounted and 
examined as described for the TUNEL assay. Positively staining cells were counted 
as described for the TUNEL assay.
2.18 Band Shifts
Oligonucleotides (oligos) E2F wildtype 19 ‘AGCTAGTTTTCGCGCTTAAATT’, 
20 ‘AGCTAATTTAAGCGCGAAAACT’ and E2F mutant M3 
’TCGATAGTTATCTGAGTAAACTAGTG’ and M5
TCGACACTAGTTTACTCAGATAACTA’ derived from the adenovirus E2A 
promoter sequence were synthesised by Genosys. Single stranded oligos were 
annealed by heating at 100°C for 10 minutes and then allowed to cool slowly before 
storage at -20°C.
^^P-labelling was carried out by incubation of Ipl DNA probe with Ipl kinase buffer,
1 jL il T4 kinase enzyme (Promega) and 1 jL il 32P y  ATP (Amersham). The reaction 
was incubated at 37“C for 30 minutes and then purified on a Quickspin column 
(Roche) in TE buffer (lOmM Tris pH 7.4, ImM EDTA).
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Bandshifts were performed in 20pil reactions containing 150ng un-labelled mutant 
oligo, 2 pg salmon sperm DNA, 4x reaction buffer (60% glycerol, 4mM DTT, 
0.8mM EDTA, 200mM Tris pH 8.0, 24mM MgClJ and the indicated in vitro 
translated or purified proteins. Proteins were in vitro translated using the Promega 
T7 coupled TNT kit to the manufacturers instructions, or bacterially purified and 
eluted as previously described (2.9). Where complexes were identified by antibody 
shifts Ipl of the indicated antibody was added to the reaction. Reactions were 
incubated at room temperature for 10 minutes, then Ipl radio-labelled probe was 
added to each reaction and incubated for a further 20 minutes at room temperature. A 
non-denaturing polyacrylamide gel was pre-run for 30 minutes before loading the 
samples and running for 100 minutes at 230V. Reactions were visualised by 
autoradiography.
2.19 Colony Forming assay
SAOS2 cells were plated at 1x10  ^and transfected by the calcium phosphate method 
with the indicated plasmids. 16 hours post-transfection, cells were washed and 30 
hours post-transfection were split 2x10^ and 8x10  ^ into a further 5x10^ untransfected 
SAOS2 cells. Cells were placed under G418 selection (0.8pg/ml) for approximately 
17 days until colonies were clearly observed. Colonies were stained with crystal 
violet and independently counted at least 3 times.
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2.20 Degradation Assay
SAOS2 cells or p53~^7mdm2^~ MEFs were plated at 1x10° or 0.5x10° cells in 10cm 
plates respectively and transfected 16 hours later with the indicated plasmids and 
Ipg CMV-|3gal as an internal control. 16 hours post-transfection cells were washed 
in PBS. Cells were harvested 48 hours post-transfection and whole cell extracts were 
prepared as described (2.11). Transfection efficiency was determined by P- 
galactosidase assay (2.8) and then lysates were analysed by SDS-PAGE and western 
blotting.
2.21 Far Western Blot
Purified GST proteins were subjected to SDS-PAGE and transfer to nitrocellulose 
membrane (Inverclyde Biologicals). Membranes were washed twice in PBS and then 
blocked in 2% milk/PBS for 1 hour at 4°C. Proteins were prepared by in vitro 
translation (Promega) as described (2.13). After blocldng, membranes were washed 
twice for 5 minutes in AC buffer (10% glycerol, lOOmM NaCl, 20mM Tris, 0.5mM 
EDTA, 0.1% Tween-20). In vitro translated proteins were diluted in 10ml AC 
buffer/1% milk overnight at 4°C. Membranes were dried and binding of ^^S-labelled 
proteins was determined by autoradiography.
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Chapter 3. pl4^^ Regulates the activity of the E2F-1/DP-1 
Heterodimer.
3.1 Introduction
The E2F-1/DP-1 heterodimeric transcription factor has been shown to induce S- 
phase progression, and apoptosis in mammalian cells (Johnson et al., 1993; Wu and 
Levine, 1994). E2F-1 rra?î5activates a number of target genes required for S-phase 
progression and apoptosis, including cyclinE (Ontani et al., 1995), «//(DeGregori et 
al., 1997; Bates et al., 1998), apaf-1 (Moroni et al., 2001) and dhfr (Helin, 1998). 
PI4 / I 9ARF jg important regulator of the p53-MDM2 pathway. pl4/19^^^ stabilises 
p53 by binding to MDM2, sequestering MDM2 away from p53 and preventing 
MDM2 mediated p53 degradation (Honda et ah, 1999).
It has been shown previously that MDM2 can target E2F-1 and DP-1 for degradation 
(Loughran and La Thangue, 2000). MDM2 also overcomes E2F-1 mediated 
apoptosis (Loughran and La Thangue, 2000). It was of interest to further study these 
cellular pathways in order to define new mechanisms of control for E2F.
E2F-1 and pl4^^^ are both important cell cycle regulatory proteins, E2F-1 
?ran.?activates the a 7/ promoter and leads to an accumulation of pl4^^^ (Bates et al.,
1998). MDM2 is involved in the regulation of both the E2F pathway (Loughran and 
La Thangue, 2000) and the p53 pathway, through p l4 ^ ^  (Honda et a l, 1999). This 
led us to ask the question; is pl4^*^^ involved in the regulation of E2F-1.
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Results
3.2 p 14^^ regulates E2F-1/DP-1 mediated apoptosis.
In addition to its role in cell cycle progression, E2F-1 has also been shown to induce 
apoptosis (Wu and Levine, 1994). E2F-1 and DP-1 co-operate to induce higher levels 
of apoptosis than E2F-1 alone, and this apoptosis is overcome by the MDM2 
oncoprotein (Loughran and La Thangue, 2000). As pl4^^^ acts as a negative 
regulator of MDM2, causing p53 stabilisation and increased apoptosis (Honda et aL,
1999), it was of interest to examine whether pl4^^^ had an effect on MDM2 activity 
in E2F-1 mediated apoptosis.
In order to study the ability of p I4 ^ ^  to regulate the E2F-1 apoptotic response, p53'^' 
frh''' SAOS2 cells were assayed for the DNA fragmentation phenotype characteristic 
of apoptosis. Fluorescent-labelled nucleotide incorporation into fragmented DNA 
was visualised directly by immuno-fluorescence using the TUNEL assay. As 
expected the transient transfection of E2F-1 or DP-1 alone under low serum 
conditions induced apoptosis (Figure 3.1 A) and together E2F-1 and DP-1 co-operate 
to increase the number of apoptosing cells (Figure 3.1 A). Populations of cells over­
expressing E2F-1 and DP-1, as determined by immunostaining, showed a 15% 
increase in the level of apoptosis relative to those non-transfected. As expected the 
over-expression of MDM2 in E2F-1 and DP-1 transfected cells was able to reduce 
the level of heterodimer induced apoptosis by approximately 50% (Figure 3.1 A).
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More interestingly, over-expression of pl4^^^ in SAOS2 cells produced only a small 
increase in the level of apoptosis over mock transfected cells (Figure 3.IB). 
However, over-expression of p i4^^^, together with the E2F-1 and DP-1 heterodimer 
resulted in a decrease of 85% in the level of induced apoptosis, to levels observed 
with p i4^^^ alone. As pl4^^^ is able to increase the p53 apoptotic response by 
sequestering MDM2 away from p53, it was of interest to examine the dual effect of 
PI4 ARF and MDM2 on E2F induced apoptosis. In this experiment, the over­
expression of E2F-1, DP-1, p l4 ^^F and MDM2 together resulted in the re­
establishment of an E2F-1, DP-1 apoptotic response (Figure 3.1C).
The initial objective of this experiment was to examine whether p l4 ^^F could 
regulate the effect of MDM2 on E2F in a manner analogous to its effect on p53. The 
fact that p i4^^^ is able to overcome MDM2 mediated reduction of the E2F apoptotic 
response implies that this may indeed be the case. However, p i4^^^ is also able to 
overcome E2F mediated apoptosis and these data suggest that p i4 ^^^ may be able to 
directly down-regulate E2F mediated apoptosis in a mechanistic pathway separate to 
that of MDM2s regulation of E2F.
3.3 p l4^ ^  down-regulates E2F dependant transcription.
It has been demonstrated that the p 14/19^^^ promoter is sensitive to E2F-1 over­
expression (Bates et aL, 1998; Robertson and Jones, 1998; Inoue et aL, 1999). The 
p l4 ^^F luciferase reporter construct consists of the Exonlp promoter region, from -  
805 to +59 which contains four potential anti-sense strand E2F consensus sites, fused
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to a luciferase reporter gene (Figure 3.2A) (Bates et aL, 1998; Robertson and Jones,
1998). It is consistent with these results that the over-expression of E2F-1 efficiently 
activated the p l4 ^^F promoter in a p53 and pRb negative SAOS2 background (Figure 
3.2B).
Given that p l4 '^ ^F \yas able to down-regulate E2F-1 induced apoptosis it was of 
interest to examine the effect of p l4 "^ F^F E2F-1 mediated transcription. SA0S2 
cells transfected with E2F-1, or DP-1 and the p l4 ^^ F^ Eip-luciferase reporter gene 
showed activation of the reporter gene and, as expected E2F-1 and DP-1 transfected 
together showed a co-operative effect (Figure 3.2B). pld'^^^F transfected with the 
Eip-luciferase reporter showed no significant effect (similar luc/pgal readings). 
However, interestingly pl4^^^ was able to down-regulate the transcription activation 
by E2F-1-DP-1 in a titratable manner (Figure 3.2B). These data suggest that p l4 ^^F 
is able to act to down-regulate E2F transcription in a dose-dependent, p53- 
independent manner.
3.4 p l4^ ^  is a general down-regulator of E2F dependent transcription
Members of the E2F family of transcription factors are able to activate a number of 
cellulai- genes including; dhfr, cyclinE and a?/(Helin et aL, 1998). As p l4 ^^^ can 
down-regulate E2F mediated transcription on the p l4 ^^^ Eip-luciferase reporter 
gene, it was of interest to ask if this effect was specific for the p l4 ^^F promoter or 
whether pld^^^ could down-regulate the transcription of other E2F responsive genes.
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And, is this down-regulation specific for E2F or is pl4^^^ a general down-regulator 
of activated transcription.
In order to address the issue of E2F specificity, synthetic promoter constructs were 
used: 3Xwild-type-luciferase, which has three E2F sites engineered into the promoter 
of the luciferase reporter gene, and 3Xmutant-luciferase which has three mutated 
E2F sites engineered into the promoter (Zamanian and La Thangue, 1992). These 
promoter constructs were transfected into SAOS2 cells together with E2F-1, pl4"^^^ 
orbothE2F-l a n d p l4 ^ ’'.
As expected, on the wild-type luciferase reporter, E2F-1 caused activation (2 fold), 
while p l4 ^^F slightly increased reporter gene activity (0.3 fold increase over mock). 
p l4 ^^F was able to down-regulate E2F-1 mediated transcription to a level 
comparable to that of p l4 ^^^ alone (Figure 3.3A). The same experiment was carried 
out concun'ently on the mutant luciferase reporter gene. As expected E2F-1 was 
unable to significantly activate the mutant promoter (0.3 fold increase over mock, 
compare to the 2 fold increase in figure 3.3A), due to the inability of E2F to bind to 
the mutated E2F binding sites (Figure 3.3B). However, the addition of p l4^ F  had no 
effect on the promoter, as did the expression of E2F-1 and pl4^^^ together. These 
data suggest that the observed down-regulation of E2F dependent transcription by 
p l4^^F -g specific for E2F, and that p l4 ^^F is probably not affecting other 
components of the basal transcriptional complex.
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In order to determine whether p l4 ^^F was able to affect transcription from other 
cellular E2F target genes, a similar experiment was earned out on the cyclinE- 
luciferase reporter gene. The cyclinE promoter is a well-defined physiological target 
of E2F (Ohtani et aL, 1995). As expected, E2F-1, or DP-1 transfected together with 
the cyclinEAuciferase reporter gene caused an increase in the level of transcription, 
and p l4 ^^F had no significant effect on the cyc/mE-luciferase gene activity (Figure 
3.3C). Together E2F-1 and DP-1 co-operated to increase the amount of reporter 
activity relative to the level seen with either E2F-1 or DP-1 alone (Figure 3.3C). 
When p l4 ^ F  was transfected together with E2F-1, DP-1 and cyc/mE-luciferase a 
down-regulation of E2F mediated transcription was again observed (Figure 3.3C).
3.5 p 14^^ may down-regulate E2F mediated apoptosis through down- 
regulation of avaf-1 transcription.
Recent studies have identified the gene for the apoptotic factor apaf~l as a 
transcriptional target for E2F-1 (Moroni et aL, 2001). It was therefore of interest to 
investigate the effects of pld'^ '^ ^F tmnsactivaiion of this promoter by E2F-1.
Firstly, the reporter gene constructs (Moroni et aL, 2001) were checked for their 
ability to be activated by both E2F-1 and p53.
As expected (Moroni et aL, 2001) the Apaf-1 -871/+208 reporter gene was activated 
by both E2F-1 and p53 (Figure 3.4A). The Apaf-1 -396/+208 reporter gene was 
activated by E2F-1 but not by p53 (Figure 3.4B) and the +35/+208 reporter construct
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was not activated by E2F-1 (Figure 3.4C). However, unexpectedly, this reporter did 
respond to p53, an effect not reported by the authors (Figure 3.4C).
In order to investigate the effect of p 14^^Fqu E2F and p53 activity on the Apaf-1 
promoter, reporter assays were performed. Firstly, the reporter constructs were 
transfected into SAOS2 cells along with E2F-1 or p53. All reporter activities were 
consistent with what was observed above (Figure 3.4) and described by Moroni et al. 
(2001).
Additionally, cells were transfected with p l4 ^^F ^oth alone, and in combination with 
E2F-1 or p53 in order to determine the effect of pl4^^^ on the activity of these 
reporter genes. Firstly the -396 construct was investigated and as expected, this 
reporter gene was activated by E2F-1 but not by p53 (Figures 3.4 and 3.5A). 
Additionally, p l4 ^^F had no significant effect on this promoter, however when 
transfected together with E2F-1, pl4^^^ caused a decrease in the reporter activity 
observed when compared with E2F-1 alone. This decrease was dose-dependent and 
consistent with previous results obtained from E2F-1 responsive promoters (Figures 
3.2B and 3.3) pM^’^F ^nd p53 transfected together in this experiment showed no 
difference compared to p53 alone, indicating that p i4 ^^F affecting p53 activity 
(Figure 3.4A).
From these combined experiments it is possible to conclude that pld^^P can 
specifically down-regulate E2F-1, and consequently E2F-1/DP-1 mediated 
transcription. This effect may have physiological significance in that p l4 ^^F may be
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able to down-regulate the expression of cellular proteins, such as cyclinE, Apaf-1 
and p l4 ^^ F^  which are regulated by E2F-1.
3.6 p l4^ ^  can activate transcription and co-operate with E2F-1 to fmwyactivate 
reporter gene constructs.
The Apaf-1-871/+208 reporter construct was also investigated in SA0S2 cells, this 
reporter gene responded to both E2F-1 and p53 as previously described (Figure 3.4A 
and 3.5B). p l4 ^^F was transfected alone and in combination with both E2F-1 and 
p53. Unexpectedly, p l4 ^^F caused an increase in reporter gene activity when 
compared to mock (Figure 3.5B, 2 fold increase). In contrast to previous 
observations, p l4 "^F co-operated with E2F-1 to increase reporter gene activity 
(Figure 3.5B). When p53 and p l4 ^^^ were transfected together with the Apaf-1 -  
871/+208 reporter gene an increase in reporter gene activity was observed when 
compared to p53 alone (Figure 3.5B).
As a negative control for these experiments, the Apaf-1 +35/+208 reporter gene 
construct was used. This construct lacks both the p53 and E2F-1 binding sites, 
however has been shown previously (Figure 3.4C) to be responsive to p53. As 
expected, E2F-1 was unable to activate reporter gene expression, and p53 caused a 
slight activation of this promoter construct (Figure 3.4C). When pM^^^was 
transfected with the +35/+208 Apaf-1 reporter gene construct, activation of the 
reporter gene was observed (Figure 3.5C), and when p l4 ^^^ ^nd E2F-1 were 
transfected together then an increase in activation was observed (Figure 3.5C).
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also caused an activation of this promoter when transfected together with p53 
(Figure 3.5C).
These results suggest a role for p l4 ^^P transcriptional activation, and that it can 
positively regulate the transcription of certain reporter genes in combination with 
site-specific DNA binding transcription factors.
3.7 p 14^^ can overcome E2F mediated S-phase entry.
Given that E2F is a transcription factor that plays a role in the regulation of S-phase 
entry, through expression of genes required for S-phase progression, and that pl4^^^ 
is able to down-regulate E2F dependent transcription it was of interest to ask if 
p l4 ^^F any effect on cell cycle progression. In order to investigate the role of 
E2F-I and pM^^F cell cycle progression, a BiDU assay was employed. Cells 
incorporating BrDU were counted and normalised for transfection efficiency.
E2F-1 over-expression in p53 and pRb negative SAOS2 cells led to an increase in 
the number of cells undergoing S-phase, over the mock transfected population 
(Figure 3.6 A, B). DP-1 and pl4^^^ over-expression also caused an increase in the 
number of cells in S-phase relative to mock transfected cells (Figure 3.6 A, B). As 
expected, when E2F-1 and DP-1 were expressed together an increase in the number 
of S-phase cells over either E2F-I or DP-1 alone was observed (Figure 3.6 A, B) and 
when p l4 ^^F was over-expressed together with E2F-1 and DP-1 the number of cells 
in S-phase reverted back to that observed with p l4^^^ alone.
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These data support the observations made from the reporter assay experiments. As 
able to down-regulate E2F mediated transcription, then it is not surprising 
that this also leads to a cell cycle arrest. Also, the data support a physiological 
consequence of pl4^^^ having an effect on E2F, namely a block of cell cycle 
progression.
3.8 p 14^^ down-regulates E2F mediated cell growth
It has previously been shown that expression of E2F-1 and DP-1 together in a colony 
forming assay resulted in a much decreased level of colonies than with empty vector 
alone (Loughran and La Thangue., 2000), suggesting that the E2F-1 and DP-1 
heterodimer has tumour suppressor properties. As pl4^^^ overcomes E2F mediated 
cellular proliferation (Figure 3.6A) I reasoned that p l4 "^ F^ may also co-operate with 
E2F in cell viability.
As expected from previous experiments E2F-1 and E2F-1/DP-1 together caused a 
significant decrease in the number of colonies observed from the empty vector 
control, however DP-1 alone had no significant effect over the pcDNA control 
population (Figure 3.7B). pl4^^^ alone reduced colony formation, and when 
expressed together with E2F-1 and DP-1 caused a decrease in viability compared to 
E2F-1 and DP-1 alone (Figure 3.7 A,B). This effect of p l4 ^^F E2F-1-DP-1 was 
suggestive of a role for p l4 *^^ F and E2F-1/DP-1 in the suppression of cell growth.
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3.9 Conclusions
The experiments performed in this chapter show that p i4^^^ can down-regulate E2F 
transcription, and overcome E2F-1/DP-1 mediated apoptosis, cell cycle progression 
and growth. These data show that p l4 ^^F jg able to down-regulate E2F-1 activity and 
that the observed effects on apoptosis and cell cycle progression may be linked to 
down-regulation of E2F target genes. In some situations, pl4^^^ may be able to act 
as a transcriptional activator, and increase transcription mediated by other cellular 
transcription factors. p l4 ^^F ^^s been shown to induce apoptosis and this could be a 
result of its ability to activate Apaf-1 reporter gene constructs. Further work is 
required in order to elucidate the mechanisms by which p l4 ^^F regulates E2F 
function.
3.10 Discussion
The data presented establish the previously described role for p l4 "^F a growth 
suppressor and also suggest a role for pl4"^^^ in the E2F pathway, pld^^^^ has 
previously been shown to induce a p53 dependent and independent cell cycle arrest 
(Quelle et at, 1995; Pomerantz et al, 1998; Zhang et al, 1998; Kurokawa et al,
1999), and these experiments imply that this may be through the targeting of E2F 
activity. p l4 ^^ F^ jg able to down-regulate E2F-1 activity in a number of independent 
transfection assays, suggesting that these effects may occur in vivo.
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The fact that E2F-1 is able to activate expression, and pl4^^^ itself can
down-regulate E2F-1 mediated expression of the p l4 ^^F promoter suggests the 
presence of an auto-regulatory feedback loop, where p l4 ^^^ jg able to regulate its 
own expression as well as that of other E2F target genes. Many genes can control 
their own regulation in this manner, an example of such being the p53-MDM2 auto- 
regulatory feedback loop (Prives, 1998).
Recent data which shows that E2F-1 can rran^activate the Apaf-1 gene (Moroni et 
a l, 2001), could explain the ability of p l4 ^^^ to down-regulate E2F mediated 
apoptosis, through its transcriptional inhibition of E2F-1 responsive genes. However, 
the results presented suggest that p l4^^^ may act as both an activator and repressor 
of transcription under certain circumstances.
Consistently, p l4 ^^F has been described as a regulator of p53 activity (Pomerantz et 
al, 1998), these data show that p l4 ^^F may also regulate the E2F pathway in cells 
and further investigation of the mechanisms involved is required.
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Figure 3.1 p i4^ ^  regulates E2F-1/DP-1 mediated apoptosis.
(A) SA0S2 cells were transfected as described with 6 |Ug of each indicated 
plasmid: pcHDM2, CMV-DP-1, and pRcHA-E2F-l. After transfection cells 
were washed and further grown overnight in 0.2% fetal calf serum in DMEM. 
Apoptosis was assayed approx 18 hours post transfection and data is 
expressed as % apoptosis relative to the total number of transfected cells. The 
data shown is representative of at least three independent experiments.
(B) SAOS2 cells were transfected as described with 6pg of each p l4 ^^ ^^  CMV- 
DP-1, and pRcHA-E2F-l. After transfection cells were washed and further 
grown overnight in 0.2% fetal calf serum in DMEM. Apoptosis was assayed 
18 hours post transfection and data is expressed as % apoptosis relative to the 
total number of transfected cells. The data shown is representative of at least 
three independent experiments.
(C) SAOS2 cells were assayed as described for (A) and (B).
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Figure 3.2. p l4^ ^  effect on E2F-1 mediated transcriptional activation of the
ElB-iuciferase promoter.
(A) Schematic representation of the ExonlB-luciferase promoter construct. The 
four potential anti-sense E2F sites are shown as blue lines and SPl sites are 
shown as red spots. The E2F sites at -265 and +27 are good matches to the 
E2F consensus site (TTTCCCGCCA/TA/T) whereas the sites at -249 and -69 
are poor matches (Robertson and Jones, 1998). The indicated initiation codon 
for luciferase expression is located at +59 and the previously mapped 
transcriptional stait site within the pl4*^^ promoter is defined as position +1 
(Mao et al., 1995). The previously described E2F-1 responsive site at -275 to 
-261 is highlighted (Bates et al., 1998).
(B) SA0S2 cells were transfected with the following plasmids per 6cm plate; 
pRcHA-E2F-l (50ng), CMV-DPl (500ng), p l + ‘" ’(250ng,500ng,750ng,lng 
respectively), EiP-luciferase (4|Lig), CMV-Pgal (500ng). Lysates were assayed 
40 hours post-transfection and each assay was performed in duplicate. Data is 
shown as luciferase/Pgal value. The data shown is representative of at least 
three typical experiments.
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Figure 3.3. 014"^^ effect on E2F1 mediated transcriptional activation of E2F- 
1 responsive genes.
(A)SAOS2 cells were transfected with the following amounts of plasmids per 
6cm plate; 3X wild-type-luciferase (Ifig), CMV-pgal (500ng), pRcHA-E2F-l 
(500ng)pl4^*^^(500ng).
(B) SAOS2 cells were transfected as described in (A) except 3X mutant-luciferase 
(Ipg) was used in place of 3X wild-type-luciferase.
(C) SAOS2 cells were transfected with the following amounts of the indicated 
plasmids per 6 cm plate: CyclinE-luciferase (200ng), CMV-Pgal (500ng), 
pRcHA-E2F-l (200ng), CMV-DPl (Ipg), pl4^''(500ng).
(A), (B) and (C). Lysates were harvested 40 hours post-transfection and each plate 
was performed in duplicate. Data are shown as luciferase/pgal value. The data 
shown is representative of at least three experiments.
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Figure 3.4. Characterisation of the A v a f-1  reporter genes.
SAOS2 cells were transfected with the following plasmids per 6 cm plate; pRcHA- 
E2F-1 (500ng, Ipg), p53 (Ipg, 2pg), Apaf-1 reporter gene (2pg), CMV-|3gaI 
(500ng). Lysates were assayed 40 hours post-transfection and each assay was 
performed in duplicate. Data are shown as luciferase/pgal value. The data shown 
are representative of at least three typical experiments.
(A) The Apaf-1 -871/+208 reporter gene was used.
(B) The Apaf-1 -396/+208 reporter gene was used.
(C) The Apaf-1 +35/+208 reporter gene was used.
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Figure 3.5 p14^^ can regulate the apaf-1 reporter gene constructs.
SAOS2 cells were transfected with the following plasmids per 6cm plate; pRcHA- 
E2F-1 (500ng), p53 (2|Lig) pl4^^^(+3)Lig, ++ 6 jiig), Apaf-1 reporter gene (2pg), 
CMV-Pgal (500ng). Lysates were assayed 40 hours post-transfection and each 
assay was peifonned in duplicate. Data is shown as luciferase/pgal value. The 
data shown is representative of at least three typical experiments.
(A)The Apaf-1 -396/+208 reporter gene was used.
(B) The Apaf-1 -871/+208 reporter gene was used.
(C) The Apaf-1 +35/+208 reporter gene was used.
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Figure 3.6 p l4^ ^  down-regulates E2F-1/DP-1 mediated S phase progression.
(A) SAOS2 cells were transfected as described with 5j4g of each pRcHA-E2F-l, 
CMV-DP-1, pl4^^^. After transfection cells were washed and further grown 
overnight. BrDU incoiporation was assayed 18 hours post-transfection and data is 
presented as %BrDU incorporated relative to number of transfected cells/p- 
galactosidase value. The data shown is representative of at least three independent 
experiments.
(B) BrDU data are presented as number of cells counted. Data shown is from a 
single experiment. BrDU incorporation was calculated by dividing the number of 
BrDU positive cells by the total number of cells counted and then normalised for 
transfection efficiency (determined by pgal activity).
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Figure 3.7 overcomes E2F mediated colony forming activity.
(A) SAOS2 cells were transfected with lO^g each of pcRHA-E2F-l, CMV-DP-1 
and p i4^^^. Total DNA transfected was normalised with pcDNA3. After 3 
days, cells were split 1:5 with non-transfected SAOS2 cells. Transfected cells 
were selected in G418 antibiotic (Sigma) for 2 weeks and colonies were 
stained with crystal violet solution.
(B) Graphical representation of colony forming data. Experiments were performed 
as described in (A). The average number of colonies from the counts was 
plotted against the pcDNA3 control plate. The data shown is representative of 
at least three independent experiments.
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Figure 3.8 Model for p l4^ ^  down-regulation of E2F.
(A) Model for the pl4^^^-E2F-l auto-regulatory feed-back loop. Black lines 
indicate previously identified pathways. The red line shows the pM '^^
mediated down-regulation of E2Factivity.
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Chapter 4. pl4^^ and E2F-1 biochemical analysis.
4.1 Introduction
The interactions between cellular proteins are commonly required for them to 
regulate the activity of one another. E2F-1 binds to, and is regulated by a large 
number of cellular proteins including; pRb (Helin et ah, 1993), cyclin A (Krelc et 
a l, 1993) and MDM2 (Martin et al., 1995).
Both p i4^^^ and p i9^^^ have been shown to bind directly to MDM2 and form a 
ternary complex with p53 (Pomerantz et al, 1998). Whether or not p i4/19^^^ is 
able to bind directly to p53 or not is yet to be elucidated but evidence suggests 
that it is unable to bind p53 directly (Stott et al, 1998; Zhang et al., 1998). 
Recently has been shown to bind to topoisomerase I, a protein required for
S-phase progression (Karayan et al., 2001).
Given that p l4 ^ ^  can regulate the activity of E2F, it is of interest to investigate 
whether E2F-1 and DP-1 can bind to pl4^^^, and if this binding occurs in cells. 
Additionally, it is also important to attempt to elucidate the domains in E2F-1 and 
DP-1 which pl4^^^ can interact with in order to provide us with further clues as to 
the method of regulation of E2F by pl4^^^.
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4.2 p l4^ ^  interacts with E2F-1 and DP-1
The ability of p i4^^^ to interact with MDM2 and regulate p53 has been well 
documented (Zhang et al, 1998; Weber et al, 1999; Zhang and Xiong, 1999; 
Lohrum et al, 2000). Given that p i4^^^ can regulate E2F activity it was of 
interest to ask whether pl4"^^^ is able to interact with either the E2F or DP 
components of the heterodimer. In order to address this question, a GST binding 
assay in a cell free system was utilised, and the ability of in vitro translated 
MDM2, E2F-1 and DP-1 to interact with a bacterially purified GST-pl4^^^ 
protein was examined (Figure 4.1 A and 4. IB). E2F-1, DP-1 and a equimolar 
mixture of the two proteins were all able to bind to bacterially expressed GST- 
pl4^^^. The specificity of each binding reaction was confirmed by the inability of 
a non-specific luciferase control protein to bind. In all cases GST alone failed to 
bind to any of the in vitro translated proteins (Figure 4. IB).
In order to confirm this reaction with endogenous E2F-1 the same GST and GST- 
pl4^^^ proteins (Figure 4.1AÜ) were used in a pull-down assay from cell extracts. 
p53 null SAOS2 cells were used in order to rule out the involvement of p53 in any 
interaction. Endogenous E2F-1 binds efficiently to GST-pl4^^^, but not to the 
GST protein (Figure 4.1C) suggesting that this interaction may indeed exist in 
vivo and so may be physiologically significant.
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4.3 Components of the E2F complex interact with 014"^^ in vivo
In order to investigate whether E2F-1 and DP-1 could bind in vivo to p i a n  
endogenous immunoprécipitations was performed. HeLa cells, which have the 
p53 pathway inactivated were used for the endogenous immunoprécipitations due 
to their high levels of p i4^^^. As expected pl4^^^ immunoprecipitated efficiently 
with MDM2 (Figure 4.2) and failed to immunoprecipitate with a non-specific 
antibody (Figure 4.2). When immunoprécipitations were performed with an E2F-1 
antibody, pl4^^^ was detected in the immunoprecipitates (Figure 4.2) and in 
reverse, when a pl4^^^ antibody was used to immunoprecipitate, E2F-1 was 
detected in the immunoprécipitations (Figure 4.2). Additionally, MDM2 was 
present in the E2F-1 and p i4^^^ immunoprécipitations but E2F-1 was not present 
in the MDM2 immunoprecipitate (Figure 4.2).
4.4 p l4^ ^  binds to a region in the heterodimerisation domain of DP-1
A GST binding assay approach was used in SAOS2 cells to confirm the DP-1 
interaction in cell extracts. Cell extracts were prepared from p53'^' rh'‘^  SA0S2 
cells and endogenous DP-1 was found to interact specifically with GST-pl4"^^’ 
but not with GST protein alone (Figure 4.3A). In order to gain further insight into 
the DP-1-p i4^^^ interaction a cell free pull down system was utilised to 
investigate the binding properties of in vitro translated DP-1 mutants (Figure 
4.3B). The N-terminal deleted mutants in DP-1 delta 97, deltalTl and an internal 
fragment of DP-1, encompassing the heterodimerisation domain 205-310 were all
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able to bind efficiently to GST-pl4^^^. In contrast an N-terminal mutant deleted 
up to amino acid 242, encompassing the C terminal region of DP-1 was unable to 
bind to GST-pl4^^. In all cases, GST protein alone failed to bind to any of the in 
vitro translated proteins (Figure 4.3C). These data suggest that pl4^^^ binds to 
DP-1 in a region within DP-1 205 to DP-1 242. As this is the region in DP-1 
which binds to E2F, it is possible that p i4^^^ may affect heterodimer formation 
and hence explain its ability to compromise the function of E2F in transcription 
and apoptosis.
4.5. p l4^ ^  binds to a number of distinct domains in E2F-1.
Given that pl4^^^ binds to the heterodimerisation domain in DP-1, and that E2F-1 
has a similar domain, it was of interest to determine whether pl4^^^ also bound to 
the heterodimerisation region in E2F-1, and if not, then which region of E2F-1 
does pl4"^^^ bind to.
A number of mutants in E2F-1 (Figure 4.4A) were in vitro translated and tested 
for binding to GST-pl4^^^ in the pull-down assay system. The E2F-1 mutants 
E2F-1-Y411C, a point mutant compromised in pRb binding (Helin et aL, 1992) 
and E2F-1 delta C, lacking the fm^jactivation domain were able to bind pl4^^^ 
with equal affinity to wild-type E2F-1 (Figure 4.4B).
In order to further identify binding domains for pl4^^^ in E2F-1, E2F-1 delta 24, 
compromised in cyclin A binding, and E2F-1 constructs encompassing the regions 
from amino acid 141-261 and 181-261 were in vitro translated and tested for
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binding to GST-pl4'^^^. Both of these central regions of E2F-1 were able to bind 
to p i4^^^ (Figure 4.4C), suggesting a role for the DNA binding domain in the 
ARF-E2F-1 interaction. These data suggest that p i4^^^ may bind to the DNA 
binding domain in E2F-1 and prevent E2F-1 from contacting the DNA and 
activating transcription. In addition to this, the delta 24 E2F-1 mutant could also 
bind to G ST-pl4^^ (Figure 4.4C), indicating that the inability to bind to cyclin A 
does not affect ARF-E2F-1 binding.
4.6 Conclusions
These experiments show that p i4"^^ and E2F-1, and pl4"^^^ and DP-1 can interact 
with one another both in vivo and in vitro. Mapping data indicates that a number 
of binding domains exist for pl4"^^^ in E2F-1 and that the binding domain for 
pl4^^^ in DP-1 is in the heterodimerisation domain.
4.7 Discussion
Experiments performed both in vivo and in vitro indicate that p i4^^^ can bind to 
both components of the E2F heterodimer, E2F-1 and DP-1. The interaction 
between p l4 ^ ^  and E2F-1 occurs in cells and so may be physiologically 
significant for the regulation of E2F activity by pl4'*'^^. This binding of E2F-1 to 
p l4^^^ could be direct or could be mediated by a cellular protein, and further 
work is required to investigate these possibilities. The fact that MDM2 is detected 
in p i4^^^ and E2F-1 immunoprecipitates also indicates that the three proteins may 
exist in a trimeric complex, and that pl4^^^ regulation of E2F-1 could be 
mediated through MDM2.
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The mapping data presented suggest that may be able to disrupt the E2F-1-
DP-1 interaction by binding to the heterodimerisation domain in DP-1, however 
further mapping of the E2F-1 interaction domain is required to confirm this 
observation. It is possible that p i 4^^^ may act to prevent E2F-DP 
heterodimerisation, and prevent efficient heterodimer activities, although both 
proteins are able to bind to p i4^^^ at the same time (Figure 4 .IB). pl4^^^ is able 
to bind to a number of domains in E2F-1 (Figure 4.4B, C). More work is required 
to identify the exact binding domains in E2F and their function in cells in order to 
fully understand the E2F-pl4^^^ interaction and its physiological consequences.
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Figure 4.1 p l4^ ^  binds to E2F-1 and its heterodimeric partner DP-1
(A)(i) in vitro translated inputs used for pull-down assay. The indicated plasmids 
were in vitro translated and 10% of each input ran on an SDS-PAGE gel. (ii) 
GST proteins were purified from bacteria and expression verified by SDS-gel 
elecrophoresis.
(B) Equal amounts of pcMDM2, pRcHA-E2F-l, CMV-DP-1, and firefly 
luciferase in vitro translates were incubated with approx. 1 p,g GST or GST- 
pl4^^^protein (detei*mined by electrophoresis) for 1 hour at 4°C. Reactions 
were washed 3 times before SDS-PAGE analysis and exposure to film 
overnight.
(C) Nucleai' extracts were prepared from S A0S2 cells. Equal amounts of extract 
(200pg) were incubated with GST or G ST-pl4^^ overnight at 4°C. Samples 
were washed 3 times before SDS-PAGE analysis and western blotting with an 
E2F-1 specific antibody KH95 (Santa Cruz).
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Figure 4.2 p l4^ ^  binds to E2F-l!n cells.
HeLa cell nucleai' extract (Computer Cell Culture) (500jLtg) was incubated in 
lOOp.1 TNE with anti-E2F-l, anti-pl4*^, anti-MDM2 or anti-HA antibody 
overnight at 4°C with rotation. Protein A agarose was then added to samples for 3 
hours at 4°C with rotation. Immunoprecipitates were washed 3 times in binding 
buffer and resuspended in 3x SDS loading buffer, analysed by SDS-page and 
western blotting.
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Figure 4.3 014"^^ binds to DP-1
(A)(i) Nucleai' extracts prepared from SA0S2 cells were incubated with approx. 
l|ag purified GST protein overnight at 4°C. Samples were washed and 
resuspended in SDS loading buffer prior to SDS-PAGE analysis. (ii)Westem 
blotting was performed with the DP-1 specific anti-sera 098 ().
(B) Schematic of mutant constmcts used in the in vitro binding assay, and their 
binding to E2F-1 and pl4**^.
(C) The indicated DP-1 constructs (Figure 3.6B) were in vitro translated and an 
equimolar amount of each protein was incubated with approx. lp,g of purified 
GST protein for 1 hour at 4°C. Samples were washed before re-suspension in 
SDS loading buffer and SDS-PAGE analysis. Gels were dried and exposed on 
film overnight.
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Figure 4.4. 014"^^ binds to a number of domains in E2F-1.
(A)The pRc-HA-E2F-l, Y C llC  and pRcHAE2F-ldeltaC plasmids were in vitro 
translated and an equimolai* amount of each in vitro translate was incubated 
with Ipg of GST or GST-pI4^^^ protein for 1 hour at 4°C. Reactions were 
washed extensively before being subjected to SDS-page analysis.
(B)The plasmids HAE2F-1, HA-E2F-I delta 24, 141-261 and HAE2F-1 181-261 
were in vitro translated and analysed for p i4 ^ ^  binding as described in (A),
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Figure 4.5 Model for E2F regulation bv pl4^^.
Diagram showing possible mechanism for regulation of E2F activity through 
binding to Red ovals indicate pocket proteins (pp) and green circles (P)
phosphorylation.
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Chapter 5. pl4^^ regulation of E2F is MDM2
independent.
5.1 Introduction
MDM2 was first identified as an amplified gene in a transformed mouse 3T3 cell 
line (Cahilly-Snyder et al, 1987). Since then it has been shown that the human 
form of MDM2 is over-expressed in a number of human tumours, particularly 
sarcomas, leukaemias, breast carcinomas and malignant gliomas (Cordon-Cardo 
et al, 1994, Ladanyi, et al, 1993, Leach et al, 1993, Sheikh et al, 1993).
MDM2 is involved in a negative feedback loop with its transcriptional activator, 
p53 (Wu et al, 1993). p53 up-regulates MDM2 expression, and in turn MDM2 
can export p53 from the nucleus, and target it for ubiquitin mediated degradation 
(Haupt, et al, 1997; Honda et al. 1997). MDM2 can also bind directly to the p53 
rraw.yactivation domain and down-regulate p53 dependent transcription and 
apoptosis (Haines et al, 1994). The functional relationship between MDM2 and 
p53 is dramatically illustrated by the finding that a p53-null state in mice can 
completely rescue the early embryonic-lethal phenotype of MDM2 deficiency 
(Jones et a l, 1995), demonstrating that the p53-MDM2 pathway is essential in 
development, and that the regulation of p53 by MDM2 in development is crucial.
Both pl4*^^ and p i9"^ ^^  have been shown to bind directly to MDM2 and form a 
ternary complex with p53 (Pomerantz et al, 1998). MDM2 normally shuttles 
between the nucleus and the cytoplasm in order to target p53 for degradation 
(Roth et a l, 1998). Honda et a l  (1999) demonstrated that association of pl9*^^
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with MDM2 inhibits the ubiquitin ligase activity of MDM2 for p53, and that the 
activity of a pl9^^^-MDM2 complex in a ubiquitination assay is lower than the 
activity of free MDM2 (Honda et al, 1999). These data highlight the importance 
of pl9*^^ mediated p53 stabilisation.
Co-expression of pl9**^ and MDM2 prevents nuclear-cytoplasmic shuttling of 
MDM2, and as time increases, MDM2 can move to the nucleolus (Tao et al,
1999). Much data supports this MDM2 nucleolar localisation, and re-localisation 
of MDM2 also occurs following Myc activation and replicative senescence 
(Weber et al, 1999). Data imply that pl9**^ binding to MDM2 may induce a 
conformational change that facilitates nucleolar import of the ARF-MDM2 
complex (Weber et al, 2000)
In order to investigate the role of MDM2 in the p53-ARF pathway, triple knock 
out (TKO) mice were generated lacking p i 9^ "^ ,^ MDM2 and p53 (Weber et al,
2000). TKO mice developed more tumours than p53'^'/mdm2'‘\  or p53''' mice and 
the réintroduction of ARF into TKO cells resulted in a G1 arrest (Weber et al, 
2000). Interestingly, re-introduction of ARF into p53'^larf‘' cells did not result in 
G1 arrest, implying that pl9^^^ interacts with targets other than MDM2 to inhibit 
cell proliferation. MDM2 antagonises some activity of ARF on targets other than 
p53, and in the absence of MDM2 this other ARF activity is revealed. These data 
suggest that ARF and p53 loss contributes independently to some aspects of 
tumour progression (Weber et al, 2000). pl9"^^ is also able to suppress colony 
formation in p53~'' cells by targeting the Rb pathway (Camero et a l, 2000), 
providing further evidence for p53 independent targets for p 14/19^^^.
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Given that MDM2 can regulate E2F activity (Martin et a l, 1995; Loughran and 
La Thangue 2000), and that pl4^^^ is a known regulator of MDM2 function 
(Pomerantz et a l, 1998), it was of interest to investigate whether p l4 ^ ^  was 
controlling E2F activity through MDM2 or an independent mechanism.
5.2 p 14^^ can down-regulate E2F mediated transcription in p53'‘'!mdm2''' 
cells
In order to investigate the role of MDM2 in p i4^^^ mediated down-regulation of 
E2F-1 transcription, p53''lmdm2'‘' mouse embryonic fibroblasts were used for 
transfection experiments. As these cells lack both the p53 and MDM2 proteins, 
any effects observed in these cells must occur independently of MDM2. We have 
previously shown that E2F-1 can activate the activity of two reporter genes, 
ExoniP-luciferase (Figure 3.2), and 3X wild-type (Figure 3.3A) in p53'^' SAOS2 
cells.
In p53'''lmdm2'^' cells transfected with the 3X wild-type luciferase reporter gene, 
E2F-1 caused activation, while pl4**^ had no significant effect on reporter gene 
activity (Figure 5.1A). When pl4^^^ was co-expressed with E2F-1, pl4*^^ was 
able to down-regulate E2F-1 mediated transcription to a level comparable to that 
of pl4*^^ alone (Figure 5.1 A). The same experiment was carried out concurrently 
on the mutant luciferase promoter. As expected E2F-1 was unable to significantly 
activate the mutant promoter, due to the inability of E2F to bind to the mutated
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E2F binding sites (Figure 5.IB). However, the addition of had no effect on
the promoter, as did the expression of E2F-1 and pl4^^^ together.
These data suggest that the observed down-regulation of E2F dependant 
transcription by pl4*^^ is specific for E2F, and that p i4^^^ is not affecting other 
components of the basal transcriptional complex, in cells lacldng MDM2 and p53 
as well as in SAOS2 cells. In addition to this, MDM2 is not required for pl4*^^ to 
down-regulate E2F-1 mediated transcription.
In order to further investigate the role of MDM2 in the ARF-E2F pathway, and to 
verify that the observed effects were not promoter specific, the ExoniP- 
luciferease promoter was also used in the p53'''lmdm2''~ cells. 
p53'''lmdm2'^' cells transfected with E2F-1, DP-1 and the pl4*^^ Elp-luciferase 
reporter gene showed activation of the reporter (Figure 5.1C). pl4^^^ transfected 
with the Elp-luciferase reporter had a slight effect on reporter gene activity 
(Figure 5.1C), however, pl4^^^ was able to down-regulate the transcription 
activation by E2F-1/DP-1 to a similar level as observed in SAOS2 cells (Figure 
5.1C). These data suggest that pl4**^ is able to act to down-regulate E2F 
transcription in an MDM2 independent manner, and as a result of this down- 
regulation may consequently act to regulate its own expression and steady state 
levels via a negative feedback loop which does not involve MDM2.
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5.3 p14^^ can down-regulate E2F mediated S-phase progression in v53''' 
Imdml'^' cells
Given that we have previously shown that pl4*^^ can down-regulate E2F 
mediated S-phase progression in a p53 independent manner, and that p i4"^ ^^  is 
able to down-regulate E2F dependant transcription in the absence of MDM2 it 
was of interest to ask if pl4*^^ can still prevent E2F mediated S-phase 
progression in the absence of MDM2. In order to investigate the role of E2F-1 and 
PI4 ARF cell cycle progression in p53'''lmdmT'' cells, a BrDU assay was 
employed. Cells incorporating BrDU were counted and normalised for 
transfection efficiency.
E2F-1 over-expression in p53'^'/mdm2'^' cells led to an increase in the number of 
cells undergoing S-phase, over the mock transfected population (Figure 5.2), and 
DP-1 over-expression had no effect on the number of cells in S-phase relative to 
mock-transfected cells (Figure 5.2). As expected, when E2F-1 and DP-1 were 
expressed together, an increase in the number of S-phase cells over either E2F-1 
or DP-1 alone was observed (Figure 5.2).
Interestingly, in these cells p l4 ^ ^  caused a marked decrease in the number of 
cells undergoing S-phase when expressed alone, and when pl4**^ was over­
expressed together with E2F-1 and DP-1 the number of cells in S-phase decreased 
to the levels observed with mock-transfected cells (Figure 5.2). These data further 
supports the observations made from the transcription assay data. pl4*^^ is able 
to down-regulate E2F-1 mediated transcription in the absence of MDM2, and can
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/-also prevent E2F-1 mediated cell cycle progression. Interestingly, in the p53 
Imdm2’^ ' cells p 14^^^ has a significant effect on S-phase progression when over­
expressed alone, indicating a p53/MDM2 independent function for pl4*^^ in cell 
cycle regulation.
5.4 p 14^^ can bind to E2F-1 in the absence of MDM2
The ability of pl4^^^ to interact with MDM2 and regulate p53 has been well 
documented (Zhang et ai, 1998; Weber et ai, 1999; Zhang and Xiong, 1999; 
Lohrum et al, 2000). We have previously shown that bacterially expressed 
piqARF interact with exogenous E2F-1 from SAOS2 cells (Figure 4.1AÜ). 
pl4*^^ can down-regulate E2F-1 mediated transcription and S-phase progression 
in p53'''/mdm2'^' cells and so we decided to investigate whether pl4^^^ could still 
bind to E2F-1 in these cells.
In order to test this interaction with endogenous E2F-I the same GST and GST- 
proteins (Figure 4.1AÜ) were used to do a pull-down assay from p53’^ ' 
Imdm2''~ cell extracts. Endogenous E2F-1 bound efficiently to GST-pl4^^^, but 
not to the GST protein (Figure 5.3A) indicating that MDM2 is not required for 
this interaction to occur. We further confirmed the pl4^^^-E2F-l interaction to be 
independent of MDM2 through the use of a direct binding assay. Bacterially 
expressed His-E2F-1 was purified and equimolar amounts of His-E2F-1 were 
incubated with equal amounts of the indicated bacterially purified GST proteins, 
direct binding was analysed by SDS-page. As expected GST-DP-1 bound to His- 
E2F-1 and pl4^^^ also bound to F[is-E2F-1 (Figure 5.3B). In contrast a minimal
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amount of p i4^^^ background binding was observed with or GST beads (Figure 
5.3B), indicating that the interaction of E2F-1 and p l4 ^ ^  is direct, specific and as 
efficient as the interaction between E2F-1 and DP-1. These data further support an 
MDM2 independent and direct E2F/pl4^^^effect.
5.5 Conclusions
Together these data imply that pl4*^^ is able to regulate E2F activity 
independently of MDM2. pl4^^^ can bind independently of MDM2 and directly 
to E2F1. In addition to this, pl4^^^ can down-regulate E2F mediated transcription 
and E2F mediated E2F S-phase progression independently of MDM2.
5.6 Discussion
MDM2 is an important mediator of many cell cycle regulatory pathways. Its 
importance as a cell cycle regulator is highlighted by the embryonic-lethal 
phenotype observed in MDM2 knock out mice (Jones et ah, 1995). MDM2 can 
regulate the p53 pathway through a variety of mechanisms. Firstly, through a 
negative feedback loop, in which p53 activates MDM2 expression and in turn 
MDM2 down-regulates p53 activity (Wu et al, 1993) and also through its 
interactions with the p300 co-activator protein (Grossman et al, 1998). MDM2 
binds to p300 and has a role in p53 degradation (Grossman et al, 1998). p300 also 
acts in an MDM2 negative feedback loop to regulate p53, and is required for 
mdml induction by p53 and the subsequent inhibition of p53 stabilisation 
(Thomas and White, 1998).
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MDM2 has also been shown to bind to and regulate the activity of E2F-1 and DP- 
1 (Martin et al., 1995; Loughran and La Thangue 2000). MDM2 can bind to E2F- 
1 and DP-1 in vitro and can increase the activity of the heterodimer in reporter 
assay experiments (Martin et a l, 1995). In addition to this, MDM2 co-operates 
with E2F-1 and DP-1 to promote growth and S-phase progression, while 
additionally overcoming E2F dependent apoptosis and down-regulating the 
cellular levels of the E2F sub-units (Loughran and La Thangue, 2000).
We have previously shown that pl4*^^ can regulate E2F-1 activity in a p53 
independent manner. This data led us to further investigate the role of MDM2 in 
this interaction. Previous studies have implied targets other than p53 for 
p 14/19^^^ (Camero et a l, 2000; Weber et a l, 2000). One study in particular 
directly implicated that pl9*^^ can regulate the Rb pathway independently of 
MDM2 (Camero et a l, 2000). The evidence presented here indicate an MDM2 
independent, E2F-l-pl4^^^ interaction. In addition to this, pl4**^ can overcome 
both E2F mediated transcription and S-phase progression in p53'''lmdm2'^' cells 
(Figure 5.1 and 5.2), indicating that pl4*^^ is able to regulate E2F activity 
independently of MDM2.
Interestingly, in p53'‘lmdm2''' cells pl4*^^ causes a reduction in the number of 
cells undergoing S-phase compared to mock-transfected cells (Figure 5.2). This 
phenomenon has been observed by others (Weber et al., 2000) and further 
highlights a cell cycle regulatory role, independent of the p53-MDM2 pathway for 
piqARF in cell cycle regulation.
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Various studies have centred on the role of MDM2 in cell cycle regulation and 
although most MDM2 in the cell is bound to most pl4^^^ is not bound to
MDM2 (Llanos et al., 2001), (Figure 5.4)). The majority of MDM2 has also been 
shown to bind to p300 (Grossman et al, 1998). Whether this binding of MDM2 is 
cell type or status dependent is yet to be elucidated. However, it could be that 
PI4 ARF MDM2 and p300 exist in a multi-protein complex which can regulate 
both p53 and E2F activity, depending on the cellular signals received; or that 
MDM2 can bind preferentially to different cell-cycle regulatory proteins 
depending on yet unknown cellular conditions (Figure 5.4). In addition to this 
PI4AKF can regulate E2F activity independently of MDM2, suggesting that while 
some pl4*^^ may be bound to MDM2, some must also be free to bind and 
regulate the activity of other cellular proteins.
Further work is required to elucidate the mechanisms by which MDM2 governs 
cell-cycle progression, and to investigate whether MDM2 can also be involved in 
E2F regulation by and whether the p300 co-activator can affect this
pathway.
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Figure 5.1. pl4 ' transcriptional repression of E2F-1 is MDM2 independent
(A) p53'^’lmdm2'^' MEFs were transfected with the following amounts of the 
indicated plasmids per 6 cm plate; 3xWT-luciferase (Ipg), CMV-Pgal (500ng), 
HA-E2F-1 (500ng), pl4*^^ (5|Lig). Lysates were assayed 40 hours post­
transfection and each plate was performed in duplicate. Data are shown as 
luciferase/Pgal value. The data shown are representative of at least three 
typical experiments.
(B)Cells were transfected and assayed as described in (A) except 3XMutant- 
luciferase was used in place of 3Xwild-type-luciferase.
(C)Cells were transfected and assayed as described in (A) except Elp-luciferase 
(4pg per 6cm plate) was used as the reporter.
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Figure 5.2. p l4^ ^  down-regulation of E2F mediated S-phase progression is 
MDM2 independent
{A)p53'^'!mdm2''^ct\\s were transfected as described with 5pig of each pRcHA- 
E2F-1, CMV-DP-1, pl4^^^. After transfection cells were washed and further 
grown overnight for 15 hours. BrdU incorporation was assayed 18 hours post­
transfection and data is presented as %BrdU incorporated relative to number 
of transfected cells/p-glactosidase value. The data shown is representative of 
at least three independent experiments.
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Figure 5.3. E2F-1 binding to p l4^ ^  is MDM2 independent
(A) Nucleai' extracts were prepared from p53'''Imdml'^' cells. Equal amounts of 
extract (200pig) were incubated with GST or GST-pl4^^^ overnight at 4°C. 
Samples were washed 3 times before SDS-PAGE analysis and western blotting 
with an E2F-1 specific antibody KH95 (Santa Cruz).
(B) Equal amounts of GST-proteins (0.5pig), DP-1, p i4 ^ ^  and GST were 
incubated with an equimolar amount of eluted His-E2F-1. Binding was carried out 
for 30 minutes at 4°C. Samples were washed 3 times before SDS analysis and 
western blotting with an E2F-1 specific antibody KH95 (Santa Cruz).
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Figure 5.4 Model for MDM2 independent 014"^^ regulation of E2F.
can regulate E2F independently of MDM2. p l4  can bind to both E2F-1 
and MDM2 independently of one another. However, the possibility that E2F-1, 
pl4'*^^^and MDM2 may form a ternary complex under certain conditions still 
exists.
The coiTelation between p i4^^^ binding to E2F-1 and E2F-1 transcriptional 
regulation suggests that binding of p i4^^^ to E2F-1 may be required for 
regulation of E2F-1. However, pl4^^^ may also be able to indirectly affect E2F-1 
activity,
p300 is bound to MDM2 in cells and p300 also transcriptionally co-activates E2F- 
1 activity. It is possible that p300, MDM2 and p l4 ^ ^  can exist in a multiprotein 
complex in cells.
144

Chapter 6._________________________________________________________Results
Chapter 6. Mutational analysis of the pl4^^-E2F 
function
6.1 Introduction
The main role of p 14/19^^^ so fai' elucidated is its ability to regulate p53 through 
binding and sequestering the negative regulator MDM2 (Zhang and Xiong, 1998). 
The N-terminal region of pl9"^^^ and the C-terminus of MDM2 mediate the 
p29ARF_jvjj^M2 interaction. The two regions identified so far in pl9^^^ which 
bind to MDM2, are from amino acids 1-14 and 26-37 (Weber et ah, 2000) and 
binding of p i9^^^ to MDM2 may induce a conformational change that facilitates 
nucleolai- import of the ARF-MDM2 complex (Weber et ah, 2000).
A number of domains have been identified in pl4^^^’ which are important for its 
targeting of, and interactions with MDM2 (Lohrum et ah, 2000). Small fragments 
of pl4^^^, tagged with a Tx-Myc tag were expressed in cells and 
immunoprecipitated with MDM2. The Tx tag is the active site loop of thioredoxin 
(Lohrum et al,, 2000). In these experiments the regions of pl4"^^^ identified, 
which ai'e able to bind to MDM2 in cells, were from amino acid residues 1-22, 
and 65-132 (Lohrum et ah, 2000). Interestingly however, in vitro, only a peptide 
corresponding to the first 20 amino acids of p i4^^^ could bind to MDM2 
(Midgley et at,, 2000). These differing results could imply that, although p i4^^^ 
can interact with MDM2 directly in vitro, other cellular factors may be involved 
in the pl4^^^-MDM2 complex in cells.
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All of the Tx-mutants of p i4"^ ^^  that interact with MDM2 can also relocalise 
MDM2 to the nucleolus and inhibit MDM2-dependent p53 degradation (Llanos et 
aL, 2000). Recently however, a more physiological approach to looking at 
pl4^^L]y[[)]vi2 nucleolar localisation has suggested that pl4^^^ nucleolar 
localisation is not essential for its ability to regulate MDM2 dependent p53 
degradation (Llanos et aL, 2000).
Given that I had shown that p i4^^^ could interact with E2F-1 and regulate its 
activity in cells, it was of interest to identify the regions in p i4"^ ^^  that are 
responsible for this binding and regulation of E2F-1. More detailed analysis of 
this interaction and its function should give us more complete information 
regarding the importance of the E2F-pl4^^^ interaction and the effects it has on 
cell cycle regulation.
Results
6.2 Purification and identification of GSTp 14^^C65 and GSTp 14^^N64.
In order to identify the region of p i4^^^ that binds to E2F, GST fusion proteins 
expressing the N-terminus or C-terminus of pl4^^^ were constructed and purified. 
The purified proteins ran at the expected size and could be discriminated between 
by a slight difference in migration in SDS-PAGE gel analysis (Figure 6.1 A).
To confirm that the constructs being expressed were the N and C terminal regions 
of the pl4^^^ protein the recombinant bacterial fusion proteins were subjected to 
SDS-PAGE analysis and immunoblotting. Purified proteins were first detected
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using a polyclonal antibody. Where the epitope recognised has been
mapped to the C-terminal region and in line with this observation GST- 
pl4^*^*^C65 was exclusively recognised with this antibody (Figure 6 .IB). Proteins 
were also detected using the p i4^^^ monoclonal antibody (Figure 6 .IB), which 
recognised the N-terminal region of pl4^^^
6.3 p l4^ ^  binds to E2F-1 and DP-1 in vitro via the p l4^ ^  N-terminus.
In order to determine the region of pl4^ *^ *" that bound to E2F-1 and DP-1 in vitro 
far western blotting was carried out. Equal amounts of purified GST-pl4^^^, 
GST-pl4^^^N64, GST-pl4^^^C65 and GST were immobilised on nitro-cellulose 
and membranes were probed with equal amounts of ^^S-labelled in vitro translated 
proteins (Figure 6.2(i)). As previously described, MDM2 bound to both GST- 
pl4^^^ and GST-pl4^^^N64 (Zhang and Xiong, 1998), but not to GST- 
pl4^^^C65 or GST (Figure 6.2(ii)A). Both in vitro translated E2F-1 and DP-1 
also bound to both GST-pl4^^^ and GST-pl4^’^ ^N64), but not to GST-pl4^^^C65 
or GST (Figure 6.2(ii)B,C). A luciferase negative control protein showed minimal 
binding to the GST proteins compared to MDM2, E2F-1 and DP-1 (Figure 
6.2(ii)D).
6.4 Down-regulation of E2F transcription is through the N-ter minus of 
p 1 4 ^^
Given that I had demonstrated that over-expression of pl4*^^ can overcome E2F- 
1 ?ran^activation in reporter gene assays, it was of interest to identify the region of
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pl^ARF j-esponsible for the down-regulation. SAOS2 cells transfected with the 
Elp-luciferase reporter gene, and both E2F-1 and DP-1 showed transcriptional 
activation and, as previously demonstrated over-expression of pl4**^ , together 
with E2F-1 and DP-1, showed a decrease in the level of reporter gene activity 
relative to that observed with the heterodimer alone (Figure 6.3B).
Increasing amounts of the Myc-tagged N- and C-terminal regions of p i4^^^, Myc- 
ARF(N) and Myc-ARF(C) (Figure 6.3A) were transfected, together with the El(3- 
luciferase promoter and E2F-1 and DP-1 expression plasmids. The N-terminal 
region of p i4"^^ was able to down-regulate E2F-1 and DPI on reporter activity 
independently of the C-terminus (Figure 6.3B). The N-terminal region of pl4*^^ 
was able to down-regulate the transcriptional activation by E2F-1 and DP-1 in a 
dose-dependent manner (Figure 6.3CÜ), whereas the C-terminus had little effect 
(Figure 6.3B)
In order to check the expression level of the Myc-tagged constructs and rule out 
that the effect of Myc-ARF(C) was due to a lack of expression, SA0S2 cells were 
transfected with each construct and immuno-blotted with a Myc antibody (Figure 
4.3Ci). As expected all constructs were expressed: Mycpl4"^^*  ^and Myc-ARF(C) 
more efficiently than Myc-ARF(N) (Figure 6.3Ci).
These data show that the N terminal region of pl4^^^ is responsible for the 
observed down-regulation of E2F transcription, whilst the C-terminal region of 
PI4 ARF appeared to be dispensable for this transcriptional down-regulation.
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Indeed, the N terminus can regulate the transcriptional activity by E2F in a
dose-dependent manner analogous to that of wild-type pl4^^^
6.5. Further identification of the E2F-pl4^^ binding domain: E2F-1 hinds to 
a region in p l4^ ^  distinct to that of MDM2.
In order to further identify the regions in pl4^^^ that bind to E2F-1 an immuno­
précipitation approach was undertaken in SA0S2 cells. A panel of Tx-Myc tagged 
tieiej;ion mutants (Figure 6.4A) (Lohrum et al., 2000) were examined for 
their ability to bind to E2F-1 in vivo (Figure 6.4B and Figure 6.5).
Anti-E2F-1 immuno-precipitates from SAGS2 cells over-expressing pRc-HA- 
E2F-1 all contained an HA-specific polypeptide that conesponded to the expected 
size of E2F-I (Figure 6.5). E2F immunoprecipitates from over-expressing pl4**^ 
mutants, Tx-Myc-pl4^^^ 1-132, Tx-Myc-pl4^^^ 1-34 and Tx-Myc-pl4^^^ 65- 
132 Tx-Myc-pl4^^^1-64 cells contained the pl4^^^ mutant derivative in complex 
with E2F-1 (Figure 4.5, 4.6). In contrast, E2F immuno-complexes from over­
expressing pl4*^^ mutant Tx-Myc-p 14^ *^  ^ 1-22 or Tx-Myc-pl4^^^ 54-64 
contained no traces of the pl4*^^ mutant derivatives (Figure 6.5, 6 .6 ). These 
results indicate that firstly, E2F-1 and pl4*^^ can interact in cells when over­
expressed, providing further evidence for the relevance of the E2F-pl4^^^ 
interaction, and that E2F-1 can bind to distinct regions of pl4^^^ including one N 
(amino acids 22-34 and one C terminal region (amino acids 65-132).
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6.6 p l4^ ^  binding to E2F-1 correlates with its ability to down-regulate 
transcription.
Given that the E2F-1 binding region in has been mapped to amino acids
22-34 it was of interest to investigate the relationship between pl4"^^^-E2F-l 
binding, and pl4^^^ mediated down-regulation of E2F transcription.
It was important to check that the addition of a large tag to the p i4 ^ ^  protein did 
not affect its ability to down-regulate E2F trancription before using these 
constructs in functional assays. SAOS2 cells transfected with the Eip-luciferase 
reporter gene, E2F-1 and DP-1, showed activation of the reporter, and as 
expected, E2F-1, DP-1 and Tx-Myc-pl4^^^ 1-132 showed a decrease in the level 
of reporter gene activity observed with the heterodimer alone, comparable to that 
observed with wild-type p i4^^^ (Figure 6.7A). Indicating that despite the Tx-Myc 
tag, Tx-Myc-pi4^^^ is able to overcome E2F mediated transcription with the 
same efficiency as untagged pl4^^^ (Figure 6.7A).
Tx-Myc-pl4^^^1-22, Tx-Myc-pi 4"^ ^^  1-64 and Tx-Myc-pl4^^^65-132 (Figure 
6 .4A) were transfected with the E l (3-luciferase promoter, E2F-1 and DP-1 and as 
previously observed, the N-terminal region of pl4*^^ was able to down-regulate 
the effect of E2F-1 and DP-1 on reporter gene activity, as efficiently as wild-type 
 ^ while the C-terminal region had no effect on the level of E2F/DP-1 
reporter gene activity (Figure 6.7B). In contrast to this effect, the Tx-Myc- 
pl4^^^1-22 mutant was unable to overcome E2F mediated transcriptional
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activation and an increase in the reporter gene activity, compared to that of the 
heterodimer was observed (Figure 6.7B).
To further clarify these observations, and correlate the activity of pl4^^^ mutants 
in E2F mediated transcription with E2F-1 binding, a similar experiment was 
performed. In this case, Tx~Myc-pl4^^^1-22, Tx-Myc-pl4^^^1-34 and Tx-Myc- 
pl4^^^1-132 (Figure 6.4A) were transfected with the El|3-luciferase promoter, 
and both Tx-Myc-pl4^^^1-34 and Tx-Myc-pl4^^^1-132 were able to overcome 
E2F mediated transcription (Figure 6.7C). As previously demonstrated the Tx- 
Myc-pl4^^^1-22 mutant was unable to overcome E2F mediated transcriptional 
activation, and an increase in the reporter gene activity, compared to that of the 
E2F heterodimer alone was observed (Figure 6.7C),
These observations imply that N-terminal regions of pl4^*^^ which can bind to 
E2F-1 are able to regulate E2F-I activity. In contrast, the region of p i4^^^ 
encompassing amino acids 1-22 which is unable to bind to E2F-1 is also unable to 
down-regulate E2F mediated transcriptional activation (Figure 6 .6  B and C).
Consistently, in reporter assay experiments, the N terminal constructs Myc- 
pl4^^^N64 and Tx-Myc-p 14^^^ 1-64 could decrease the levels of reporter assay 
activity observed with E2F-1 and DP-1 to a greater degree than wild-type pl4"^^^ 
(Figure 6.4B and Figure 6 .6B). This effect appears not to be due to expression 
levels, as the C terminal Myc-ARF(C) and Tx-Myc-p 14^^^ constructs are 
expressed more efficiently than wild-type pl4^^^, while less expression of the N
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terminal constructs is generally observed compared to wild-type pl4^^^ (Figure 
6.3Bi and data not shown).
6.7 p l4^ ^  binding to E2F-1 correlates with its ability to prevent cell-cvcle 
progression.
As p i4^^^ binding to E2F-1 correlates with its ability to repress E2F transcription 
it was of interest to assess whether this interaction influenced S-phase 
progression, a property ascribed to E2F (Johnson et al., 1993). A BrDU assay was 
utilised to measure cells in S-phase in cells transfected with E2F-1, DP-1 and 
mutants of p i4^^^.
SA0S2 cells transfected with plasmids expressing E2F-1 and DP-1 displayed a 
detectable increase in BrDU incorporation over mock-transfected cells (Figure 
6 .8A). In order to confirm that Tx-Myc tagged p i4^^^ was able to act similarly to 
wild-type p i4^^^. I directly compared the activity of the two proteins in 
combination with E2F-1 and DP-1. It was observed that Tx-Myc-pl4^^^ was able 
to overcome E2F mediated S-phase progression to a similar level as wild-type 
pl4^^^(Figure 6 .8A).
SAOS2 cells were transfected with E2F-1 and DP-1 either together, or in 
combination with the pl4^^^mutants Tx-Myc-pl4^^^1-132, Tx-Myc-pi 4^^^ 1-22, 
Tx-Myc-p 14^^^1 -64 and Tx-Myc-pl4^^^65-132. As expected Tx-Myc-pi 4^^^1- 
132 was able to reduce E2F-mediated S-phase progression, and the N-terminal 
region of p i4"^ ^^  Tx-Myc-p 14^^^ 1-64 also reduced the amount of BrDU
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incorporation observed, in combination with E2F-1 and DP-1 together (Figure 
6 .8B).
Interestingly, Tx-Myc-p 14^^^65-132 in combination with E2F-1 and DP-1 also 
caused a slight decrease in the amount of BrDU incorporation observed compared 
to that of the heterodimer alone (Figure 6 .8B). Although this decrease was slight, 
it was consistently observed throughout different experiments, indicating that the 
C-terminus of pl4^^^ may also be capable of overcoming E2F mediated S-phase 
progression to a slight extent. This effect of the C-terminal region of p i4^^^ could 
be transcriptionally independent, and this would explain the lack of effect in 
reporter assay experiments. In agreement with the reporter assay data, expression 
of Tx-Myc-pl4^^^1-22 was unable to overcome E2F-mediated S-phase entry, but 
in fact showed a significant increase in the number of cells incorporating BrDU 
when co-expressed with E2F-1 and DP-1 than observed when E2F-1 and DP-1 
were together transfected (Figure 6 .8B).
6.8 Conclusions.
The data presented shows that both the N and C terminus of p i4^^^ can bind to 
E2F-1 in cells, and that a region encompassing amino acid residues 1-22 of 
PI4 ARF  ^ that is important for ARF-MDM2 binding, is unable to bind to E2F- 
1.Therefore the binding regions of MDM2 and E2F-1 to pld'^^^ are distinct. 
p t4^RFg ability to overcome E2F mediated transcriptional repression and S-phase 
entry is mediated by an N terminal region of pl4^^^ which can bind to E2F-1,
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indicating that regulation of E2F activity by is dependent on pl4^^^
binding.
6.9 Discussion.
Previous studies have centred on a panel of p i4^^^ mutants and their role in p53 
stabilisation mediated through ARF binding to MDM2 (Lohrum et aL, 2000).
Regions of p i4^^^ were identified which could bind and regulate MDM2 activity 
(Lohrum et a l, 2000), and these investigations led us to study E2F-1 regulation by 
PI4 ARF mutants in order to further understand the E2F-ARF interaction.
Sudies showed that the N-terminal region of pl4"^^^ could bind to E2F-1 in a 
direct binding assay (Figure 6.2). This led me to investigate the regulation of E2F 
activity in a reporter assay system using the N and C terminal regions of pl4^^^. I 
found that the N-terminus of p i4^^^ is responsible for the p i4"^ ^^  mediated 
transcriptional repression of E2F-1, and that the C-terminus had little effect on 
E2F activity (Figure 6.3B). Interestingly, this is also the situation reported for 
MDM2 regulation by pl4^^^. Although both the N- and C-terminus of pl4^^^ can 
bind to MDM2, only the N-terminal region can regulate its activity in the context 
of p53 stabilisation (Zhang and Xiong, 1998; Stott et a l, 1998, Lohrum et a l, 
2000).
Given that the N-terminal region of pld"^^^ is responsible for the observed down- 
regulation of E2F-1 activity, it was of interest to further map the interaction and 
regulatory domains in ARF for E2F-1. We used a panel of pl4"^^^ mutant
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constructs (Lohrum et ah, 2000 (Figure 6.4)) in an immuno-precipitation assay in 
order to identify the binding domain in pl4^^^ for E2F-1.
Interestingly, we identified the region of pI4'^'^^ 1-22 as unable to bind E2F-1 
while a larger region from 1-34 can bind to E2F-1 (Figure 6.5). This suggests that 
the pl4^^^-E2F-l binding domain may be between amino acids 22-34. As the 1- 
22  amino acid region has previously been identified as the pl4^^^-MDM2 binding 
region, these results suggest an interesting scenario where E2F-1 and MDM2 may 
actually both be able to bind to p i4^^^ at the same time and form a ternary 
complex. Alternatively, E2F-1 and MDM2 could compete for p i4^^^ binding or, 
one could bind to pl4^^^ in the absence of the other. The binding and possible 
competition between E2F-1 and MDM2 for pl4^^*^ could be cell, or tissue 
dependant. Also of interest is the fact that the C-terminus of pl4^^^ can also bind 
to E2F-1 in cells, although the results suggested that this interaction did not alter 
E2F activity. This is also the case with MDM2, where the C-terminus of pl4^^^ 
does not influence MDM2 activity, but nevertheless is able to bind MDM2 and 
form nuclear bodies with p53 (Zhang and Xiong, 1999).
It may be that the C-terminus of p i4^^^ regulates E2F under certain 
circumstances, although more work is required to understand the importance of 
the ARF C-terminus, in the context of both E2F-1 and MDM2 regulation.
Reporter assay experiments were carried out in order to investigate which region 
of p i4"^ ^^  is responsible for the observed down-regulation of E2F activity. The 1- 
34 amino acid region of p i4"^ ^^  was shown to be able to efficiently down-regulate
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E2F mediated reported gene activity while the 1-22 region was not (Figure 6 .6C). 
Additionally, the pl4^^^ 1-22 mutant was observed to enhance the activity 
observed with E2F-1 and DP-1 (Figure 6 .6 B,C). This activity of pl4^^^1~22 was 
unexpected and may be due to a dominant-negative effect on endogenous pl4^^^ 
or perhaps amino acid residues 1-22, through binding to MDM2, can somehow 
regulate E2F activity indirectly? (Figure 6.9)
The ability of the pl4"^^^ mutants to regulate E2F activity in a BrDU assay was 
also examined and the results obtained with the p i4^^^ 1-64 and pl4^^^1-22 
constructs were similar to those from the reporter gene assays. The effect of the 1- 
22  region of p i4^^^ in these experiments was particularly striking and a large 
increase in the number of cells incorporating BrDU compared to E2F-1 and DP-1 
transfected cells was observed when pl4^^^1-22 was transfected in the presence 
of E2F-1 and DP-1 (Figure 6.7B). This effect may occur as a result of the 
observed transcriptional enhancement, however it is possible that amino acids 1- 
22 of pl4^^^ may be responsible for other, E2F independent, cell cycle regulatory 
mechanisms.
Interestingly, the C-terminus of p i4^^^ showed a slight down-regulation of the 
number of S-phase cells in the presence of E2F-1 and DP-1 compared to E2F-1 
and DP-1 activity (Figure 6 .8B). This effect was unexpected compared to the 
effect of the C terminal region in reporter assay experiments and may simply be a 
consequence of over-expression. However, it is possible that C-terminal binding 
of p i4"^ ^^  to E2F-1 in cells may have an effect on cell cycle regulation through an 
as yet unidentified mechanism.
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The data presented here provides an important link between pl4'^^^ binding to 
E2F-1, and the ability of pl4^^*^ to regulate E2F activity. These experiments also 
show that the domain of p i4"^ ^^ , which is important for MDM2 regulation, does 
not regulate E2F activity and that E2F-1 and MDM2 bind to different regions of 
PI4 ARF Yhese data indicate the possibility that the pl4^^’^ regulation of E2F could 
be either dependent on, or independent of MDM2. Further investigations are 
required to fully elucidate the role of pl4"^^^ in E2F regulation, in particular the 
observed effects of the 1-22 and C-terminal regions of p i4"^ ^^  are of interest.
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Figure 6.1 Purification and identification of pGEX-pl4^^-N64 and pGEX- 
p14Ai^-C65.
(A) The indicated GST-tagged proteins were purified from bacteria as described 
(chapter 2). Bead bound proteins were resuspended in 3x SDS loading buffer 
and subjected to SDS-PAGE analysis, then stained with commassie blue.
(B) Purified proteins were prepared and analysed as described in (A), then 
transferred to nitrocellulose membrane and immunoblotted with pld^^^ 
specific antibodies.
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Figure 6.2 0 1 4 ^ ^  binds to E2F-1 and DP-1 through the N terminal domain
(i) The in vitro translated proteins used for input in the far western blot are 
shown. The indicated plasmids were in vitro translated and 5% was 
subjected to SDS-PAGE, Labelled proteins were detected by exposure to 
film overnight,
(ii) The indicated GST-proteins were prepared and immobilised on membrane 
as previously described. Membranes were incubated with one of each of in 
vitro translated MDM2, HA-E2F-1, DP-1 or luciferase protein in milk/AC 
buffer. Following incubation, membranes were washed and exposed 
overnight on film to identify bound proteins.
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Figure 6.3 The pl4 N terminal region is responsible for p l4  ' mediated
transcriptional repression.
(A) Schematic of the mutant constructs used (Zhang and Xiong., 1998).
(B) Reporter assay. SA0S2 cells were transfected with the following plasmids per 
6cm plate; pRcHA-E2F-l (50ng), CMV-DPl (500ng), p l4 ^ " ' (12pg), Myc- 
ARF(N) (12 |Lig), Myc-ARF-(C) (12 jug) Elj3-luciferase (4p,g) and CMV-Pgal 
(500ng). Lysates were assayed 40 hours post-transfection and each plate was 
performed in duplicate. Data are shown as luciferase values/pgal value. The 
data shown is representative of at least three typical experiments,
(C) (i)Expression of the Myc-tagged ARF constructs. 10|Ag each plasmid was 
transfected into SAOS2 cells. Cells were harvested, run on a 15% SDS gel 
and blotted with the anti-Myc antibody,
(ii) SAOS2 cells were transfected with the following plasmids per 6 cm plate; 
pRcHA-E2F-l (50ng), CMV-DPl (SOOng), pl4^"’' (12pg), Myc-ARF(N) (5,
7.5, 12 pg), Elp-luciferase (4pg) and CMV-Pgal (500ng). Experiments were 
performed and analysed as described in (B)
160
A.
M yc-A R F
M yc-A R F(N )
M yc-A R F(C )
B.
100
L uc/
Pgal
50
□
X .
H A -E2F-1
DP-1
pl4A RF
M yc-A R F(N )
M y o A R F (C )
+ +
+ +
+
+ +
+  +
E x o n ip -lu c
C .(i(!)
i ^ E
2
100-1
H A  E 2F  1 + + + +
DP-1
M yc-pl4*"'TS63;
Figure 6.4. p l4^ ^  mutant binding properties.
(A) Schematic of Tx-myc tagged constructs used for binding assays (Lohrum et 
aL, 2000).
(B) Binding properties of Tx-tagged pl4^^^ constructs. Constructs were tested for 
binding to MDM2 (Lohrum et aL, 2000), or E2F-1 by immuno-precipitation 
(Figure 4.5).
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C onstruc t Binding to IMDM2 B inding to E2F-1
Tx-M yc-pl4ARFl-132 + +
T  x-M yc-pl -64 + +
Tx-lVIyc-pl4^**'65-132 + +
T  x-M yc-pl4^'^''l -34 + +
Tx-M yc-pl4^RFl-22 + -
T  x-M yc-p 14^‘**'54-64 - -
Figure 6.5. The pl4 -E2F binding site maps to the region 22-34.
SA0S2 cells were transfected with 25pg each of pRc-HA-E2F-l and the indicated 
Tx-Myc-p 14^^^ plasmids. Cells were washed 8 hours post-transfection and 
harvested 24 hours post-transfection. Extracts were prepared and immuno­
précipitations performed.
Tx-Myc-p 14^^^ proteins are indicated by a yellow star.
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Figure 6.6. E2F-1 does not bind to p l4^ ^  amino acid residues 56-64
SAOS2 cells were transfected with 25p.g each of pRc-HA-E2F-l and the indicated 
Tx-Myc-p 14^^^ plasmids. Cells were washed 8 hours post-transfection and 
harvested 24 hours post-transfection. Extracts were prepared and immuno­
précipitations performed. Tx-Myc-p 14^^^ proteins are indicated by a yellow star.
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Figure 6.7 pl4'^^-E2F-l binding correlates with transcriptional repression.
(A) SAOS2 cells were transfected with each of the following plasmids per 6cm 
plate: Elp-luciferase (4pg) CMV-pgal (500ng) pRc-HA-E2F-l (50ng), CMV- 
DPl (500ng), pl4^^^ (5^g) and Tx~p 14^^^1-132 (lOpg). Lysates were 
assayed 40 hours post-transfection and each plate was performed in duplicate. 
Data is shown as luciferase values/Pgal value. The data shown is 
representative of at least three typical experiments.
(B) SA0S2 cells were transfected with each of the following plasmids per 6cm 
plate: Eip-luciferase (4p,g) CMV-Pgal (SOOng) pRc-HA-E2F-l (SOng), CMV- 
DPl (SOOng), Tx-pl4^’^ ^l-132 (lO^ig), Tx-pl4^^^1-22 (10|Ltg),Tx-pl4^^^1-64 
(lOjLig) and Tx-pl4^^^65-132 (lOpg) Lysates were assayed as described in
(A).
(C) SA0S2 cells were transfected with each of the following plasmids per 6 cm 
plate: Eip-luciferase (4pg) CMV-pgal (SOOng) pRc-HA-E2F-l (SOng), CMV- 
DPI (SOOng), Tx-Myc-pl4^''''l-132 (lOpg), Tx-Myc-pl4^'''’l-22 (lOpg).Tx- 
Myc-pl4''*"’l-64 (lOpg) and Tx-Myc-pl4*'*'’l-34 (10p,g) Lysates were 
assayed as described in (A).
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Figure 6.8. pl4^^-E2F-l binding correlates with S-phase progression.
(A) SAOS2 cells were transfected with 5 i^g each of the following plasmids: pRc- 
HA-E2F-1, CMV-DPl, pl4^^^ and Tx-Myc-pl4^^^1-132. After transfection 
cells were washed and further grown overnight. BrdU incorporation was 
assayed 18 hours post-transfection and data are presented as %BrdU 
incoiporated relative to number of transfected cells/P-galactosidase value. The 
data shown are representative of at least three independent experiments.
(B) SAOS2 cells were transfected with 5fxg of each of the following plasmids: 
pRc-HA-E2F-l, CMV-DPl, Tx-Myc-pl4'^’^ ''l-132, Tx-Myc-pl4*’^ ''l-22, Tx- 
Myc-pI4'^'""l-64 and Tx-Myc-pl4^’*’’65-132. Cells were assayed for BrDU 
incoiporation as described in (A).
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Figure 6.9. Model for p l4^ ^  1-22 Effect on E2F activity.
Wild-type pi 4^^^ can bind to E2F-1 and DP-1 and down-regulate the activity of 
the E2F complex. pl4^^^1-22 is unable to bind to E2F-1 and cannot down- 
regulate E2F activity. pl4^^^1-22 does however, reproducibly enhance the
activity of E2F.
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Chapter 7: The pl4^^ Regulation of E2F
7.1 Introduction
p 14^^^ has previously been shown to regulate the p53 pathway through MDM2. 
The mechanism of regulation described is thought to be partially due to the ability 
of pl4/pl9^^^ to promote the degradation of MDM2 (Zhang et a l, 1998).
MDM2 normally shuttles between the nucleus and the cytoplasm in order to target 
p53 for degradation (Roth et a l, 1998). Honda et al, demonstrated that 
association of p i9^^^ with MDM2 inhibits the ubiquitin ligase activity of MDM2 
for p53, and that the activity of a pl9^^^-MDM2 complex in a ubiquitination 
assay is lower than the activity of free MDM2 (Honda et al, 1999). These data 
highlight the importance of p i9^^^ mediated p53 stabilisation.
Co-expression of p i9"^ ^^  and MDM2 prevents nuclear-cytoplasmic shuttling of 
MDM2, and as time increases, MDM2 can move to the nucleolus (Tao et al, 
1999). Much data supports this MDM2 nucleolar localisation and this 
relocalisation also occurs following Myc activation and replicative senescence 
(Weber et al, 1999). MDM2, p53 and p i4/19^^^ are able to form nuclear bodies, 
blocking nuclear export of p53 and MDM2, or else retaining them in the 
nucleolus. Formation of these nuclear bodies requires both the N and C terminus 
of ARF (Zhang and Xiong. 1999). Studies by Weber et al. suggest that p i9"^ ^^  
contains two NrLS signals which both contribute to nucleolar localisation, 
however, MDM2 also contains a NrLS and so the nucleolar co-localisation of 
pj^ qARF MDM2 can be viewed as a bi-directional interaction. Data implies that 
p i9^^^ binding to MDM2 may induce a conformational change that facilitates 
nucleolar import of the ARF-MDM2 complex (Weber et al, 2000).
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7.2. Over-expression of p l4^ ^  affects its cellular localisation.
Given that pl4/pl9^^^ have been shown to re-localise p53 and MDM2 to the 
nucleolus (Zhang and Xiong 1998) it was of interest to investigate whether pl4^^^ 
could affect E2F cellular localisation. Normally, E2F-1 is nuclear, while DP-1 is 
cytoplasmic, but becomes nuclear in the presence of E2F-1 (de la Luna et ah, 
1996; Allen et aL, 1997). pl4^^^ is localised mainly to the nucleolus (Stott et a l, 
1998; Zhang et a l, 1998; Weber et al., 1999). In order to investigate the 
localisation of pl4^^^ immuno-staining experiments were carried out in SA0S2 
cells, using both endogenous pM^^^and over-expressed pl4^^^ .
Firstly, the localisation of pl4^^^ was determined by immuno-staining. SAOS2 
cells were either mock transfected, or transfected with pl4^^^ and localisation of 
determined by staining with anti-pl4^^^ antibody (Figure 7.1 A). As 
expected, endogenous p i4^^^ was detected almost exclusively in the nucleolus 
(Figure 7.1 A). However, interestingly, different staining patterns were observed 
when using over-expression vectors. pl4"^^^ when over-expressed was detected in 
the nucleolus and occasionally in the nucleus (Figure 7.1 A). Stained cells were 
counted in each instance in order to determine precisely how much the 
localisation of p i4^^^ can change with expression (Figure 7. IB).
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7.3 pl4"^^ does not affect E2F-1 or DP-1 cellular localisation.
In order to determine whether could change the cellular localisation of
E2F-1 or DP-1, immuno-staining experiments were again carried out in SA0S2 
cells. Cells were transfected with E2F-1 and DP-1 or E2F-1, DP-1 and p i4^^^. 
Firstly, the localisation of E2F-1 and DP-1 was determined by staining cells 
transfected with E2F-1 and DP-1 with either anti-E2F-l or anti-DP-1 antibody. As 
expected, when expressed together E2F-1 and DP-1 were nuclear.
The localisation of pl4^^^, E2F-1 and DP-1 were then examined in cells over­
expressing combinations of all three proteins. When E2F-1 and pl4"^^^ were 
expressed together, pl4^^^ was found to be nucleolar while E2F-1 was nuclear 
and excluded from the nucleolus (Figure 7.2A). Additionally, in cells expressing 
E2F-1, DP-1 and pl4^^^, E2F-1 was again nuclear, and excluded from the 
nucleolus while p l4 ^ ^  was nucleolar (Figure 7.2B). Similarly, cells over­
expressing all three proteins were co-stained with DP-1 and p i4^^^ antibodies. 
DP-1 was nuclear and pl4^^^ was nucleolar in this situation (Figure 7.2C).
These data together indicate that p i4^^^, E2F-1 and DP-1 do not affect the 
cellular localisation of one another, under the experimental conditions used.
7.4 p l4^ ^  does not affect binding of the E2F complex to DNA.
PI4 ARF ]^ as been shown to overcome E2F mediated transcription, S-phase 
progression and apoptosis (Chapter 3), and also to bind to both E2F-1 and DP-1
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(Chapter 4). One possible mechanism by which pl4^^^ could regulate these 
activities could be through binding to the E2F complex on DNA and somehow 
blocking transcription. Alternatively, pl4^^^ may be able to prevent the E2F-DP 
complex from forming and associating with DNA through direct binding to the 
individual partners. Therefore, it was of vital importance to investigate the 
mechanism by which pl4"^^^ regulated the E2F complex on DNA.
In order to investigate the effect of pl4^^^on E2F complex DNA binding, in vitro 
bandshift assays were performed. It was decided to use in vitro translated proteins 
in the binding assays in order to define specifically E2F-1-DP-1 complexes. 
Firstly, E2F-1-DP-1 complexes were identified by binding to the E2A 
oligonucleotide. As expected, neither E2F-1 or DP-1 alone bound efficiently to 
the DNA probe while efficient binding was observed when both E2F-1 and DP-1 
in vitro translates were incubated together with the same probe (Figure 7.3A).
Complexes were identified by antibody shifts with the relevant antibodies (Figure 
7.3B). Complexes were incubated without (lanes 4&5) or with (lanes 6-14) 
antibody and then visualised on a non-denaturing polyacrylamide gel by auto­
radiography. As expected, E2F heterodimers were effectively shifted with anti- 
HA, anti-E2F-l and anti-DP-1 antibodies, demonstrating that the E2F-1 and DP-1 
proteins were in the complex. In contrast, a Gal4 antibody did not shift the DNA 
bound complex, indicating that the observed bands were specific for E2F-1 and 
DP-1 (Figure 7.3B).
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In order to investigate the effect of on E2F complex binding to DNA, in
vitro translated E2F-1 and DP-1 proteins were incubated with purified GST, GST- 
pRb or GST-pl4^^^ protein. As expected GST-pRb when incubated with E2F 
complexes caused a mobility shift, indicating that binding of pRb to E2F-1 had 
occurred (Figure 7.4 Lane II). In contrast, addition of p i4^^^ to the E2F-1-DP-1 
reaction had no effect on the size of the complex. A decrease in the binding 
activity of the E2F complex to DNA was observed in the presence of GST- 
pl4"^^^, however, this was not significant when compared to the effect of GST 
protein or heat denatured GST-pl4^^^ on the complex (Figure 7.4 Compare lanes 
5, 6 , 7 to 9&10).
PI4 ARF has previously been shown to bind to E2F-1 and DP-1 directly in vitro 
(Chapter 4) and to E2F-1 in in vitro binding experiments (Figure 5.3). It was 
therefore expected that purified pM^R^ would bind to the E2F heterodimer and 
have some effect on DNA binding. These data suggests that pM^RR may not affect 
E2F binding to DNA and may not form a complex with E2F on DNA. However, 
the experimental conditions used in these experiments did not reflect the 
physiological situation in the cell and pM^RR may still regulate E2F DNA binding 
activity under certain cellular conditions. Although pl4"^RRcan bind to E2F it may 
alternatively regulate the activity of E2F at a level other than at the DNA binding 
level.
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7.5 PI4ARR degrades the E2F-1 protein.
E2F-1 is regulated in a number of different ways, including cellular localisation, 
acétylation, phosphorylation and degradation (de la Luna et ah, 1996; Marti et aL, 
1999; Martinez-Balbas et aL, 2000; Morris et aL, 2000). Given that plT^^R has 
significant effects on the activity of E2F in cells, and that studies of cellular 
localisation and DNA binding activities showed no significant effect of pH^^R on 
E2F in these contexts, it became important to look at the post-translational effects 
ofpUARR on E2F-1.
It was decided to investigate whether over-expression of pM^RR affected E2F-1 
protein levels in cells. Previously MDM2 has been shown to decrease levels of 
E2F-1 in cells (Loughran and La Thangue 2000). SAOS2 cells were transfected 
with E2F-1 and either plT^RR or MDM2. As expected MDM2 caused a decrease 
in E2F-1 protein levels compared to E2F-1 alone (Figure 7.5). Interestingly 
PI4 ARR also caused a dose dependent decrease in the level of E2F-1 protein 
compared to E2F-1 alone, and this decrease was greater than that observed with 
MDM2 (Figure 7.5).
7.6 Conclusions
These data show that under the experimental conditions used plT^RR does not 
regulate E2F cellular localisation or binding of the E2F complex to DNA. 
However pM^RR does decrease E2F-1 protein levels, indicative of a post- 
translational effect on E2F activity.
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7.7 Discussion
pl^ARF |g thought to be involved in relocation of MDM2 to the nucleolus and this 
is the mechanism by which pH^RR is supposed to regulate p53 activity, through 
sequesterisation of MDM2 (Weber et aL, 1999). Recent evidence has suggested 
that this re-localisation of MDM2 to the nucleolus is not essential for its function 
and that further studies are required (Llanos et aL, 2001).
pl4^RF has no effect on the cellular localisation of E2F-1, or its heterodimeric 
partner DP-1 (Figure 7.2). This result may be dependent on the particular cells, 
experimental conditions or time scales used and so cannot completely exclude the 
fact that PI4 ARR and E2F may co-localise in the cell under certain conditions. 
However the result does indicate that over-expression of plT^RR does not force re­
location of E2F, and that under these particular experimental conditions the two 
proteins do not co-localise.
E2F-1 and its heterodimeric binding partner bind efficiently to E2F site in DNA 
(Zheng et aL, 1998) in order to activate or repress transcription of E2F target 
genes (Dyson 1998). pl4^RR down-regulates E2F activity (Chapter 3) and so one 
possibility was that pl4^RR could be binding to the E2F complex, either before 
DNA binding or while the complex is bound to DNA and preventing E2F from 
?ra/z5activating target genes. In vitro binding assays showed that plT^RR has no 
significant effect on E2F binding to DNA in that it does not cause a shift or a 
decrease in complex binding to DNA, compared to negative control proteins 
(Figure 7.4).
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PI4 ARR does cause a reduction in the levels of E2F-1 protein levels in cells, 
suggesting that the observed effects of pM^^R on E2F activity may be due to a 
post-translational down-regulatory mechanism of E2F protein levels. It would be 
of interest to investigate how pM^^R can down-regulate E2F-I protein levels, and 
whether it has intrinsic ubiquitin ligase activity or somehow targets E2F for 
degradation.
174
Figure 7.1 0 1 4 ^^  ^localisation
(A)SAOS2 cells were either mock transfected or transfected with 6pg CMV- 
PI4 ARR. Cells were then stained with an antibody to pl4ARR and examined for 
immunoflourescence. Nuclear localisation was confirmed by DAPI staining.
(B) Cells were counted to determine the percentage of pM^^R present in the 
nucleus and nucleolus as a result of overexpression.
175
A.
a  pl4^RR Dap:
Endogenous
Over­
expressed
B.
Nucleolar Nuclear
Endogenous pM^ RF 100% 0%
Overexpressed pM^ RF 84% 16%
Figure 7.2 0 1 4 ^^  ^does not affect E2F cellular localisation.
SAOS2 cells were transfected with 6 jig HA-E2F-1, CMV-DP-1, CMV-pl4 ARR 
together, or in combination. Cells were stained with either pM^RR, HA, or DP-1 
antibodies to detect the overexpressed proteins and examined for 
immunoflourescence. Nuclear localisation was confirmed by DAPI staining.
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Figure 7.3 Detection of E2F complexes.
(A) labelled probe containing the E2A E2F binding site was incubated with in 
vitro translated HA-E2F-1 and DP-1 or a mixture of the two proteins. 
Complexes bound to DNA were analysed by gel electrophoresis and 
autoradiography.
(B) ^^ P labelled probe containing the E2A E2F binding site was incubated with in 
vitro translated HA-E2F-1 and DP-1 or a mixture of the two proteins. 
Additionally, antibodies specific for HA, E2F-1, DP-1 and Gal4 were added to 
the E2F complex in order to determine the nature of these complexes. 
Complexes bound to DNA were analysed by gel electrophoresis and 
autoradiography.
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Figure 7.4. 0 1 4 ^^  ^does not affect E2F binding to DNA
labelled probe containing the E2A E2F binding site was incubated with in 
vitro translated HA-E2F-1 and DP-1 or a mixture of the two proteins. 
Additionally, purified, GST-pU^RR denatured GST-pM^RR, GST-pRb or GST 
was added to the E2F probe/mixture. Complexes bound to DNA were analysed by 
gel electrophoresis and autoradiography.
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Figure 7.5 0 1 4 ^^  ^causes a decrease in E2F-1 protein levels.
SAOS2 cells were mock transfected or transfected with 15|ig of HA-E2F-1, Ijig 
CMV-pgal and CMV-pl4 ARR, (15, 30pg) or pCMDM2 (30|ig). Extracts were 
prepared and normalised for Pgal activity to ensure equal loading. Proteins were 
analysed by SDS-page and western blotting.
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Chapter 8. Discussion
8.1 Activation of p l4^^.
is a protein of central importance in cell cycle control. Expression of 
is induced by the action of a diverse array of oncogenic signals (Bates et 
aL, 1998; De Stanchina et aL, 1998; Palmero et aL, 1998; Radfar et aL, 1998; 
Zindy et aL, 1998; Lin and Lowe, 2001), which results in either cell cycle arrest, 
apoptosis or senescence (Sherr and Weber, 2000). An established mechanism by 
which p i4 ^^^ can prevent aberrant cellular proliferation is through its physical 
interaction with MDM2 to prevent the destabilisation of p53 and therefore 
facilitate the p53 response (Pomerantz et aL, 1998).
MDM2 is clearly an important target in mediating the effects of pl4^^^, however, 
some studies have suggested that mechanisms other than the direct regulation of 
MDM2 may exist (Camero et aL, 2000; Weber et aL, 2000). Probably the most 
interesting study regards the effects of p i9"^ ^^  in triple knock-out mice for 
MDM2/p53/pl9^^^, indicating a role for p i9^^^ independent of MDM2 (Weber et 
aL, 2000). These mice develop tumours at a greater frequency than p53'^7mdm2'^' 
mice, demonstrating that pl9^^^ can interact independently of the p53-mdm2 axis 
in tumour surveillance (Weber et aL, 2000).
Previous studies have documented a role for MDM2 in the regulation of the 
E2F/pRb pathway (Martin et aL, 1995; Loughran and La Thangue., 2000), and 
MDM2 can increase E2F transcriptional activity and S-phase progression while 
simultaneously overcoming E2F mediated apoptosis (Martin et aL, 1995;
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Loughran and La Thangue., 2000). Given that MDM2 can regulate E2F activity, 
and that pl4^^^is a modulator of MDM2 activity, it was of interest to investigate 
the role of pl4^^^, if any, in the control of E2F activity. The results presented here 
identify E2F-1 as a new target for pl4"^^^ and provide evidence that p i4"^ ^^  can 
arrest cell growth in a p53 independent manner, probably through modulation of 
E2F activity.
8.2 p l4^ ^  overcomes E2F mediated transcription
E2F-1 activates p 14/19"^^  ^ in a transcriptionally dependent fashion as previously 
described (Bates et aL, 1998). I also found that E2F-1 can activate the pl4^^^ 
promoter and using the pl4"^ ^^  promoter in a reporter gene assay I further showed 
that pl4^^^ can negatively regulate E2F-1 mediated rraw^activation (Figure 3.2). 
These data suggest that p i4^^^ is able to act to down-regulate E2F transcription in 
a dose-dependent, p53-independent manner and, as a result of this down- 
regulation may consequently act to regulate its own expression and steady state 
levels via an as yet, undescribed negative feedback loop.
E2F transcriptionally activates a number of cellular genes, which control many 
cellular processes including apoptosis, cell cycle progression, and differentiation 
(chapter 1) so it was of interest to investigate the effects of pl4^^^ mediated 
suppression of E2F transcription on other E2F target genes. Experiments were 
performed to investigate these effects and here I showed that p i4^^^ can 
overcome E2F mediated transcription on a number of different E2F responsive 
reporter gene constructs, including the cellular target genes cyclinE (Figure3.3C)
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and A/7<3/ - 7(Figure 3.4B). was unable to repress basal transcription on the
reporter gene constructs tested, and also fails to negatively regulate p53 activity 
on the Apaf-1 -871/+208, reporter gene construct which contains a p53 binding 
site and is responsive to p53 fra«.sactivation (Figure 3.5). Taken together these 
observations imply a specific effect for p i4'^^  ^on E2F transcription.
During the course of this thesis Eymin et aL, (2001a) published similar data 
showing that p i4^^^ inhibited E2F transcriptional activity. These authors showed 
that p i4^^^ can overcome E2F activity on exogenous reporter gene constructs, 
including the cyclinE gene. These data further support a role for p i4^^^ in 
targeting E2F-1 and down-regulating its transcriptional activity.
Intriguingly, pl4^^^ can also act to up-regulate E2F-mediated transcription, 
although on the majority of E2F responsive promoters tested, p i4^^^ down- 
regulated E2F mediated transcription. Surprisingly, p i4^^^ itself acted as a 
transcriptional activator on both the Apaf-1 reporter gene constructs -871/+208 
and -t-35/+208, and additionally co-activated both E2F-1 and p53 transcription 
(Figure 3.5). Although only one of these reporter genes contains a p53 site, p53 
could activate both, and this observation could be due to some secondary p53 
independent cell cycle affect of p i4^^^. The co-activation observed with p53 and 
is probably due to p i4^^^ binding to MDM2 and preventing MDM2 from 
degrading p53. p i4^^^ could be stimulating E2F transcriptional activity through 
binding directly to the transcription factor, or by some other cellular mechanism. 
As yet there have been no reports on the ability of p i4^^^ to bind to DNA,
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however, it may be possible that p i4^^^ activates transcription by binding to other 
transcription factors or other cellular proteins.
The transcription factor p53 has also been described as being able to act as both a 
transcriptional activator and a transcriptional repressor (Ryan et al., 2001). p53 
can repress promoters that lack its response element and p53 transcriptional 
repression is in part mediated by an interaction with the mSin3a and histone 
deacetylase complex (Zilfou et a l, 2001). Additionally, binding of MDM2 to the 
transactivation domain of p53 directly inhibits both transcriptional activation and 
repression by p53 (Haines et al., 1994). p53 is also a general down-regulator of 
RNA polymerase III transcription (Cairns and White, 1998). p53 can specifically 
inactivate TFIIIB, however, only before its assembly into the pre-initation 
complex (Cairns and White, 1998). It is possible that pl4*^^ could act as both a 
transcriptional activator and repressor, through similar interactions with cellular, 
transcriptional regulators.
8.3 pl4^^/E2F, an example of a negative feedback loop.
E2F-1 activates p i4/19^^^ in a transcriptionally dependent manner as previously 
described (Bates et al, 1998). I showed that pl4*^^can overcome E2F-1 mediated 
^ran^activation. These data suggest that pl4*^^ is able to down-regulate E2F 
transcription and, as a result of this down-regulation may consequently act to 
regulate its own expression and steady state levels via a negative feedback loop. A 
number of cellular activities are regulated in this way, and one example of a 
negative feed back loop is the p53/MDM2 pathway. p53 transcriptionally
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activates expression of its negative regulator MDM2, which in turn, mediates the 
degradation of high levels of p53 protein (Haupt, et al, 1997; Honda et a l, 1997). 
When the MDM2-p53 interaction is prevented, through pl4*^^ binding to MDM2 
(Honda et a l, 1999) for example, then p53 activity is released. It may be that 
acts in a similar way on E2F and removal of pl4^^^-E2F binding would 
allow release of E2F activity. Another example of E2F regulation of its own 
activity is the E2F-pl07 interaction. E2F activates transcription of the pl07 gene 
and pl07 binds to members of the E2F family to repress E2F mediated 
transcription.
Recently more evidence is emerging which suggests that the HIF-1 transcription 
factor and its negative regulator the VHL tumour suppressor may exist as a 
negative feedback loop (Blagosklonny, 2001). An intriguing model is that an 
oncoprotein and a tumour suppressor may form functional pairs and couple 
transacûyaûon with feedback protein degradation (Blagoskonny., 2001). In this 
context, E2F-1 could be the oncoprotein and pl4^^^ the tumour suppressor of a 
functional pair. These functional pairs must also overlap however, for example, 
piqARF and MDM2 target both p53 and E2F-1.
8.4 p l4^ ^  regulates E2F mediated apoptosis.
Here I showed that pl4^^^ can decrease the levels of E2F mediated apoptosis in 
cells (Figure 3.1). The initial objective of this experiment was to examine whether 
pl^ARF could regulate the effect of MDM2 on E2F in a manner analogous to its 
effect on p53. The fact that pl4*^^ is able to overcome MDM2 mediated
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reduction of the E2F apoptotic response implies that this may indeed be the case. 
However, p i4"^ ^^  is also able to overcome E2F mediated apoptosis and these data 
suggest that p i4^^^ may be able to directly down-regulate E2F mediated 
apoptosis in a mechanistic pathway separate to the MDM2 mediated regulation of 
E2F apoptosis. In this situation, either pl4**^ is able to overcome MDM2 
mediated reduction of E2F apoptosis or MDM2 is able to overcome pl4*^^ 
mediated reduction of E2F apoptosis. This can be viewed as a bi-directional 
phenomenon, where either protein could be affecting the other, or merely 
sequestering each other away from the E2F heterodimer.
It is of interest to question whether the effects of pl4**^ on E2F mediated 
apoptosis are specific or whether this may be a result of cell cycle arrest imposed 
by pl4*^^. Indeed, when expressed in combination with the E2F and DP 
components of the E2F heterodimer, pl4^^^ caused a decrease in cell cycle 
progression (Figure 3.6) and this cell cycle arrest may be connected to the 
observed reduction in apoptosis.
Additionally, the data showing that E2F-1 can activate the Apaf-1 promoter, and 
that pl4^^^ can overcome this transcriptional activation on the Apaf-1 -396/+208 
reporter gene construct also implies a situation where pl4**^ could directly 
regulate E2F-1 mediated apoptosis through its transcriptional down-regulatory 
effect. p53 transcriptionally activates the Bax pro-apoptotic factor and this 
partially mediates the ability of p53 to induce apoptosis (Miyashita et al., 1994). 
Although it has been shown that the fran.yactivation domain of E2F-1 is not 
required for apoptosis (Hsieh et al., 1997), the fact that pl4*^^ could decrease the
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level of Apaf-1 ^ran^activation by E2F-1 may explain the partial effect of pl4*^^ 
in reducing apoptosis. It should also be noted, however that p i4"^ ^^  can also 
activate transcription of some Apaf-1 reporter genes, this may suggest a role for 
piqARF under certain conditions it acts to induce apoptosis, while under
others it can suppress apoptosis. Perhaps under normal cellular conditions pl4^^^ 
can suppress apoptosis by inhibiting E2F activity, but when oncogenic signalling 
occurs it then acts to induce apoptosis to prevent tumour development.
8.5 p l4^ ^  regulates E2F cell cycle progression
Experiments were carried out to examine the effect of pl4^^^ and E2F in cell 
cycle control. Considering that pl4*^^ induces a G1 arrest, in part through p53 but 
also independently of p53 (Quelle et ah, 1995, Pomerantz et ah, 1998, Zhang et 
al., 1998). While E2F over-expression forces S phase progression (Johnson et a l, 
1994) it was interesting to note that, together with pl4**^ the two proteins caused 
a decrease in S-phase progression, compared to E2F alone when examined in a 
cell cycle assay (Figure 3.6). Interestingly, in these experiments an increase in the 
number of cells undergoing S-phase was observed with the overexpression of 
pl4*^^ alone. This result is surprising as pl4^^^ is documented as causing a G1 
arrest, however, as I had observed that pl4^^^ can sometimes act as a 
transcriptional activator then this may explain this observation. Although, the fact 
that this may be an artefact of pl4*^^ overexpression cannot be excluded in this 
type of experiment.
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Other ceil cycle arresting proteins such as the CDKIs, and p27^*  ^may
also cause cell cycle arrest in combination with E2F. Indeed previous studies have 
outlined a role for p21 in down-regulating E2F-1 transcription, independently of 
pRb (Delavaine and La Thangue, 1999). It would be of interest to investigate the 
effects of these proteins on E2F activity and compare them to the effects of 
PI4 ARF would further elucidate the contribution of p i4^^^ to the modulation 
of E2F activity and to rule out that the observed effects are not a general 
consequence of cell cycle arrest.
Additionally, in a growth assay, pl4**^ and E2F both act as growth suppressors, 
and pl4*^^ had a highly potent effect (Figure 3.7). When examined together, the 
observed effect is less than the effect of E2F but more than that of pl4**^ (Figure 
3.7), indicating that while pl4*^^ is overcoming E2F activity, it could also be 
described as E2F overcoming the negative growth activity of p i4^^^. These data 
are further supported by the paper from Eymin et al., (2001), where the authors 
also observed a decrease in growth with p l4 ^ ^  and E2F-1 in comparison to E2F 
alone, whilst an interesting study from Martelli et al., (2001) also highlights a 
similar role for E2F-1 and p i9^^^ in the regulation of cell growth.
These results suggest a general role for pl4^^^ modulating E2F activity, however 
the possibility that pl4*^^ may be targeting E2F at the transcriptional level cannot 
be excluded. As E2F is responsible for the activation of so many genes required 
for cell cycle progression and apoptosis, then the results implied by these assays 
could be a consequence of the transcriptional down-regulation of cellular genes 
such as cyclin E.
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8.6 Physical interaction between E2F-1 and p l4^^
pl^ARF previously been described as interacting with the cellular proteins 
MDM2 (Pomerantz et al., 1998) and topoisomerase I (Karayan et al., 2001). The 
results presented in this thesis show that pl4^^^ and E2F-1 can interact both 
directly in vitro and under physiological cellular conditions (Chapter 4). 
Additionally, pl4**^ also interacts with the E2F-1 heterodimeric binding partner, 
DP-1. These data provide evidence for E2F being a physiological target of p i4^^^ 
as the two proteins are found completed together in cells. Eymin et al., also 
described an interaction between pl4^^^ and E2F-1, mapping the N-terminal 
domain of ARE as binding to E2F-1. It has also recently been shown that pl9*^^ 
can bind to E2F-1, 2 and 3 (Martelli et al., 2001), but not E2F-6. It would be of 
interest to investigate whether pl4*^^ can bind to other members of the E2F 
family, and to elucidate a role for more specific regulation of the E2F family 
members by p i4^^^.
Mapping data identified a number of sites in E2F for binding to pl4^^^ and 
excluded the rra/i^sactivation domain from being required for binding. p l4 ^ ^  
binds to mutants in E2F-1 which are deficient in pRb and cyclin A binding, 
suggesting that the binding site is not involved in phosphorylation or negative 
regulation by pRb. pl4**^ also bound to domains encompassing the central DNA 
binding region of E2F-1 (Figure 4.3). These data indicate that pl4^^^ may not 
compete with pRb for E2F-1 mediated binding and transcriptional repression, and 
that the E2F-1 franj'activation domain is not required for pl4**^ binding.
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Although not conclusive, these data suggest that mediated E2F-1
transcriptional repression is probably not regulated directly by binding to the 
rran^yactivation domain of E2F but may be due to a secondary non-transcriptional 
activation domain masking effect. Additionally, pl4*^^ binds to a region of DP-1, 
which encompasses the heterodimerisation domain further suggesting that the 
binding of pl4*^^ to E2F may prevent formation of the heterodimeric complex. 
Further work is required to map the exact binding domain of pl4*^^ on E2F-1 and 
DP-1, in order to correlate binding with function.
8.7 Mutational analysis of p l4^ ^
MDM2 has been shown previously to bind to both the N and C terminal regions 
of p i4^^^, however only the N-terminal region is able to regulate MDM2 activity 
on p53 (Zhang et a l, 1998). Furthermore, detailed mapping of the MDM2/pl4'^^^ 
interaction identified an N-terminal region of pl4*^^ within the first 22 amino 
acid residues which was capable of interacting with MDM2, sequestering it to the 
nucleolus and inhibiting its ability to degrade p53 (Lohrum et a l, 2000). Although 
these data suggest that nucleolar relocalisation of MDM2 by pl4*^^ is required 
for the activation of p53, contradictory evidence has also been published 
indicating that this is actually not required and that pl4*^^ can still inactivate 
MDM2 when not relocalised to the nucleolus (Llanos et a l, 2001).
My data show that while the 1-34 region of pl4**^ can interact with E2F-1 and 
regulate its transcriptional activity, the 1-22  region in contrast can neither bind 
E2F-1 nor have a negative effect on transcriptional activity or S-phase 
progression. Experiments failed to identify whether this was a dominant negative
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effect and it is possible that pl4^*^^s effect on E2F is directly related to binding. It 
is possible that the 1-22  region of pl4**^ may be having a dominant negative 
effect on E2F transcription, or may be removing other, as yet undefined, negative 
regulatory complexes which are affecting E2F activity.
Given that E2F-1 is unable to bind to the TxMyc-pl4^^^ 1-22 mutant, while 
MDM2 does bind to this region (Figure 4.4B and Figure 4.5), this result is 
indicative of the possibility that E2F-1 and MDM2 may be able to bind to pl4*^^ 
and form a ternary complex. Alternatively, separate binding of E2F-1 and MDM2 
may be required for the distinct control and function of pl4*^^ .
An interesting feature of pl4*^^ is the ability of the C-terminal region of the 
protein to bind to both MDM2 and E2F-1 in cells, while at the same time having 
little effect on the activity of either protein. A nucleolar localisation signal has 
been identified in the C-terminus of pl4"^^^, and tumour associated mutations 
have been mapped to the C-terminus which affect pl4*^^ nucleolar localisation 
(Zhang et al., 1998). This has interesting implications for the regulation of E2F 
activity. It could be that the C terminal region of pl4*^^ has other, as yet 
undefined effects on E2F activity. Possibly, the C terminal half of pl4^^^ is more 
stable, or active, than the full-length protein, indicating that the C-terminal region 
of pl4*^^ may be required for protein stability and the increased activity observed 
with the N-terminus of p i4^^^ may be due to an as yet undefined release of 
activity from the p i4 ^ ^  C-terminus.
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8.8 The role ofMDM2
The MDM2 oncogene has been shown to be an important cellular target of 
p l4 /p l9 ^ ^  and its effects on p53 activity are mediated through regulation of 
MDM2 (Pomerantz et ah, 1998). Previous studies however, have documented 
MDM2 independent pathways for pl4*^^ cell cycle regulation (Camero et al., 
2000; Weber et al., 2000). The data presented show that the interaction between 
E2F-1 and pl4^^^ is at least in part independent of MDM2, and that the effect of 
on E2F activity occurs in the absence of MDM2. This suggests the 
presence of a novel regulatory mechanism where piq^RF to directly
regulate E2F activity.
We cannot exclude the possibility, however that in a p53'^7mdm2'^' background, 
the MDM2 homologue MDMX may be able to compensate for the activity of 
MDM2 and act in a similar manner. Deletion of MDMX has recently been shown 
to cause embryonic lethality due to loss of cellular proliferation and this 
phenotype can be rescued by deletion of p53 (Parant, et al., 2001), in a manner 
similar to that of MDM2. These data indicate that MDM2 and MDMX are non­
overlapping regulators of p53 activity and so define a new pathway of p53 
regulation. It would be of interest to further investigate the role of MDM2 and its 
homologue MDMX in the regulation of E2F activity by pl4^^^.
The binding sites for E2F-1 and pl4*^^ on MDM2 are distinct, suggesting that the 
three proteins may exist in a trimeric complex, which indeed appears to exist in 
immunoprécipitation experiments (Figure 4.2). This could also mean that both
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E2F-1 and can bind to MDM2 independently of one another and that the
components of this pathway could depend on specific cellular states. This 
situation is particularly indicative in that Eymin et al. (2001a) suggest that MDM2 
is required for the modulation of E2F activity by pl4^^^.
This observation by Eymin et al. (2001a) contrasts with the data presented here 
which outlines an MDM2 independent role for p i4'^^^ in the E2F pathway. 
Interestingly however, this study also identifies the E2F-l/pl4^^^ interaction as 
being independent of MDM2 despite their inability to see an effect of pl4*^^ on 
E2F activity in reporter assay experiments in p53'^Vmdm2'^' cells. In my 
experiments I saw a clear effect of pl4^^^ on E2F activity in two different 
functional assays, and previous studies have indicated an MDM2 independent role 
for pl4*^^ in cell cycle regulation (Camero et al., 2000; Weber et al., 2000). 
Together these data imply that p l4 ^ ^  can act on E2F activity independently of 
MDM2 under certain cellular conditions. There also exists the potential for 
MDM2 to regulate pl4^^^s effect on E2F-1. MDM2 has been previously shown to 
interact with E2F-1 and DP-1 and modulate E2F activity (Martin et al., 1995, 
Loughran and La Thangue 2000). Given that pl4^^^ regulates p53 through 
MDM2 it seems probable that MDM2 could be involved in some aspects of E2F 
regulation by pl4^^^.
8.9 Mechanism of p l4^ ^  regulation of E2F.
E2F activity is tightly regulated during the cell cycle and is subject to a number of 
modifications including; binding to pRb (Helin et al., 1993), cellular localisation
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(de la Luna et a l, 1996) and ubiquitin mediated degradation (Marti et al., 1999; 
Loughran and La Thangue., 2000). It was of interest to investigate whether pl4^^^ 
could regulate the activity of E2F in a manner analogous to any of the previously 
described E2F regulatory cellular proteins, such as NPCD-1 (Sansal et al., 2000) 
and Pur a  (Darbinian et al., 1999). These proteins bind to the E2F 
heterodimerisation domain and decrease E2F DNA binding, which in turn reduce 
the transaoMyaiion of E2F responsive genes.
Initially, experiments were carried out using both endogenous and over-expressed 
PI4 ARF in SAOS2 cells and it was interesting to discover that while endogenous 
pl^ARF jg nucleolar, over-expressed pl4^^^ is localised to both the nucleolus and 
the nucleus. These data correlate with another recent study which also questions 
the use of over-expressed pl4*^^ in immunostaining studies, and questions the 
true cellular localisation of over-expressed proteins (Llanos et al., 2001).
The ability of pl4^^^ to regulate E2F cellular localisation was investigated and 
my experiments indicated that in a p53 negative background pl4*^^ and E2F 
stayed in their separate cellular compartments when over-expressed together 
(Figure 7.2). At no point could I observe co-localisation of pl4*^^ and E2F-1 or 
DP-1, indicating that the regulation of E2F activity by p 14^^^ may not be through 
relocalisation of the proteins as implied for p53/MDM2 (Zhang and Xiong, 1999). 
However, the possibility that pl4*^^ may move E2F to the nucleolus or itself 
move into the nucleus is not excluded as this may only occur at specific cell cycle 
stages or for brief time windows that are beyond the scope of immunostaining 
experiments.
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It has been published however that p l9 ^ ^  and E2F-1 can co-localise to the 
nucleolus and this result opens a number of questions (Martelli et al., 2001). It 
may be that pl4^^^ can relocalise E2F to the nucleolus under certain cellular 
conditions, or indeed that pl4**^ may move out into the nucleus in order to 
interact with E2F. The importance of pl4**^ localisation is yet to be elucidated 
and recent studies have questioned previous data suggesting that pl4^^^/MDM2 
co-localisation is required for pl4*^^ regulation of p53 (Llanos et al., 2001). 
Much more work is required to investigate the effects of nuclear and nucleolar 
localisation of pl4^^^ and its ability to relocalise proteins such as MDM2 (Zhang 
and Xiong, 1998), and then to further question how E2F and pl4^^^ may co- 
localise in the cell.
The in vitro binding data presented in this thesis suggested that p i4^^^ may bind 
to E2F-1 and DP-1 through the DNA binding and heterodimerisation domains of 
these proteins. As heterodimerisation of the partners occurs before DNA binding 
(Zheng et al., 1999), if pl4*^^ could interfere with this binding, then down- 
regulation of transcription would occur, Bandshift assays were performed to 
investigate whether pl4*^^ could bind to E2F on DNA or disrupt the E2F 
complex. Unexpectedly, p i4^^^ had no effect on E2F binding to DNA in vitro 
(Figure 7.4). As the proteins clearly bind to one another under various different 
assay conditions this result was not expected (Chapter 4). It may be possible that 
the conditions used in these assays were not conducive to allow pl4*^^ to bind 
E2F and that this interaction may indeed occur under physiological conditions, 
and may be a tightly regulated process which only occurs at specific cell cycle
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stages. Alternatively, p i4^^^ may not act directly on E2F activity at the 
transcriptional level but may have a post-translational affect.
The fact that pl4**^ showed no immediate effects upon E2F DNA binding 
activity points to a post-translational affect for p i4^^^ on E2F activity. A number 
of cellular proteins such as SCF and MDM2 have been shown to bind and degrade 
E2F at various stages of the cell cycle (Marti et al., 1999; Loughran and La 
Thangue, 2000), and it was possible that p 14^^^ could have been having a similar 
effect. My data showed that overexpression of pl4*^^ and E2F together results in 
a decrease in the levels of E2F-1 protein (Figure 7.5), suggesting a role for pl4*^^ 
in E2F degradation. pl4*^^ may have E3 ubiquitin ligase activity and could target 
E2F for degradation in a manner analogous to MDM2.
The degradation of E2F-1 by pl4^^^ could provide an explanation for the 
observed pl4**^ down-regulation of E2F transcription, cell cycle progression and 
apoptosis. Over-expression of pl4^^^, may degrade E2F-1 therefore preventing it 
from performing its usual functions, namely transcriptional activation and cell 
cycle progression (Figure 8.1). It would be of great interest to investigate the 
mechanism by which pl4^^^ causes degradation of E2F, and whether it can 
degrade other cellular proteins.
Recently, pl9^^^ has been shown to bind and downregulate the E2F family 
members E2F-1, 2 and 3 at the post-translational level, however does not effect 
E2F-6 levels (Martelli et al., 2001). This E2F downregulation is proteasome 
dependent, suggesting that p i9^^^ may act as an adapter for ubiquitination. These
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data may help elucidate the mechanism by which pl4**^ degrades E2F. In 
combination with these data, the authors also showed that E2F-1 mediated 
proliferation is suppressed by p i a n  effect that can be partially reversed by 
the re-introduction of E2F-1, and that pl9*^^ could relocalise E2F-1 to the 
nucleolus (Martelli et ah, 2001). It seems that p i9^^^ targeting of certain E2F 
species may co-operate with a stimulation of the p53 pathway to counteract 
oncogenic growth signals.
8.10 General Discussion
The majority of these experiments were carried out in SA0S2 cells, which do not 
contain functional p53 or pRb in order to study p53 independent pl4*^^ effects on 
E2F. These data define a p53 and MDM2 independent effect for pl4*^^ namely 
in the regulation of E2F activity. It would be of great interest to create a pl9'^^ 
/E2F-1'^' mouse and investigate the phenotype of these animals. However, the 
complexities of the many E2F family members would make this study difficult. It 
should also be remembered that although pl4*^^ and p i9"^ ^^  are homologues of 
each other, the two proteins only share 50% amino acid similarity and many 
differences do exist between them.
It is becoming apparent that many human tumours that retain wild-type p53 suffer 
loss of p i4^^^, and are therefore unable to activate p53 in response to abnormal 
proliferative signals. It would be useful to examine the levels of E2F-1 and pl4*^^ 
in tumours and see whether a similar situation exists and indeed, whether loss of 
both p53 and E2F within the same tumour occurs frequently. A recent paper
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published by Eymin et al. (2001b) shows that E2F-1 levels are frequently 
increased or lost in some lung carcinomas, and it would be interesting to 
investigate the levels of pl4*^^ in these tumours, which contain high levels of 
E2F.
The ability to self-replicate is a fundamental basis of life, reflected at the cellular 
level by the highly regulated process of committing to a round of DNA replication 
and cell division at the G 1/S phase of the cell cycle. The ability of pl4^^^ to 
regulate E2F activity and prevent S-phase progression identifies another cellular 
pathway, which infringes upon the Gl/S-phase transition. A number of pathways 
have been identified which converge at this stage of the cell cycle including the 
p53 pathway and the pai'allel pathways of E2F-pRb and Myc; both of which 
control the activity of cdk2 at the S-phase boundary (Figure 8.2) (Bartek and 
Lukas, 2001).
It would be of interest to investigate the effect of pl4*^^ on the Myc pathway, 
given that Myc also activates pl4**^ and is involved in S-phase progression. The 
cyclin E gene is rran.yactivated by both E2F and Myc, and is emerging as a key 
regulator of S-phase progression (Duronio et al., 1998; Bartek and Lukas, 2001).
can repress E2F mediated transcription of the cyclin E reporter gene 
(chapter 3 and Eymin et al., 2001a) and it would be of interest to see whether this 
was also the case for Myc mediated transcription. Cross talk exists between the 
pRb/E2F and Myc pathways, for example through Myc-mediated transcriptional 
activation of E2F-2 and E2F-3, which are negatively controlled by pRb and again, 
piqARF may be involved in these cellular pathways.
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pl^ARF causes cell cycle arrest at both the G1 and G2 phases of the cell cycle 
(Kamijo et aL, 1998; Stott et a i, 1998). However, cells lacking p53 alone are 
refractory to ARF-induced arrest, and in this setting ARF protein expression is 
greatly increased. This suggests that p53 suppresses ARF through negative 
feedback, and consistent with this observation réintroduction of p53 into these 
cells returns ARF protein expression to lower levels (Sherr, 2001). Perhaps a 
similar effect would be observed in e l f  cells and it would be interesting to 
investigate the levels of pl9**^ protein in these cells, and vice versa, the levels of 
E2F-1 protein in ARF knock out MEFs.
ARF acts as a fuse to filter inappropriate mitogenic signals flowing through the 
cyclin D-cdk-pRb-E2F circuit (Sherr, 2001), inducing p53 under conditions in 
which abnoiTnal proliferative signals are generated. ARF normally acts to protect 
cells from Myc over-expression by facilitating Myc-induced, p53-dependent 
apoptosis. Cells corrupted in the ARF-MDM2-p53 pathway are resistant to Myc- 
induced killing, enabling Myc to act as a pure growth promoter in this setting. It is 
likely that pl4/19*^^ activity will also be tightly interlinked with the E2F and 
Myc regulatory pathways and future studies on human tumours and transgenic 
mice should help elucidate these pathways.
8.11 Overall conclusions and future work.
These data and the studies published during the course of this thesis have clearly 
identified E2F as a cellular target of p i4^^^. It is becoming increasingly apparent 
that piqAKF is a highly important tumour suppressor protein, and these data
198
Chapter 8.______________________________________________________Discussion
highlight a role for an E2F-pl4^^^ pathway, which may regulate the cell cycle. 
Furthermore, this pathway is independent of MDM2. These data highlight pl4**^ 
as a particularly important cell cycle regulator, in that it targets both the p53 and 
E2F pathways, albeit in opposite ways. While the previously described role of 
pl^ARF -g upregulate p53 activity to cause cell cycle arrest and apoptosis, it 
down-regulates E2F activity, leading to a decrease in apoptosis but also a cell 
cycle arrest.
Much more work is required, both to elucidate the role for pl4*^^ in cell cycle 
regulation and to identify those activities which impinge upon both the p53 and 
E2F pathways.
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Figure 8.1 Summary diagram
Summai'y diagram showing pl4^^^-E2F cellular effects. E2F rran.yactivation leads 
to increased levels of pl4^^^. In turn, the high levels of p l4 ^ ^  down-regulate 
E2F activity, possible through binding and/or degradation of E2F-1.
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Figure 8.2 Gl-S-phase regulatory pathways.
Summary diagi'am outlining the pathways regulating the Gl-S-phase transition. 
The p53, Myc and E2F transcription factors all regulate the cell cycle at the G1 
stage. Both E2F and Myc target Cyclin E which itself is important for regulation 
of the restriction point.
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